{"PMC3248566": [["IntroductionBluetongue is a major infectious disease of ruminants caused by an arbovirus (Bluetongue virus, BTV) transmitted by biting midges (Culicoides spp.) [1]\u2013[3].", [["IntroductionBluetongue", "CHEMICAL", 0, 22], ["infectious disease of ruminants", "DISEASE", 34, 65], ["ruminants", "ORGANISM", 56, 65], ["Bluetongue virus", "ORGANISM", 90, 106], ["BTV", "ORGANISM", 108, 111], ["Culicoides spp.", "ORGANISM", 143, 158], ["Bluetongue virus", "SPECIES", 90, 106], ["Culicoides spp.", "SPECIES", 143, 158], ["Bluetongue virus", "SPECIES", 90, 106], ["BTV", "SPECIES", 108, 111], ["Culicoides spp.", "SPECIES", 143, 158], ["an arbovirus (Bluetongue virus", "PROBLEM", 76, 106], ["major", "OBSERVATION_MODIFIER", 28, 33], ["infectious", "OBSERVATION", 34, 44], ["arbovirus", "OBSERVATION", 79, 88]]], ["Historically, bluetongue has been endemic almost exclusively in temperate and tropical areas of the world where the climatic conditions favour both the spread of the susceptible insect vector population and the virus replication cycle within the vector [4].", [["bluetongue", "DISEASE", 14, 24], ["bluetongue", "ORGANISM", 14, 24], ["bluetongue", "SPECIES", 14, 24], ["bluetongue", "SPECIES", 14, 24], ["endemic", "PROBLEM", 34, 41], ["the climatic conditions", "PROBLEM", 112, 135], ["the susceptible insect vector population", "TREATMENT", 162, 202], ["the virus replication cycle", "TREATMENT", 207, 234], ["endemic", "OBSERVATION_MODIFIER", 34, 41], ["tropical", "OBSERVATION_MODIFIER", 78, 86], ["areas", "OBSERVATION_MODIFIER", 87, 92], ["spread", "OBSERVATION_MODIFIER", 152, 158], ["virus replication", "OBSERVATION", 211, 228]]], ["However, in the last decade BTV has spread extensively in several geographical areas including Southern Europe and also, unexpectedly, in Northern Europe causing a serious burden to both animal health and the economy [5], [6].IntroductionFrom a molecular and structural virology perspective BTV is one of the best understood animal viruses.", [["BTV", "ORGANISM", 28, 31], ["BTV", "ORGANISM", 291, 294], ["BTV", "SPECIES", 28, 31], ["BTV", "SPECIES", 291, 294], ["a serious burden", "PROBLEM", 162, 178], ["spread", "OBSERVATION_MODIFIER", 36, 42], ["several", "OBSERVATION_MODIFIER", 58, 65], ["geographical", "OBSERVATION_MODIFIER", 66, 78], ["areas", "OBSERVATION_MODIFIER", 79, 84], ["Southern", "OBSERVATION_MODIFIER", 95, 103], ["Europe", "OBSERVATION_MODIFIER", 104, 110], ["serious", "OBSERVATION_MODIFIER", 164, 171], ["viruses", "OBSERVATION", 332, 339]]], ["BTV is a member of the Orbivirus genus, within the Reoviridae family, and possesses a double-stranded RNA genome formed by 10 segments (Seg-1 to Seg-10) of approximately 19200 base pairs in total [1], [3].", [["BTV", "ORGANISM", 0, 3], ["Orbivirus genus", "ORGANISM", 23, 38], ["Reoviridae", "GENE_OR_GENE_PRODUCT", 51, 61], ["Seg-1", "GENE_OR_GENE_PRODUCT", 136, 141], ["Seg-10", "GENE_OR_GENE_PRODUCT", 145, 151], ["double-stranded RNA genome", "DNA", 86, 112], ["Seg", "PROTEIN", 136, 139], ["19200 base pairs", "DNA", 170, 186], ["BTV", "SPECIES", 0, 3], ["Seg", "TEST", 136, 139], ["Seg", "TEST", 145, 148]]], ["Until now, the BTV genome has been shown to encode for 7 structural and 3 non-structural proteins.", [["BTV", "ORGANISM", 15, 18], ["BTV genome", "DNA", 15, 25], ["7 structural and 3 non-structural proteins", "PROTEIN", 55, 97], ["BTV", "SPECIES", 15, 18], ["the BTV genome", "PROBLEM", 11, 25], ["7 structural and 3 non-structural proteins", "PROBLEM", 55, 97]]], ["The BTV genome is packaged within a triple layered icosahedral protein capsid of approximately 90 nm in diameter [1], [7]\u2013[10].", [["BTV", "ORGANISM", 4, 7], ["[7]\u2013[10]", "SIMPLE_CHEMICAL", 118, 126], ["BTV genome", "DNA", 4, 14], ["triple layered icosahedral protein capsid", "PROTEIN", 36, 77], ["BTV", "SPECIES", 4, 7], ["a triple layered icosahedral protein capsid", "TREATMENT", 34, 77], ["BTV genome", "OBSERVATION", 4, 14], ["90 nm", "OBSERVATION_MODIFIER", 95, 100]]], ["The outer capsid of the virion is composed by 60 trimers of VP2 and 120 trimers of VP5 [11] and differences within this outer capsid define the 26 BTV serotypes which have been described so far [12], [13].", [["virion", "CELLULAR_COMPONENT", 24, 30], ["VP2", "GENE_OR_GENE_PRODUCT", 60, 63], ["VP5", "GENE_OR_GENE_PRODUCT", 83, 86], ["60 trimers", "PROTEIN", 46, 56], ["VP2", "PROTEIN", 60, 63], ["VP5", "PROTEIN", 83, 86], ["outer capsid", "PROTEIN", 120, 132], ["The outer capsid of the virion", "TREATMENT", 0, 30], ["VP2", "TEST", 60, 63], ["VP5", "TEST", 83, 86], ["the 26 BTV serotypes", "PROBLEM", 140, 160], ["outer", "ANATOMY_MODIFIER", 4, 9], ["capsid", "OBSERVATION", 10, 16], ["virion", "OBSERVATION", 24, 30], ["26 BTV", "OBSERVATION_MODIFIER", 144, 150]]], ["The outer capsid proteins, and VP2 in particular, stimulate virus neutralizing antibodies which in general protect only against the homologous serotype [14].", [["VP2", "GENE_OR_GENE_PRODUCT", 31, 34], ["outer capsid proteins", "PROTEIN", 4, 25], ["VP2", "PROTEIN", 31, 34], ["virus neutralizing antibodies", "PROTEIN", 60, 89], ["The outer capsid proteins", "TEST", 0, 25], ["VP2", "TEST", 31, 34], ["stimulate virus neutralizing antibodies", "PROBLEM", 50, 89], ["outer", "ANATOMY_MODIFIER", 4, 9], ["capsid proteins", "ANATOMY", 10, 25]]], ["The internal core is formed by two layers, constituted by VP3 (sub-core) and the immunodominant VP7 (intermediate layer) [7].", [["VP3", "GENE_OR_GENE_PRODUCT", 58, 61], ["VP7", "GENE_OR_GENE_PRODUCT", 96, 99], ["VP3", "PROTEIN", 58, 61], ["immunodominant VP7", "PROTEIN", 81, 99], ["VP3", "TEST", 58, 61], ["internal", "ANATOMY_MODIFIER", 4, 12], ["formed", "OBSERVATION", 21, 27], ["two", "OBSERVATION_MODIFIER", 31, 34], ["layers", "OBSERVATION_MODIFIER", 35, 41], ["immunodominant VP7", "ANATOMY", 81, 99]]], ["Three minor enzymatic proteins, VP1 (RNA dependent RNA polymerase), VP4 (capping enzyme and transmethylase) and VP6 (RNA dependent ATPase and helicase) are contained within the core that is transcriptionally active in infected cells [15]\u2013[21].IntroductionThe BTV genome encodes also 3 non-structural proteins: NS1, NS2 and NS3/NS3a.", [["cells", "ANATOMY", 227, 232], ["VP1 (RNA dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 32, 65], ["VP4 (capping enzyme", "GENE_OR_GENE_PRODUCT", 68, 87], ["transmethylase", "GENE_OR_GENE_PRODUCT", 92, 106], ["VP6", "GENE_OR_GENE_PRODUCT", 112, 115], ["RNA dependent ATPase", "GENE_OR_GENE_PRODUCT", 117, 137], ["cells", "CELL", 227, 232], ["BTV", "ORGANISM", 259, 262], ["NS1", "GENE_OR_GENE_PRODUCT", 310, 313], ["NS2", "GENE_OR_GENE_PRODUCT", 315, 318], ["NS3", "GENE_OR_GENE_PRODUCT", 323, 326], ["NS3a", "GENE_OR_GENE_PRODUCT", 327, 331], ["enzymatic proteins", "PROTEIN", 12, 30], ["VP1", "PROTEIN", 32, 35], ["RNA dependent RNA polymerase", "PROTEIN", 37, 65], ["VP4", "PROTEIN", 68, 71], ["capping enzyme", "PROTEIN", 73, 87], ["transmethylase", "PROTEIN", 92, 106], ["VP6", "PROTEIN", 112, 115], ["RNA dependent ATPase", "PROTEIN", 117, 137], ["helicase", "PROTEIN", 142, 150], ["infected cells", "CELL_TYPE", 218, 232], ["BTV genome", "DNA", 259, 269], ["non-structural proteins", "PROTEIN", 285, 308], ["NS1", "PROTEIN", 310, 313], ["NS2", "PROTEIN", 315, 318], ["NS3", "PROTEIN", 323, 326], ["NS3a", "PROTEIN", 327, 331], ["BTV", "SPECIES", 259, 262], ["Three minor enzymatic proteins", "TEST", 0, 30], ["VP1 (RNA dependent RNA polymerase", "PROBLEM", 32, 65], ["VP4 (capping enzyme", "TEST", 68, 87], ["transmethylase", "TEST", 92, 106], ["VP6 (RNA dependent ATPase", "PROBLEM", 112, 137], ["transcriptionally active in infected cells", "PROBLEM", 190, 232], ["NS1", "TREATMENT", 310, 313], ["NS2", "TREATMENT", 315, 318], ["NS3", "TREATMENT", 323, 326], ["NS3a", "TREATMENT", 327, 331], ["enzymatic proteins", "OBSERVATION", 12, 30], ["active", "OBSERVATION_MODIFIER", 208, 214]]], ["NS1 and NS2 are highly expressed viral proteins and their multimers are morphological features of BTV-infected cells.", [["cells", "ANATOMY", 111, 116], ["BTV-infected", "DISEASE", 98, 110], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS2", "GENE_OR_GENE_PRODUCT", 8, 11], ["BTV", "ORGANISM", 98, 101], ["cells", "CELL", 111, 116], ["NS1", "PROTEIN", 0, 3], ["NS2", "PROTEIN", 8, 11], ["viral proteins", "PROTEIN", 33, 47], ["BTV-infected cells", "CELL_TYPE", 98, 116], ["BTV", "SPECIES", 98, 101], ["NS1", "PROBLEM", 0, 3], ["NS2", "PROBLEM", 8, 11], ["viral proteins", "PROBLEM", 33, 47], ["BTV", "PROBLEM", 98, 101], ["infected cells", "PROBLEM", 102, 116], ["NS2", "OBSERVATION", 8, 11], ["viral proteins", "OBSERVATION", 33, 47], ["infected cells", "OBSERVATION", 102, 116]]], ["Multimers of the NS1 protein form tubules (approximately 50 nm in diameter and up to 1000 nm in length) that appear to be linked to cellular cytopathogenicity [22], while NS2 is the major component of the viral inclusion bodies.", [["tubules", "ANATOMY", 34, 41], ["cellular", "ANATOMY", 132, 140], ["NS1", "GENE_OR_GENE_PRODUCT", 17, 20], ["tubules", "TISSUE", 34, 41], ["cellular", "CELL", 132, 140], ["NS2", "GENE_OR_GENE_PRODUCT", 171, 174], ["NS1 protein", "PROTEIN", 17, 28], ["NS2", "PROTEIN", 171, 174], ["the NS1 protein form tubules", "PROBLEM", 13, 41], ["cellular cytopathogenicity", "PROBLEM", 132, 158], ["NS2", "TREATMENT", 171, 174], ["the viral inclusion bodies", "PROBLEM", 201, 227], ["NS1 protein", "OBSERVATION", 17, 28], ["tubules", "OBSERVATION_MODIFIER", 34, 41], ["approximately", "OBSERVATION_MODIFIER", 43, 56], ["50 nm", "OBSERVATION_MODIFIER", 57, 62], ["diameter", "OBSERVATION_MODIFIER", 66, 74], ["1000 nm", "OBSERVATION_MODIFIER", 85, 92], ["appear to be", "UNCERTAINTY", 109, 121], ["cellular", "OBSERVATION_MODIFIER", 132, 140], ["cytopathogenicity", "OBSERVATION", 141, 158], ["major", "OBSERVATION_MODIFIER", 182, 187], ["component", "OBSERVATION_MODIFIER", 188, 197], ["viral inclusion bodies", "OBSERVATION", 205, 227]]], ["NS2 plays a key role in viral replication and assembly as it has a high affinity for single stranded RNA and possesses phosphohydrolase activity [23].", [["NS2", "GENE_OR_GENE_PRODUCT", 0, 3], ["phosphohydrolase", "SIMPLE_CHEMICAL", 119, 135], ["NS2", "PROTEIN", 0, 3], ["single stranded RNA", "RNA", 85, 104], ["phosphohydrolase", "PROTEIN", 119, 135], ["NS2", "TREATMENT", 0, 3], ["viral replication", "TREATMENT", 24, 41], ["a high affinity", "PROBLEM", 65, 80], ["single stranded RNA", "TREATMENT", 85, 104], ["phosphohydrolase activity", "TEST", 119, 144], ["viral replication", "OBSERVATION", 24, 41]]], ["NS3/NS3a are glycosylated proteins involved in BTV exit.", [["NS3", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS3a", "GENE_OR_GENE_PRODUCT", 4, 8], ["BTV", "ORGANISM", 47, 50], ["NS3", "PROTEIN", 0, 3], ["NS3a", "PROTEIN", 4, 8], ["glycosylated proteins", "PROTEIN", 13, 34], ["BTV", "SPECIES", 47, 50], ["NS3", "TREATMENT", 0, 3], ["NS3a", "TREATMENT", 4, 8], ["glycosylated proteins", "TREATMENT", 13, 34]]], ["There are two isoforms of NS3: NS3 and NS3a with the latter lacking the N-terminal 13 amino acid residues [24]\u2013[26].IntroductionTherefore, the segmented genome of BTV has been thought to be monocistronic (i.e. ten genome segments encoding for 10 proteins) for almost three decades [27], [28].", [["amino acid", "CHEMICAL", 86, 96], ["N-", "CHEMICAL", 72, 74], ["amino acid", "CHEMICAL", 86, 96], ["NS3", "GENE_OR_GENE_PRODUCT", 26, 29], ["NS3", "GENE_OR_GENE_PRODUCT", 31, 34], ["NS3a", "GENE_OR_GENE_PRODUCT", 39, 43], ["amino acid", "AMINO_ACID", 86, 96], ["BTV", "ORGANISM", 163, 166], ["NS3", "PROTEIN", 26, 29], ["NS3", "PROTEIN", 31, 34], ["NS3a", "PROTEIN", 39, 43], ["N-terminal 13 amino acid residues", "PROTEIN", 72, 105], ["monocistronic", "DNA", 190, 203], ["genome segments", "DNA", 214, 229], ["BTV", "SPECIES", 163, 166], ["NS3", "TREATMENT", 31, 34], ["NS3a", "TREATMENT", 39, 43], ["amino acid residues", "TEST", 86, 105], ["the segmented genome of BTV", "PROBLEM", 139, 166], ["thought to be", "UNCERTAINTY", 176, 189], ["monocistronic", "OBSERVATION_MODIFIER", 190, 203]]], ["Segment 9 however, contains the open reading frame (ORF) encoding VP6 but also a smaller coding sequence in the position +1 reading frame that is present in BTV and some related Orbiviruses such as African horse sickness virus and others [29].", [["horse sickness", "DISEASE", 206, 220], ["VP6", "GENE_OR_GENE_PRODUCT", 66, 69], ["BTV", "ORGANISM", 157, 160], ["Orbiviruses", "GENE_OR_GENE_PRODUCT", 178, 189], ["African", "ORGANISM", 198, 205], ["horse sickness virus", "ORGANISM", 206, 226], ["open reading frame", "DNA", 32, 50], ["ORF", "DNA", 52, 55], ["VP6", "DNA", 66, 69], ["position +1 reading frame", "DNA", 112, 137], ["horse sickness virus", "SPECIES", 206, 226], ["BTV", "SPECIES", 157, 160], ["African horse sickness virus", "SPECIES", 198, 226], ["a smaller coding sequence", "PROBLEM", 79, 104], ["BTV", "PROBLEM", 157, 160], ["some related Orbiviruses", "PROBLEM", 165, 189], ["African horse sickness virus", "PROBLEM", 198, 226], ["smaller", "OBSERVATION_MODIFIER", 81, 88]]], ["Bioinformatic analysis predicts that the BTV \u201cORFX\u201d encodes for a protein of 77\u201379 amino acid residues.", [["amino acid", "CHEMICAL", 83, 93], ["amino acid", "CHEMICAL", 83, 93], ["BTV", "ORGANISM", 41, 44], ["ORFX", "GENE_OR_GENE_PRODUCT", 46, 50], ["amino acid", "AMINO_ACID", 83, 93], ["BTV \u201cORFX\u201d", "DNA", 41, 51], ["BTV", "SPECIES", 41, 44], ["Bioinformatic analysis", "TEST", 0, 22], ["the BTV", "TEST", 37, 44], ["a protein", "TEST", 64, 73], ["amino acid residues", "TREATMENT", 83, 102]]], ["This putative ORFX is subject to functional constraints at the amino acid level and its level of conservation is higher compared to that of the overlapping VP6.", [["amino acid", "CHEMICAL", 63, 73], ["amino acid", "CHEMICAL", 63, 73], ["ORFX", "GENE_OR_GENE_PRODUCT", 14, 18], ["amino acid", "AMINO_ACID", 63, 73], ["VP6", "GENE_OR_GENE_PRODUCT", 156, 159], ["ORFX", "PROTEIN", 14, 18], ["VP6", "PROTEIN", 156, 159], ["the amino acid level", "TEST", 59, 79], ["higher", "OBSERVATION_MODIFIER", 113, 119]]], ["In addition, the ORFX putative AUG initiation codon has a strong Kozak context suggesting that this protein might be translated by leaky scanning [29].", [["ORFX", "GENE_OR_GENE_PRODUCT", 17, 21], ["ORFX putative AUG initiation codon", "DNA", 17, 51], ["this protein", "PROBLEM", 95, 107], ["leaky scanning", "TEST", 131, 145]]], ["Alternative reading frames are expressed in a variety of RNA viruses and they can play fundamental roles in viral replication and virus-host interaction.", [["Alternative reading frames", "PROBLEM", 0, 26], ["RNA viruses", "PROBLEM", 57, 68], ["viral replication", "TREATMENT", 108, 125], ["viral replication", "OBSERVATION", 108, 125]]], ["In this study, we identified a previously unknown non-structural protein and characterized its biological properties.Ethics statement ::: Materials and MethodsAll experimental procedures carried out in this study are included in protocol number 5182/2011 of the Istituto G. Caporale approved by the Italian Ministry of Health (Ministero della Salute) in accordance with Council Directive 86/609/EEC of the European Union and the Italian D.Igs 116/92.Cell cultures ::: Materials and MethodsBSR cells (a clone of BHK21, kindly provided by Karl K. Conzelmann) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS).", [["Cell cultures", "ANATOMY", 450, 463], ["MethodsBSR cells", "ANATOMY", 482, 498], ["clone", "ANATOMY", 502, 507], ["fetal bovine serum", "ANATOMY", 635, 653], ["FBS", "ANATOMY", 655, 658], ["Cell cultures", "CELL", 450, 463], ["MethodsBSR cells", "CELL", 482, 498], ["clone", "CELL", 502, 507], ["BHK21", "CELL", 511, 516], ["bovine", "ORGANISM", 641, 647], ["serum", "ORGANISM_SUBSTANCE", 648, 653], ["FBS", "ORGANISM_SUBSTANCE", 655, 658], ["non-structural protein", "PROTEIN", 50, 72], ["MethodsBSR cells", "CELL_LINE", 482, 498], ["BHK21", "CELL_LINE", 511, 516], ["bovine", "SPECIES", 641, 647], ["bovine", "SPECIES", 641, 647], ["this study", "TEST", 3, 13], ["All experimental procedures", "TEST", 159, 186], ["this study", "TEST", 202, 212], ["Cell cultures", "TEST", 450, 463], ["MethodsBSR cells", "PROBLEM", 482, 498], ["a clone of BHK21", "TREATMENT", 500, 516], ["10% fetal bovine serum (FBS", "TREATMENT", 631, 658]]], ["Bovine foetal aorta endothelium (BFAE) cells were obtained from the Health Protection Agency (HPA) cell culture collection (catalogue number 87022601), and were grown in Ham's F12 medium supplemented with 20% FBS.", [["foetal aorta endothelium", "ANATOMY", 7, 31], ["BFAE) cells", "ANATOMY", 33, 44], ["cell", "ANATOMY", 99, 103], ["FBS", "ANATOMY", 209, 212], ["Bovine", "ORGANISM", 0, 6], ["foetal aorta endothelium (BFAE) cells", "CELL", 7, 44], ["FBS", "ORGANISM_SUBSTANCE", 209, 212], ["Bovine foetal aorta endothelium (BFAE) cells", "CELL_LINE", 0, 44], ["Bovine", "SPECIES", 0, 6], ["Bovine", "SPECIES", 0, 6], ["Bovine foetal aorta endothelium (BFAE) cells", "PROBLEM", 0, 44], ["cell culture collection", "TEST", 99, 122], ["20% FBS", "TREATMENT", 205, 212], ["foetal aorta", "ANATOMY", 7, 19]]], ["CPT-Tert cells [30] are sheep choroid plexus cells immortalized with the simian virus 40 (SV40) T antigen and human telomerase reverse transcriptase (hTERT) and were kindly provided by David Griffiths.", [["CPT-Tert cells", "ANATOMY", 0, 14], ["choroid plexus cells", "ANATOMY", 30, 50], ["CPT-Tert cells", "CELL", 0, 14], ["sheep", "ORGANISM", 24, 29], ["choroid plexus cells", "CELL", 30, 50], ["simian virus 40", "ORGANISM", 73, 88], ["SV40", "ORGANISM", 90, 94], ["T antigen", "GENE_OR_GENE_PRODUCT", 96, 105], ["human", "ORGANISM", 110, 115], ["telomerase reverse transcriptase", "GENE_OR_GENE_PRODUCT", 116, 148], ["hTERT", "GENE_OR_GENE_PRODUCT", 150, 155], ["CPT-Tert cells", "CELL_LINE", 0, 14], ["sheep choroid plexus cells", "CELL_TYPE", 24, 50], ["simian virus 40 (SV40) T antigen", "PROTEIN", 73, 105], ["human telomerase reverse transcriptase", "PROTEIN", 110, 148], ["hTERT", "PROTEIN", 150, 155], ["sheep", "SPECIES", 24, 29], ["simian virus", "SPECIES", 73, 85], ["human", "SPECIES", 110, 115], ["sheep", "SPECIES", 24, 29], ["simian virus 40", "SPECIES", 73, 88], ["human", "SPECIES", 110, 115], ["CPT", "TEST", 0, 3], ["Tert cells", "PROBLEM", 4, 14], ["sheep choroid plexus cells", "TREATMENT", 24, 50], ["the simian virus", "TREATMENT", 69, 85], ["human telomerase reverse transcriptase (hTERT)", "TREATMENT", 110, 156], ["choroid plexus", "ANATOMY", 30, 44]]], ["CPT-Tert cells were grown in Iscove's modified Dulbecco's medium (IMDM), supplemented with 10% FBS.", [["CPT-Tert cells", "ANATOMY", 0, 14], ["CPT-Tert cells", "CELL", 0, 14], ["FBS", "ORGANISM_SUBSTANCE", 95, 98], ["CPT-Tert cells", "CELL_LINE", 0, 14], ["CPT", "TEST", 0, 3], ["Tert cells", "PROBLEM", 4, 14], ["10% FBS", "TREATMENT", 91, 98], ["Tert cells", "OBSERVATION", 4, 14]]], ["Mammalian cell lines were cultured at 35 to 37\u00b0C, in a 5% CO2 humidified atmosphere.", [["cell lines", "ANATOMY", 10, 20], ["CO2", "CHEMICAL", 58, 61], ["CO2", "CHEMICAL", 58, 61], ["Mammalian", "CELL", 0, 9], ["cell lines", "CELL", 10, 20], ["CO2", "SIMPLE_CHEMICAL", 58, 61], ["Mammalian cell lines", "CELL_LINE", 0, 20], ["Mammalian cell lines", "TREATMENT", 0, 20], ["a 5% CO2 humidified atmosphere", "TREATMENT", 53, 83], ["cell lines", "OBSERVATION", 10, 20]]], ["C6/36 cells are mosquitoes cells established from Aedes albopictus and were kindly provided by Richard Elliott.", [["C6/36 cells", "ANATOMY", 0, 11], ["cells", "ANATOMY", 27, 32], ["C6/36 cells", "CELL", 0, 11], ["mosquitoes cells", "CELL", 16, 32], ["Aedes albopictus", "ORGANISM", 50, 66], ["C6/36 cells", "CELL_LINE", 0, 11], ["mosquitoes cells", "CELL_TYPE", 16, 32], ["Aedes albopictus", "SPECIES", 50, 66], ["Aedes albopictus", "SPECIES", 50, 66], ["C6/36 cells", "PROBLEM", 0, 11], ["mosquitoes cells", "PROBLEM", 16, 32]]], ["C6/36 cells were grown in Leibovitz's L-15 medium supplemented with 10% FBS and 10% tryptose phosphate broth.", [["C6/36 cells", "ANATOMY", 0, 11], ["FBS", "ANATOMY", 72, 75], ["tryptose phosphate", "CHEMICAL", 84, 102], ["tryptose phosphate", "CHEMICAL", 84, 102], ["C6/36 cells", "CELL", 0, 11], ["FBS", "ORGANISM_SUBSTANCE", 72, 75], ["tryptose", "SIMPLE_CHEMICAL", 84, 92], ["C6/36 cells", "CELL_LINE", 0, 11], ["C6/36 cells", "TEST", 0, 11], ["Leibovitz", "TEST", 26, 35], ["10% FBS", "TREATMENT", 68, 75], ["10% tryptose phosphate broth", "TREATMENT", 80, 108]]], ["KC cells were grown in Schneider's insect medium and were supplemented with 10% FBS.", [["KC cells", "ANATOMY", 0, 8], ["FBS", "ANATOMY", 80, 83], ["KC cells", "CELL", 0, 8], ["FBS", "ORGANISM_SUBSTANCE", 80, 83], ["KC cells", "CELL_LINE", 0, 8], ["KC cells", "PROBLEM", 0, 8], ["10% FBS", "TREATMENT", 76, 83]]], ["Insect cells were incubated at 28\u00b0C.Plasmids and antisera ::: Materials and MethodsInitially, the open reading frame expressing ORFX (NS4) was amplified by PCR from BTV-10 (GenBank accession number D00509) and cloned into the pCI Mammalian Expression Vector (Promega) resulting into pCI-NS4.", [["cells", "ANATOMY", 7, 12], ["Insect cells", "CELL", 0, 12], ["ORFX", "GENE_OR_GENE_PRODUCT", 128, 132], ["NS4", "GENE_OR_GENE_PRODUCT", 134, 137], ["BTV-10", "ORGANISM", 165, 171], ["Promega", "GENE_OR_GENE_PRODUCT", 259, 266], ["pCI", "GENE_OR_GENE_PRODUCT", 283, 286], ["open reading frame", "DNA", 98, 116], ["ORFX", "DNA", 128, 132], ["NS4", "DNA", 134, 137], ["BTV-10", "DNA", 165, 171], ["pCI Mammalian Expression Vector", "DNA", 226, 257], ["pCI", "PROTEIN", 283, 286], ["NS4", "DNA", 287, 290], ["BTV-10", "SPECIES", 165, 171], ["Insect cells", "PROBLEM", 0, 12], ["MethodsInitially", "TREATMENT", 76, 92], ["BTV", "TEST", 165, 168], ["the pCI Mammalian Expression Vector (Promega)", "TREATMENT", 222, 267], ["pCI", "TEST", 283, 286]]], ["The BTV-8 NS4 was cloned into the peGFP-N1 vector (Clontech), resulting in plasmid pNS4-GFP. pNS47\u201377-GFP, pNS413\u201377-GFP and pNS419\u201377-GFP are mutants derived from pNS4-GFP expressing NS4 truncated of the amino terminal 6, 12 and 18 amino acid residues, respectively. pNS47\u201377-GFP, pNS413\u201377-GFP and pNS419\u201377-GFP maintain the methionine and valine residues in position 1 and 2 of NS4.", [["plasmid", "ANATOMY", 75, 82], ["amino acid", "CHEMICAL", 233, 243], ["methionine", "CHEMICAL", 327, 337], ["valine", "CHEMICAL", 342, 348], ["amino", "CHEMICAL", 205, 210], ["amino acid", "CHEMICAL", 233, 243], ["methionine", "CHEMICAL", 327, 337], ["valine", "CHEMICAL", 342, 348], ["BTV-8", "ORGANISM", 4, 9], ["NS4", "GENE_OR_GENE_PRODUCT", 10, 13], ["peGFP-N1", "GENE_OR_GENE_PRODUCT", 34, 42], ["Clontech", "GENE_OR_GENE_PRODUCT", 51, 59], ["pNS4-GFP", "GENE_OR_GENE_PRODUCT", 83, 91], ["pNS47\u201377", "GENE_OR_GENE_PRODUCT", 93, 101], ["GFP", "GENE_OR_GENE_PRODUCT", 102, 105], ["pNS413\u201377-GFP", "GENE_OR_GENE_PRODUCT", 107, 120], ["pNS419\u201377-GFP", "GENE_OR_GENE_PRODUCT", 125, 138], ["pNS4-GFP", "GENE_OR_GENE_PRODUCT", 164, 172], ["NS4", "GENE_OR_GENE_PRODUCT", 184, 187], ["amino terminal", "AMINO_ACID", 205, 219], ["amino acid", "AMINO_ACID", 233, 243], ["pNS47\u201377", "GENE_OR_GENE_PRODUCT", 268, 276], ["GFP", "GENE_OR_GENE_PRODUCT", 277, 280], ["pNS413\u201377-GFP", "GENE_OR_GENE_PRODUCT", 282, 295], ["pNS419\u201377-GFP", "GENE_OR_GENE_PRODUCT", 300, 313], ["methionine", "AMINO_ACID", 327, 337], ["valine", "AMINO_ACID", 342, 348], ["NS4", "GENE_OR_GENE_PRODUCT", 381, 384], ["BTV-8 NS4", "DNA", 4, 13], ["peGFP-N1 vector", "DNA", 34, 49], ["Clontech", "DNA", 51, 59], ["pNS4", "DNA", 83, 87], ["GFP", "DNA", 88, 91], ["pNS47\u201377-GFP, pNS413\u201377-GFP and pNS419\u201377", "DNA", 93, 134], ["GFP", "PROTEIN", 135, 138], ["pNS4", "PROTEIN", 164, 168], ["GFP", "PROTEIN", 169, 172], ["NS4", "PROTEIN", 184, 187], ["amino terminal 6, 12 and 18 amino acid residues", "PROTEIN", 205, 252], ["pNS47\u201377-GFP, pNS413\u201377-GFP and pNS419\u201377", "DNA", 268, 309], ["GFP", "PROTEIN", 310, 313], ["position 1 and 2", "PROTEIN", 361, 377], ["NS4", "PROTEIN", 381, 384], ["BTV-8 NS4", "SPECIES", 4, 13], ["The BTV", "TEST", 0, 7], ["NS4", "TREATMENT", 10, 13], ["plasmid pNS4", "TEST", 75, 87], ["GFP", "TEST", 102, 105], ["GFP", "TEST", 117, 120], ["pNS419", "TEST", 125, 131], ["GFP", "TEST", 135, 138], ["pNS4", "TEST", 164, 168], ["the amino terminal", "TEST", 201, 219], ["amino acid residues", "TEST", 233, 252], ["GFP", "TEST", 277, 280], ["GFP", "TEST", 292, 295], ["pNS419", "TEST", 300, 306], ["GFP", "TEST", 310, 313], ["the methionine", "TREATMENT", 323, 337], ["valine residues in position", "TREATMENT", 342, 369], ["NS4", "TREATMENT", 381, 384], ["acid residues", "OBSERVATION", 239, 252]]], ["Note that BTV-10 and BTV-1 NS4 are 100% identical at the amino acid level.", [["amino acid", "CHEMICAL", 57, 67], ["amino acid", "CHEMICAL", 57, 67], ["BTV-10", "ORGANISM", 10, 16], ["BTV-1 NS4", "ORGANISM", 21, 30], ["amino acid", "AMINO_ACID", 57, 67], ["BTV-1 NS4", "DNA", 21, 30], ["BTV-10", "SPECIES", 10, 16], ["BTV-1", "SPECIES", 21, 26], ["BTV", "TEST", 10, 13], ["BTV", "TEST", 21, 24], ["the amino acid level", "TEST", 53, 73]]], ["While BTV-8 and BTV-1 NS4 differ for a single amino acid residue in position 6.", [["amino acid", "CHEMICAL", 46, 56], ["amino acid", "CHEMICAL", 46, 56], ["BTV-8", "ORGANISM", 6, 11], ["BTV-1 NS4", "ORGANISM", 16, 25], ["amino acid", "AMINO_ACID", 46, 56], ["BTV-8 and BTV-1 NS4", "DNA", 6, 25], ["position 6", "PROTEIN", 68, 78], ["BTV-1", "SPECIES", 16, 21], ["BTV", "TEST", 6, 9], ["BTV", "TEST", 16, 19], ["a single amino acid residue", "TREATMENT", 37, 64], ["acid residue", "OBSERVATION", 52, 64]]], ["The set of BTV-1 and BTV-8 plasmids necessary to rescue these viruses in vitro by reverse genetics were obtained following the method recently published by Boyce and colleagues [26].", [["BTV-1", "ORGANISM", 11, 16], ["BTV-8", "ORGANISM", 21, 26], ["BTV-1 and BTV-8 plasmids", "DNA", 11, 35], ["BTV-1", "SPECIES", 11, 16], ["BTV", "TEST", 11, 14], ["BTV-8 plasmids", "TREATMENT", 21, 35]]], ["Briefly, total RNA was extracted from infected cells using Trizol (Invitrogen) according to the manufacturer's instructions.", [["cells", "ANATOMY", 47, 52], ["cells", "CELL", 47, 52], ["infected cells", "CELL_TYPE", 38, 52], ["total RNA", "PROBLEM", 9, 18], ["infected cells", "PROBLEM", 38, 52], ["Trizol (Invitrogen)", "TREATMENT", 59, 78], ["infected cells", "OBSERVATION", 38, 52]]], ["Each BTV genome segment was amplified by RT-PCR using the AccuScript PfuUltra II RT-PCR Kit (Agilent) from either BTV-1 or BTV-8 dsRNA preparations and the resulting PCR products were gel-purified (Qiagen) and cloned into either pUC57 (Fermentas) or pCI.", [["BTV", "ORGANISM", 5, 8], ["BTV-1", "ORGANISM", 114, 119], ["BTV", "ORGANISM", 123, 126], ["pUC57", "GENE_OR_GENE_PRODUCT", 229, 234], ["Fermentas", "GENE_OR_GENE_PRODUCT", 236, 245], ["BTV genome segment", "DNA", 5, 23], ["PCR products", "DNA", 166, 178], ["pUC57", "DNA", 229, 234], ["BTV", "SPECIES", 5, 8], ["BTV-1", "SPECIES", 114, 119], ["BTV", "SPECIES", 123, 126], ["Each BTV genome segment", "PROBLEM", 0, 23], ["RT", "TEST", 41, 43], ["PCR", "TEST", 44, 47], ["the AccuScript", "TEST", 54, 68], ["BTV", "TEST", 114, 117], ["BTV-8 dsRNA preparations", "TREATMENT", 123, 147], ["the resulting PCR products", "TREATMENT", 152, 178], ["pCI", "TREATMENT", 250, 253]]], ["Each BTV segment was cloned downstream of a T7 promoter and upstream of a BsaI or SapI restriction site.", [["BTV", "ORGANISM", 5, 8], ["BsaI", "GENE_OR_GENE_PRODUCT", 74, 78], ["BTV segment", "DNA", 5, 16], ["T7 promoter", "DNA", 44, 55], ["BsaI or SapI restriction site", "DNA", 74, 103], ["BTV", "SPECIES", 5, 8], ["Each BTV segment", "PROBLEM", 0, 16], ["a T7 promoter", "TREATMENT", 42, 55], ["a BsaI", "TREATMENT", 72, 78], ["SapI restriction site", "TREATMENT", 82, 103], ["T7", "ANATOMY", 44, 46]]], ["All of the mutants described in this study were obtained using the QuikChange II Site-Directed Mutagenesis Kit (Stratagene), according to the manufacturer's instructions.", [["this study", "TEST", 32, 42], ["the QuikChange II Site", "TREATMENT", 63, 85], ["Directed Mutagenesis Kit (Stratagene)", "TREATMENT", 86, 123]]], ["All plasmids used in this study were completely sequenced before use.", [["plasmids", "ANATOMY", 4, 12], ["plasmids", "DNA", 4, 12], ["All plasmids", "TREATMENT", 0, 12], ["this study", "TEST", 21, 31], ["plasmids", "OBSERVATION", 4, 12]]], ["Sequences of PCR primers used in this study are available upon request.", [["PCR primers", "DNA", 13, 24], ["PCR primers", "TEST", 13, 24], ["this study", "TEST", 33, 43]]], ["Antisera used in this study included polyclonal rabbit antisera raised against BTV VP7, NS1, NS2, NS3 and ORFX (NS4) expressed in bacteria as Glutathione S-transferase (GST)-tagged recombinant proteins (Proteintech Group, Inc.).", [["Glutathione", "CHEMICAL", 142, 153], ["Glutathione", "CHEMICAL", 142, 153], ["Antisera", "ORGANISM_SUBSTANCE", 0, 8], ["rabbit", "ORGANISM", 48, 54], ["BTV", "ORGANISM", 79, 82], ["VP7", "GENE_OR_GENE_PRODUCT", 83, 86], ["NS1", "GENE_OR_GENE_PRODUCT", 88, 91], ["NS2", "GENE_OR_GENE_PRODUCT", 93, 96], ["NS3", "GENE_OR_GENE_PRODUCT", 98, 101], ["ORFX", "GENE_OR_GENE_PRODUCT", 106, 110], ["NS4", "GENE_OR_GENE_PRODUCT", 112, 115], ["Glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 142, 167], ["GST", "GENE_OR_GENE_PRODUCT", 169, 172], ["BTV VP7", "PROTEIN", 79, 86], ["NS1", "PROTEIN", 88, 91], ["NS2", "PROTEIN", 93, 96], ["NS3", "PROTEIN", 98, 101], ["ORFX", "PROTEIN", 106, 110], ["NS4", "PROTEIN", 112, 115], ["Glutathione S-transferase (GST)-tagged recombinant proteins", "PROTEIN", 142, 201], ["rabbit", "SPECIES", 48, 54], ["rabbit", "SPECIES", 48, 54], ["BTV", "SPECIES", 79, 82], ["Antisera", "TREATMENT", 0, 8], ["this study", "TEST", 17, 27], ["polyclonal rabbit antisera", "TEST", 37, 63], ["BTV VP7", "TEST", 79, 86], ["NS1", "TEST", 88, 91], ["NS2", "TEST", 93, 96], ["NS3", "TEST", 98, 101], ["ORFX", "TEST", 106, 110], ["Glutathione S-transferase", "TEST", 142, 167], ["GST", "TEST", 169, 172], ["NS3", "ANATOMY", 98, 101]]], ["Antiserum against BTV-1 NS4 was raised against a recombinant GST fusion protein including the entire NS4 protein expressed in bacteria.", [["BTV-1 NS4", "CHEMICAL", 18, 27], ["Antiserum", "ORGANISM_SUBSTANCE", 0, 9], ["BTV-1", "ORGANISM", 18, 23], ["NS4", "ORGANISM", 24, 27], ["GST", "GENE_OR_GENE_PRODUCT", 61, 64], ["NS4", "GENE_OR_GENE_PRODUCT", 101, 104], ["BTV-1 NS4", "PROTEIN", 18, 27], ["recombinant GST fusion protein", "PROTEIN", 49, 79], ["NS4 protein", "PROTEIN", 101, 112], ["BTV-1", "SPECIES", 18, 23], ["Antiserum", "TREATMENT", 0, 9], ["BTV", "TEST", 18, 21], ["NS4", "TREATMENT", 24, 27], ["a recombinant GST fusion protein", "TREATMENT", 47, 79], ["the entire NS4 protein", "TEST", 90, 112], ["bacteria", "PROBLEM", 126, 134], ["bacteria", "OBSERVATION_MODIFIER", 126, 134]]], ["Polyclonal rabbit antiserum against BTV VP6 was kindly provided by Polly Roy as previously described [32].", [["rabbit", "ORGANISM", 11, 17], ["antiserum", "ORGANISM_SUBSTANCE", 18, 27], ["BTV", "ORGANISM", 36, 39], ["VP6", "ORGANISM", 40, 43], ["BTV VP6", "PROTEIN", 36, 43], ["rabbit", "SPECIES", 11, 17], ["rabbit", "SPECIES", 11, 17], ["BTV", "SPECIES", 36, 39], ["Polyclonal rabbit antiserum", "TREATMENT", 0, 27], ["BTV VP6", "TREATMENT", 36, 43]]], ["Antibodies against B23 and \u03b3-tubulin were obtained commercially (Sigma Aldrich).Viruses ::: Materials and MethodsBTV-8 (IAH reference collection number NET2006/04) was originally isolated from a naturally infected sheep during the 2006 outbreak in Northern Europe [33].", [["IAH", "DISEASE", 120, 123], ["B23", "GENE_OR_GENE_PRODUCT", 19, 22], ["\u03b3-tubulin", "GENE_OR_GENE_PRODUCT", 27, 36], ["Sigma Aldrich", "ORGANISM", 65, 78], ["MethodsBTV-8", "CELL", 106, 118], ["sheep", "ORGANISM", 214, 219], ["B23", "PROTEIN", 19, 22], ["\u03b3-tubulin", "PROTEIN", 27, 36], ["sheep", "SPECIES", 214, 219], ["sheep", "SPECIES", 214, 219], ["Antibodies", "TEST", 0, 10], ["B23", "PROBLEM", 19, 22], ["MethodsBTV", "TEST", 106, 116]]], ["The virus was passaged once in KC cells and once in BHK21 cells.", [["KC cells", "ANATOMY", 31, 39], ["BHK21 cells", "ANATOMY", 52, 63], ["KC cells", "CELL", 31, 39], ["BHK21 cells", "CELL", 52, 63], ["KC cells", "CELL_LINE", 31, 39], ["BHK21 cells", "CELL_LINE", 52, 63], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["BHK21 cells", "OBSERVATION", 52, 63]]], ["The reference strain of BTV-1 was originally isolated at the ARC \u2013 Onderstepoort Veterinary Institute (IAH reference collection number RSArrrr/01) and was adapted to cell culture by passaging it twice in embryonated eggs and 9 times in BHK21 cells.", [["cell culture", "ANATOMY", 166, 178], ["eggs", "ANATOMY", 216, 220], ["BHK21 cells", "ANATOMY", 236, 247], ["BTV-1", "ORGANISM", 24, 29], ["cell culture", "CELL", 166, 178], ["BHK21 cells", "CELL", 236, 247], ["BHK21 cells", "CELL_LINE", 236, 247], ["BTV-1", "SPECIES", 24, 29], ["BTV", "TEST", 24, 27], ["cell culture", "TEST", 166, 178]]], ["Both viruses were kindly provided by Peter Mertens.", [["Peter Mertens", "ORGANISM", 37, 50], ["viruses", "OBSERVATION", 5, 12]]], ["Virus stocks were prepared by infecting BSR cells at a multiplicity of infection (MOI) of 0.01 and collecting the supernatant when obvious cytpopathic effect (CPE) was observed.", [["BSR cells", "ANATOMY", 40, 49], ["supernatant", "ANATOMY", 114, 125], ["infection", "DISEASE", 71, 80], ["Virus", "ORGANISM", 0, 5], ["BSR cells", "CELL", 40, 49], ["BSR cells", "CELL_LINE", 40, 49], ["Virus stocks", "TREATMENT", 0, 12], ["infecting BSR cells", "PROBLEM", 30, 49], ["infection", "PROBLEM", 71, 80], ["obvious cytpopathic effect (CPE", "PROBLEM", 131, 162], ["BSR cells", "OBSERVATION", 40, 49], ["infection", "OBSERVATION", 71, 80]]], ["The supernatants were clarified by centrifugation at 500 g for 5 min and the resulting virus suspensions aliquoted and stored at 4\u00b0C for short term usage and at \u221270\u00b0C for long term storage.", [["supernatants", "ANATOMY", 4, 16], ["the resulting virus suspensions", "TREATMENT", 73, 104], ["long term storage", "TREATMENT", 171, 188], ["long term", "OBSERVATION_MODIFIER", 171, 180]]], ["Virus titres were determined by standard plaque assays using BSR or CPT-Tert cells [34].Sequence analysis ::: Materials and Methods65 full-length segment 9 sequences representing 24 BTV serotypes were obtained from GenBank.", [["plaque", "ANATOMY", 41, 47], ["CPT-Tert cells", "ANATOMY", 68, 82], ["Virus", "ORGANISM", 0, 5], ["CPT-Tert cells", "CELL", 68, 82], ["BTV", "ORGANISM", 182, 185], ["CPT-Tert cells", "CELL_LINE", 68, 82], ["Methods65 full-length segment 9 sequences", "DNA", 124, 165], ["BTV", "SPECIES", 182, 185], ["Virus titres", "PROBLEM", 0, 12], ["CPT", "TEST", 68, 71], ["Tert cells", "PROBLEM", 72, 82], ["Sequence analysis", "TEST", 88, 105], ["Methods65 full-length segment 9 sequences", "TREATMENT", 124, 165], ["24 BTV serotypes", "PROBLEM", 179, 195]]], ["Amino acid conservation plots and secondary structure predictions were obtained using the CLC Genomics Workbench (CLC, Aarhus, Denmark) software and bioinformatics tools available online (the PSIPRED server [http://bioinf.cs.ucl.ac.uk/psipred], and the Network Protein Sequence Analysis (nps@) server, [http://npsa-pbil.ibcp.fr/]).Reverse genetics ::: Materials and MethodsRecombinant BTVs were rescued by reverse genetics as previously described [26].", [["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["MethodsRecombinant BTVs", "DNA", 366, 389], ["Amino acid conservation plots", "TEST", 0, 29], ["secondary structure predictions", "PROBLEM", 34, 65], ["bioinformatics tools", "TEST", 149, 169], ["the Network Protein Sequence Analysis", "TEST", 249, 286], ["MethodsRecombinant BTVs", "TREATMENT", 366, 389]]], ["Briefly, plasmids containing the genomic segments of BTV-1 or BTV-8 or resulting mutants were linearized with the appropriate restriction enzymes and then purified by phenol-chloroform extraction.", [["plasmids", "ANATOMY", 9, 17], ["phenol-chloroform", "CHEMICAL", 167, 184], ["phenol", "CHEMICAL", 167, 173], ["chloroform", "CHEMICAL", 174, 184], ["BTV-1", "ORGANISM", 53, 58], ["BTV-8", "ORGANISM", 62, 67], ["phenol", "SIMPLE_CHEMICAL", 167, 173], ["chloroform", "SIMPLE_CHEMICAL", 174, 184], ["plasmids", "DNA", 9, 17], ["BTV-1 or BTV-8", "DNA", 53, 67], ["restriction enzymes", "PROTEIN", 126, 145], ["BTV-1", "SPECIES", 53, 58], ["plasmids", "TREATMENT", 9, 17], ["BTV", "TEST", 53, 56], ["BTV", "TEST", 62, 65], ["resulting mutants", "PROBLEM", 71, 88], ["the appropriate restriction enzymes", "TEST", 110, 145], ["phenol-chloroform extraction", "TREATMENT", 167, 195], ["segments", "OBSERVATION_MODIFIER", 41, 49]]], ["Digested plasmids were used as a template for in vitro transcription using the mMESSAGE mMACHINE T7 Ultra Kit (Ambion), according to the manufacturer's instructions. ssRNAs were purified sequentially by phenol/chloroform extraction and through Illustra Microspin G25 columns (GE Healthcare Life Sciences), following the manufacturer's protocol.", [["plasmids", "ANATOMY", 9, 17], ["phenol/chloroform", "CHEMICAL", 203, 220], ["phenol", "CHEMICAL", 203, 209], ["chloroform", "CHEMICAL", 210, 220], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 166, 172], ["phenol", "SIMPLE_CHEMICAL", 203, 209], ["chloroform", "SIMPLE_CHEMICAL", 210, 220], ["Digested plasmids", "DNA", 0, 17], ["Digested plasmids", "TREATMENT", 0, 17], ["vitro transcription", "TREATMENT", 49, 68], ["the mMESSAGE mMACHINE T7 Ultra Kit (Ambion)", "TREATMENT", 75, 118], ["ssRNAs", "TREATMENT", 166, 172], ["phenol/chloroform extraction", "TREATMENT", 203, 231], ["the manufacturer's protocol", "TREATMENT", 316, 343], ["plasmids", "OBSERVATION", 9, 17]]], ["Monolayers of 95% confluent BSR cells grown in 12 well plates were transfected twice with BTV RNAs using Lipofectamine 2000 (Invitrogen).", [["Monolayers", "ANATOMY", 0, 10], ["BSR cells", "ANATOMY", 28, 37], ["Lipofectamine 2000", "CHEMICAL", 105, 123], ["Monolayers", "CELL", 0, 10], ["BSR cells", "CELL", 28, 37], ["BTV", "ORGANISM", 90, 93], ["BSR cells", "CELL_LINE", 28, 37], ["BTV RNAs", "RNA", 90, 98], ["BTV", "SPECIES", 90, 93], ["Monolayers", "TEST", 0, 10], ["confluent BSR cells", "TEST", 18, 37], ["BTV RNAs", "TREATMENT", 90, 98], ["Lipofectamine", "TREATMENT", 105, 118], ["confluent", "OBSERVATION_MODIFIER", 18, 27], ["BSR cells", "OBSERVATION", 28, 37]]], ["Firstly, 0.5\u00d71011 (BTV-1) or 1\u00d71011 (BTV-8) molecules of each of the BTV segments encoding VP1, VP3, VP4, NS1, VP6 and NS2 were diluted in Opti-MEM I Reduced Serum Medium containing 0.5 U/\u00b5L of RNAsin plus (Promega) and then mixed with Lipofectamine 2000 diluted in Opti-MEM I Reduced Serum Medium.", [["RNAsin", "CHEMICAL", 194, 200], ["BTV", "ORGANISM", 69, 72], ["VP1", "GENE_OR_GENE_PRODUCT", 91, 94], ["VP3", "GENE_OR_GENE_PRODUCT", 96, 99], ["VP4", "GENE_OR_GENE_PRODUCT", 101, 104], ["NS1", "GENE_OR_GENE_PRODUCT", 106, 109], ["VP6", "GENE_OR_GENE_PRODUCT", 111, 114], ["NS2", "GENE_OR_GENE_PRODUCT", 119, 122], ["Serum", "ORGANISM_SUBSTANCE", 158, 163], ["RNAsin", "SIMPLE_CHEMICAL", 194, 200], ["Serum", "ORGANISM_SUBSTANCE", 285, 290], ["1\u00d71011 (BTV-8) molecules", "PROTEIN", 29, 53], ["BTV segments", "DNA", 69, 81], ["VP1", "PROTEIN", 91, 94], ["VP3", "PROTEIN", 96, 99], ["VP4", "PROTEIN", 101, 104], ["NS1", "PROTEIN", 106, 109], ["VP6", "PROTEIN", 111, 114], ["NS2", "PROTEIN", 119, 122], ["Opti-MEM I", "PROTEIN", 266, 276], ["BTV", "SPECIES", 69, 72], ["BTV", "TEST", 19, 22], ["BTV", "TEST", 37, 40], ["VP1", "TEST", 91, 94], ["VP3", "TEST", 96, 99], ["VP4", "TEST", 101, 104], ["NS1", "TEST", 106, 109], ["VP6", "TEST", 111, 114], ["NS2", "TEST", 119, 122], ["Serum Medium", "TEST", 158, 170], ["RNAsin plus (Promega)", "TREATMENT", 194, 215], ["Lipofectamine", "TREATMENT", 236, 249], ["BTV segments", "ANATOMY", 69, 81], ["Serum Medium", "OBSERVATION_MODIFIER", 285, 297]]], ["After 25 min of incubation at room temperature, the mixture was added to the cells.", [["cells", "ANATOMY", 77, 82], ["cells", "CELL", 77, 82], ["the mixture", "TREATMENT", 48, 59]]], ["16 to 18 h after the first transfection, the cells were transfected as before but with all 10 BTV segments.", [["cells", "ANATOMY", 45, 50], ["cells", "CELL", 45, 50], ["BTV", "SPECIES", 94, 97]]], ["3 to 4 h after the second transfection the cells were overlaid with 2 ml of minimal essential media containing 1.5% agarose type VII and 2% FBS, and monitored for development of plaques.", [["cells", "ANATOMY", 43, 48], ["FBS", "ANATOMY", 140, 143], ["plaques", "ANATOMY", 178, 185], ["plaques", "DISEASE", 178, 185], ["cells", "CELL", 43, 48], ["FBS", "ORGANISM_SUBSTANCE", 140, 143], ["plaques", "PATHOLOGICAL_FORMATION", 178, 185], ["the second transfection the cells", "TREATMENT", 15, 48], ["minimal essential media", "TREATMENT", 76, 99], ["2% FBS", "TEST", 137, 143], ["plaques", "PROBLEM", 178, 185], ["plaques", "OBSERVATION", 178, 185]]], ["Finally, individual BTV rescued clones were picked through the agarose overlay and used to infect fresh BSR cells in order to obtain a virus stock.", [["clones", "ANATOMY", 32, 38], ["BSR cells", "ANATOMY", 104, 113], ["BTV", "ORGANISM", 20, 23], ["clones", "CELL", 32, 38], ["agarose", "SIMPLE_CHEMICAL", 63, 70], ["BSR cells", "CELL", 104, 113], ["BTV rescued clones", "CELL_LINE", 20, 38], ["BSR cells", "CELL_LINE", 104, 113], ["BTV", "SPECIES", 20, 23], ["individual BTV rescued clones", "PROBLEM", 9, 38], ["the agarose overlay", "TREATMENT", 59, 78], ["a virus stock", "TREATMENT", 133, 146]]], ["Where necessary, BTV dsRNA was extracted from infected cells using Trizol (Invitrogen).", [["cells", "ANATOMY", 55, 60], ["BTV", "ORGANISM", 17, 20], ["cells", "CELL", 55, 60], ["BTV dsRNA", "DNA", 17, 26], ["infected cells", "CELL_TYPE", 46, 60], ["BTV", "SPECIES", 17, 20], ["BTV dsRNA", "PROBLEM", 17, 26], ["infected cells", "PROBLEM", 46, 60], ["Trizol (Invitrogen", "TREATMENT", 67, 85], ["BTV dsRNA", "OBSERVATION", 17, 26], ["infected cells", "OBSERVATION", 46, 60]]], ["The ssRNA fraction was precipitated using lithium chloride, and the harvested dsRNA fraction was precipitated using isopropanol in the presence of sodium acetate.Virus growth curves ::: Materials and MethodsGrowth curves of BTV recombinant viruses used in this study were derived in cells infected at a MOI of 0.05 and testing for the presence of infectious virus in supernatants collected at 8, 24, 48, 72 and 96 h post-infection.", [["cells", "ANATOMY", 283, 288], ["supernatants", "ANATOMY", 367, 379], ["lithium chloride", "CHEMICAL", 42, 58], ["isopropanol", "CHEMICAL", 116, 127], ["sodium acetate", "CHEMICAL", 147, 161], ["lithium chloride", "CHEMICAL", 42, 58], ["isopropanol", "CHEMICAL", 116, 127], ["sodium acetate", "CHEMICAL", 147, 161], ["lithium chloride", "SIMPLE_CHEMICAL", 42, 58], ["isopropanol", "SIMPLE_CHEMICAL", 116, 127], ["sodium acetate", "SIMPLE_CHEMICAL", 147, 161], ["Virus", "ORGANISM", 162, 167], ["BTV", "ORGANISM", 224, 227], ["cells", "CELL", 283, 288], ["BTV", "SPECIES", 224, 227], ["The ssRNA fraction", "TEST", 0, 18], ["lithium chloride", "TREATMENT", 42, 58], ["the harvested dsRNA fraction", "PROBLEM", 64, 92], ["isopropanol", "TREATMENT", 116, 127], ["sodium acetate", "TREATMENT", 147, 161], ["Virus growth curves", "TEST", 162, 181], ["Materials", "TREATMENT", 186, 195], ["MethodsGrowth curves", "TEST", 200, 220], ["BTV recombinant viruses", "PROBLEM", 224, 247], ["this study", "TEST", 256, 266], ["a MOI", "TEST", 301, 306], ["testing", "TEST", 319, 326], ["infectious virus", "PROBLEM", 347, 363], ["ssRNA fraction", "OBSERVATION", 4, 18], ["dsRNA fraction", "OBSERVATION", 78, 92], ["infectious", "OBSERVATION", 347, 357]]], ["Virus growth was also assessed in cells in the presence of 1000 antiviral units/ml (AVU/ml) of interferon Tau (IFNT) or universal type I interferon (UIFN).", [["cells", "ANATOMY", 34, 39], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 34, 39], ["interferon Tau", "GENE_OR_GENE_PRODUCT", 95, 109], ["IFNT", "GENE_OR_GENE_PRODUCT", 111, 115], ["type I interferon", "GENE_OR_GENE_PRODUCT", 130, 147], ["UIFN", "GENE_OR_GENE_PRODUCT", 149, 153], ["interferon Tau", "PROTEIN", 95, 109], ["IFNT", "PROTEIN", 111, 115], ["type I interferon", "PROTEIN", 130, 147], ["UIFN", "PROTEIN", 149, 153], ["Virus growth", "TEST", 0, 12], ["interferon Tau (IFNT)", "TREATMENT", 95, 116], ["universal type I interferon", "TREATMENT", 120, 147]]], ["Recombinant ovine IFNT was kindly provided by Tom Spencer.", [["ovine", "ORGANISM", 12, 17], ["IFNT", "GENE_OR_GENE_PRODUCT", 18, 22], ["Recombinant ovine IFNT", "PROTEIN", 0, 22], ["Recombinant ovine IFNT", "TREATMENT", 0, 22]]], ["IFNT was produced in Pichia pastoris and purified as described previously [35].", [["IFNT", "CHEMICAL", 0, 4], ["IFNT", "GENE_OR_GENE_PRODUCT", 0, 4], ["Pichia pastoris", "ORGANISM", 21, 36], ["IFNT", "PROTEIN", 0, 4], ["Pichia pastoris", "SPECIES", 21, 36], ["Pichia pastoris", "SPECIES", 21, 36], ["Pichia pastoris", "OBSERVATION", 21, 36]]], ["Universal type I Interferon (UIFN) was obtained from PBL InterferonSource.", [["type I Interferon", "GENE_OR_GENE_PRODUCT", 10, 27], ["UIFN", "GENE_OR_GENE_PRODUCT", 29, 33], ["type I Interferon", "PROTEIN", 10, 27], ["UIFN", "PROTEIN", 29, 33], ["PBL", "CELL_TYPE", 53, 56], ["Universal type I Interferon (UIFN)", "TREATMENT", 0, 34]]], ["BFAE cells and CPT-Tert cells were treated with 1000 AVU of IFN 20 h prior infection with BTV recombinants at a MOI of 0.1 (BFAE and CPT-Tert), 0.01 or 0.001 (CPT-Tert).", [["BFAE cells", "ANATOMY", 0, 10], ["CPT-Tert cells", "ANATOMY", 15, 29], ["IFN", "CHEMICAL", 60, 63], ["infection", "DISEASE", 75, 84], ["BFAE cells", "CELL", 0, 10], ["CPT-Tert cells", "CELL", 15, 29], ["BTV", "ORGANISM", 90, 93], ["BFAE cells", "CELL_LINE", 0, 10], ["CPT-Tert cells", "CELL_LINE", 15, 29], ["IFN", "PROTEIN", 60, 63], ["BTV", "SPECIES", 90, 93], ["BFAE cells", "PROBLEM", 0, 10], ["CPT", "TEST", 15, 18], ["Tert cells", "PROBLEM", 19, 29], ["IFN", "TREATMENT", 60, 63], ["prior infection", "PROBLEM", 69, 84], ["BTV recombinants", "TREATMENT", 90, 106], ["a MOI", "TEST", 110, 115], ["BFAE", "TEST", 124, 128], ["CPT", "TEST", 133, 136], ["Tert cells", "OBSERVATION", 19, 29]]], ["Two hours after infection, the medium was replaced and the cells maintained in the presence of either IFNT or UIFN at the original concentration.", [["cells", "ANATOMY", 59, 64], ["infection", "DISEASE", 16, 25], ["IFNT", "CHEMICAL", 102, 106], ["UIFN", "CHEMICAL", 110, 114], ["IFNT", "CHEMICAL", 102, 106], ["UIFN", "CHEMICAL", 110, 114], ["cells", "CELL", 59, 64], ["IFNT", "SIMPLE_CHEMICAL", 102, 106], ["UIFN", "SIMPLE_CHEMICAL", 110, 114], ["IFNT", "PROTEIN", 102, 106], ["infection", "PROBLEM", 16, 25], ["the cells", "TREATMENT", 55, 64], ["infection", "OBSERVATION", 16, 25]]], ["Cell supernatants were collected at 24, 48 and 72 h post-infection, centrifuged for 5 min at 500 g in order to pellet cell debris and virus infectivity was subsequently titrated by endpoint dilution analysis on BSR cells.", [["Cell supernatants", "ANATOMY", 0, 17], ["cell", "ANATOMY", 118, 122], ["BSR cells", "ANATOMY", 211, 220], ["infection", "DISEASE", 57, 66], ["Cell", "CELL", 0, 4], ["cell debris", "CELL", 118, 129], ["BSR cells", "CELL", 211, 220], ["BSR cells", "CELL_LINE", 211, 220], ["Cell supernatants", "TEST", 0, 17], ["infection", "PROBLEM", 57, 66], ["pellet cell debris", "PROBLEM", 111, 129], ["virus infectivity", "PROBLEM", 134, 151], ["endpoint dilution analysis", "TEST", 181, 207], ["BSR cells", "TREATMENT", 211, 220], ["infection", "OBSERVATION", 57, 66], ["pellet cell debris", "OBSERVATION", 111, 129]]], ["Viral titers were calculated by the method of Reed & Muench and expressed as log10 TCID50/ml [36].", [["Viral", "ORGANISM", 0, 5], ["Viral titers", "TEST", 0, 12]]], ["Each experiment was performed two to three times, each time in duplicate, using different stocks for each virus.Interferon protection assay ::: Materials and MethodsCPT-Tert cells were plated in 24-well plates and treated for 20 h with 1000 AVU/ml of IFNT or UIFN and then infected with either BTV-1 or BTV-8 at different MOIs (0.1, 0.01 and 0.001).", [["MethodsCPT-Tert cells", "ANATOMY", 158, 179], ["IFNT", "CHEMICAL", 251, 255], ["UIFN", "CHEMICAL", 259, 263], ["Interferon", "GENE_OR_GENE_PRODUCT", 112, 122], ["MethodsCPT-Tert cells", "CELL", 158, 179], ["IFNT", "SIMPLE_CHEMICAL", 251, 255], ["UIFN", "SIMPLE_CHEMICAL", 259, 263], ["BTV-1", "ORGANISM", 294, 299], ["BTV-8", "ORGANISM", 303, 308], ["Interferon", "PROTEIN", 112, 122], ["MethodsCPT-Tert cells", "CELL_LINE", 158, 179], ["BTV-1", "SPECIES", 294, 299], ["each virus", "PROBLEM", 101, 111], ["Interferon protection", "TREATMENT", 112, 133], ["Materials", "TREATMENT", 144, 153], ["MethodsCPT-Tert cells", "TREATMENT", 158, 179], ["IFNT", "TREATMENT", 251, 255], ["UIFN", "TREATMENT", 259, 263], ["BTV", "TEST", 294, 297], ["BTV", "TEST", 303, 306], ["Tert cells", "OBSERVATION", 169, 179], ["infected", "OBSERVATION", 273, 281]]], ["The medium was replaced 2 h after infection and the cells maintained in the presence of either IFNT or UIFN at the original concentration.", [["cells", "ANATOMY", 52, 57], ["infection", "DISEASE", 34, 43], ["IFNT", "CHEMICAL", 95, 99], ["UIFN", "CHEMICAL", 103, 107], ["IFNT", "CHEMICAL", 95, 99], ["UIFN", "CHEMICAL", 103, 107], ["cells", "CELL", 52, 57], ["IFNT", "SIMPLE_CHEMICAL", 95, 99], ["UIFN", "SIMPLE_CHEMICAL", 103, 107], ["IFNT", "PROTEIN", 95, 99], ["infection", "PROBLEM", 34, 43], ["the cells", "PROBLEM", 48, 57], ["medium", "OBSERVATION_MODIFIER", 4, 10], ["infection", "OBSERVATION", 34, 43]]], ["At 72 h post-infection, the cells were washed once with phosphate buffered saline (PBS; pH 7.4) and stained for 16 h using a 0.5% crystal violet/10% formaldehyde solution.", [["cells", "ANATOMY", 28, 33], ["phosphate", "CHEMICAL", 56, 65], ["formaldehyde", "CHEMICAL", 149, 161], ["phosphate", "CHEMICAL", 56, 65], ["formaldehyde", "CHEMICAL", 149, 161], ["cells", "CELL", 28, 33], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 56, 81], ["formaldehyde", "SIMPLE_CHEMICAL", 149, 161], ["infection", "PROBLEM", 13, 22], ["the cells", "PROBLEM", 24, 33], ["phosphate buffered saline (PBS", "TREATMENT", 56, 86], ["pH", "TEST", 88, 90], ["a 0.5% crystal violet", "TREATMENT", 123, 144], ["10% formaldehyde solution", "TREATMENT", 145, 170], ["infection", "OBSERVATION", 13, 22]]], ["We used Image-Pro Plus (MediaCybernetics), in order to quantify in each well the percentage of the monolayer that was disrupted after BTV replication.", [["monolayer", "ANATOMY", 99, 108], ["monolayer", "CELL", 99, 108], ["BTV", "ORGANISM", 134, 137], ["BTV", "SPECIES", 134, 137], ["Image-Pro Plus (MediaCybernetics)", "TREATMENT", 8, 41], ["BTV replication", "TREATMENT", 134, 149]]], ["Results were expressed as the percentage of destroyed monolayer by calculating for each well the following formula: (number of pixels above background: total number of pixels times) X 100.Transfections ::: Materials and MethodsBSR cells were transfected with 0.6\u20131.8 \u00b5g of either pCI-NS4, pNS4-GFP or derived deletion mutants, using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.Western blotting ::: Materials and MethodsFor western blot analyses of intracellular proteins, cells were lysed by standard techniques as described previously [37].", [["monolayer", "ANATOMY", 54, 63], ["MethodsBSR cells", "ANATOMY", 220, 236], ["intracellular", "ANATOMY", 481, 494], ["cells", "ANATOMY", 505, 510], ["Lipofectamine 2000", "CHEMICAL", 333, 351], ["monolayer", "CELL", 54, 63], ["MethodsBSR cells", "CELL", 220, 236], ["pCI-NS4", "SIMPLE_CHEMICAL", 280, 287], ["pNS4-GFP", "GENE_OR_GENE_PRODUCT", 289, 297], ["Invitrogen", "SIMPLE_CHEMICAL", 353, 363], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 481, 494], ["cells", "CELL", 505, 510], ["MethodsBSR cells", "CELL_LINE", 220, 236], ["pCI-NS4, pNS4-GFP or derived deletion mutants", "DNA", 280, 325], ["intracellular proteins", "PROTEIN", 481, 503], ["MethodsBSR cells", "TEST", 220, 236], ["pCI", "TEST", 280, 283], ["NS4", "TEST", 284, 287], ["pNS4", "TEST", 289, 293], ["derived deletion mutants", "PROBLEM", 301, 325], ["Lipofectamine", "TREATMENT", 333, 346], ["Invitrogen", "TREATMENT", 353, 363], ["western blot analyses", "TEST", 456, 477], ["intracellular proteins", "PROBLEM", 481, 503]]], ["For viral pellet analysis, cell supernatants were collected and viral particles concentrated 200 times by ultracentrifugation as previously described [38].", [["cell supernatants", "ANATOMY", 27, 44], ["cell", "CELL", 27, 31], ["viral pellet analysis", "TEST", 4, 25], ["cell supernatants", "TREATMENT", 27, 44], ["viral particles", "TREATMENT", 64, 79]]], ["Protein expression was assessed by sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting using the various antisera as indicated above.", [["sodium-dodecyl-sulfate", "CHEMICAL", 35, 57], ["sodium-dodecyl-sulfate polyacrylamide", "CHEMICAL", 35, 72], ["sodium-dodecyl-sulfate polyacrylamide", "SIMPLE_CHEMICAL", 35, 72], ["Protein expression", "TEST", 0, 18], ["sodium-dodecyl-sulfate polyacrylamide gel electrophoresis", "TREATMENT", 35, 92], ["the various antisera", "TREATMENT", 131, 151]]], ["Membranes were incubated with a horse radish peroxidase-conjugated secondary antibody (GE Healthcare Life Sciences) and developed by chemiluminescence using Amersham ECL Plus Western Blotting Detection Reagents (GE Healthcare Life Sciences).Confocal microscopy ::: Materials and MethodsExperiments were performed using BSR, BFAE, CPT-Tert or C6/36 cells cultured in two-well glass chamber slides (Lab-Tek, Nalge Nunc International).", [["Membranes", "ANATOMY", 0, 9], ["C6/36 cells", "ANATOMY", 342, 353], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["peroxidase", "GENE_OR_GENE_PRODUCT", 45, 55], ["CPT-Tert", "CELL", 330, 338], ["C6/36 cells", "CELL", 342, 353], ["horse radish peroxidase", "PROTEIN", 32, 55], ["BFAE, CPT-Tert or C6/36 cells", "CELL_LINE", 324, 353], ["horse", "SPECIES", 32, 37], ["radish", "SPECIES", 38, 44], ["horse radish", "SPECIES", 32, 44], ["a horse radish peroxidase", "TEST", 30, 55], ["Amersham ECL", "TREATMENT", 157, 169], ["Confocal microscopy", "TEST", 241, 260], ["MethodsExperiments", "TREATMENT", 279, 297], ["BSR", "TEST", 319, 322], ["BFAE", "TEST", 324, 328], ["CPT", "TEST", 330, 333], ["Tert or C6/36 cells", "TEST", 334, 353]]], ["Cells were either transfected with appropriate plasmids or infected with various BTV strains at a MOI between 0.01 and 1.5.", [["Cells", "ANATOMY", 0, 5], ["plasmids", "ANATOMY", 47, 55], ["Cells", "CELL", 0, 5], ["BTV", "ORGANISM", 81, 84], ["BTV", "SPECIES", 81, 84], ["appropriate plasmids", "TREATMENT", 35, 55], ["various BTV strains", "PROBLEM", 73, 92], ["a MOI", "TEST", 96, 101]]], ["Cells were washed with PBS and fixed with 5% formaldehyde for 15 minutes.", [["Cells", "ANATOMY", 0, 5], ["formaldehyde", "CHEMICAL", 45, 57], ["formaldehyde", "CHEMICAL", 45, 57], ["Cells", "CELL", 0, 5], ["formaldehyde", "SIMPLE_CHEMICAL", 45, 57], ["PBS", "TREATMENT", 23, 26], ["5% formaldehyde", "TREATMENT", 42, 57]]], ["The fixed cells were then processed as described previously [39] and incubated with the appropriate antisera.", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15], ["The fixed cells", "TREATMENT", 0, 15], ["fixed cells", "OBSERVATION", 4, 15]]], ["Secondary antibodies were conjugated with Alexa Fluor 488 (Invitrogen, Molecular Probes) or Alexa Fluor 594 (Invitrogen, Molecular Probes).", [["Alexa Fluor 488", "CHEMICAL", 42, 57], ["Alexa Fluor 594", "CHEMICAL", 92, 107], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 42, 57], ["Invitrogen", "SIMPLE_CHEMICAL", 59, 69], ["Alexa Fluor 594", "SIMPLE_CHEMICAL", 92, 107], ["antibodies", "PROTEIN", 10, 20], ["Alexa Fluor 488", "PROTEIN", 42, 57], ["Alexa Fluor 594", "PROTEIN", 92, 107], ["Alexa Fluor 594", "SPECIES", 92, 107], ["Secondary antibodies", "PROBLEM", 0, 20], ["Alexa Fluor", "TREATMENT", 42, 53], ["Invitrogen, Molecular Probes", "TREATMENT", 59, 87], ["Alexa Fluor", "TREATMENT", 92, 103]]], ["Slides were mounted using VECTASHIELD Mounting Medium with DAPI (4\u2032,6-diamidino-2-phenylindole, Vector Laboratories).", [["DAPI", "CHEMICAL", 59, 63], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 65, 94], ["DAPI", "CHEMICAL", 59, 63], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 65, 94], ["DAPI", "SIMPLE_CHEMICAL", 59, 63], ["4\u2032,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 65, 94], ["DAPI", "TEST", 59, 63], ["diamidino", "TREATMENT", 70, 79]]], ["Slides were analysed and images collected using a Leica TCS SP2 confocal microscope.Electron microscopy ::: Materials and MethodsBSR cells were infected with BTV-1, BTV-8 or the corresponding deletion mutants at a MOI of 0.05 in 35 mm dishes.", [["MethodsBSR cells", "ANATOMY", 122, 138], ["MethodsBSR cells", "CELL", 122, 138], ["BTV-1", "ORGANISM", 158, 163], ["BTV-8", "ORGANISM", 165, 170], ["MethodsBSR cells", "CELL_LINE", 122, 138], ["deletion mutants", "DNA", 192, 208], ["BTV-1", "SPECIES", 158, 163], ["images", "TEST", 25, 31], ["Electron microscopy", "TEST", 84, 103], ["MethodsBSR cells", "PROBLEM", 122, 138], ["BTV", "TEST", 158, 161], ["BTV", "TEST", 165, 168], ["the corresponding deletion mutants", "PROBLEM", 174, 208], ["a MOI", "TEST", 212, 217]]], ["At 24 h post-infection, cells were fixed using cold 2.5% gluteraldehyde and 1% osmium tetroxide.", [["cells", "ANATOMY", 24, 29], ["infection", "DISEASE", 13, 22], ["gluteraldehyde", "CHEMICAL", 57, 71], ["osmium tetroxide", "CHEMICAL", 79, 95], ["gluteraldehyde", "CHEMICAL", 57, 71], ["osmium tetroxide", "CHEMICAL", 79, 95], ["cells", "CELL", 24, 29], ["gluteraldehyde", "SIMPLE_CHEMICAL", 57, 71], ["osmium tetroxide", "SIMPLE_CHEMICAL", 79, 95], ["infection", "PROBLEM", 13, 22], ["cells", "PROBLEM", 24, 29], ["cold 2.5% gluteraldehyde", "TREATMENT", 47, 71], ["1% osmium tetroxide", "TREATMENT", 76, 95], ["infection", "OBSERVATION", 13, 22]]], ["Cells were subsequently pelleted through 1% SeaPlaque agarose (Flowgen), dehydrated using a graded alcohol series and embedded in Epon 812 resin, followed by cutting and analysis in a Joel 1200 EX II electron microscope.", [["Cells", "ANATOMY", 0, 5], ["alcohol", "CHEMICAL", 99, 106], ["alcohol", "CHEMICAL", 99, 106], ["Epon 812", "CHEMICAL", 130, 138], ["Cells", "CELL", 0, 5], ["agarose", "SIMPLE_CHEMICAL", 54, 61], ["Flowgen", "SIMPLE_CHEMICAL", 63, 70], ["alcohol", "SIMPLE_CHEMICAL", 99, 106], ["Cells", "TEST", 0, 5], ["1% SeaPlaque agarose", "TREATMENT", 41, 61], ["a graded alcohol series", "TREATMENT", 90, 113]]]], "PMC7330535": [["Phase 1 (semi-urgent cases) of the COVID-19 ::: Thoracic surgery triage during pandemicHere, the hospital resources are not exhausted, COVID trajectory is not in a rapid escalation phase, and the tertiary center ICU vent capacity is still available.", [["Thoracic surgery", "TREATMENT", 48, 64], ["the tertiary center ICU vent capacity", "TREATMENT", 192, 229]]], ["Surgical services are offered for those where survival could be affected in the next few days if no intervention is performed (Table 1) [1].", [["intervention", "TREATMENT", 100, 112]]]], "874ded1a490a5118efb3fadc3198cfb383fb2f3a": [["IntroductionNoroviruses are the leading cause of foodborne illness in the U.S., accounting for >21 million infections per year and resulting in >70,000 hospitalizations and nearly 800 deaths [1e3] .", [["foodborne illness", "DISEASE", 49, 66], ["infections", "DISEASE", 107, 117], ["deaths", "DISEASE", 184, 190], ["Noroviruses", "GENE_OR_GENE_PRODUCT", 12, 23], ["IntroductionNoroviruses", "PROBLEM", 0, 23], ["foodborne illness", "PROBLEM", 49, 66], ["foodborne", "OBSERVATION", 49, 58]]], ["They are also the primary cause of sporadic and epidemic acute gastroenteritis worldwide [4e5] .", [["gastroenteritis", "DISEASE", 63, 78], ["sporadic and epidemic acute gastroenteritis", "PROBLEM", 35, 78], ["epidemic", "OBSERVATION_MODIFIER", 48, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["gastroenteritis", "OBSERVATION", 63, 78]]], ["The morbidity and mortality associated with norovirus infection impacts disproportionately the elderly, immunocompromised individuals [6] and, in developing countries, children [7] .", [["norovirus infection", "DISEASE", 44, 63], ["norovirus", "ORGANISM", 44, 53], ["children", "ORGANISM", 168, 176], ["children", "SPECIES", 168, 176], ["norovirus", "SPECIES", 44, 53], ["The morbidity", "PROBLEM", 0, 13], ["norovirus infection", "PROBLEM", 44, 63], ["morbidity", "OBSERVATION", 4, 13], ["norovirus", "OBSERVATION", 44, 53]]], ["Combating noroviruses presents a major challenge because noroviruses are highly contagious, genetically diverse, environmentally stable, display prolonged and profuse viral shedding, evolve rapidly, and are capable of spreading in many different ways [8e9] .", [["noroviruses", "DISEASE", 10, 21], ["noroviruses", "ORGANISM", 57, 68], ["noroviruses", "PROBLEM", 10, 21], ["noroviruses", "PROBLEM", 57, 68], ["prolonged and profuse viral shedding", "PROBLEM", 145, 181], ["prolonged", "OBSERVATION_MODIFIER", 145, 154], ["profuse", "OBSERVATION_MODIFIER", 159, 166], ["viral shedding", "OBSERVATION", 167, 181], ["rapidly", "OBSERVATION_MODIFIER", 190, 197]]], ["There are currently no effective vaccines or norovirus-specific antivirals for norovirus infection.", [["norovirus infection", "DISEASE", 79, 98], ["norovirus", "ORGANISM", 45, 54], ["norovirus", "ORGANISM", 79, 88], ["norovirus", "SPECIES", 45, 54], ["norovirus", "SPECIES", 79, 88], ["effective vaccines", "TREATMENT", 23, 41], ["norovirus", "PROBLEM", 45, 54], ["specific antivirals", "TREATMENT", 55, 74], ["norovirus infection", "PROBLEM", 79, 98], ["no", "UNCERTAINTY", 20, 22], ["effective", "OBSERVATION_MODIFIER", 23, 32], ["vaccines", "OBSERVATION", 33, 41], ["norovirus", "OBSERVATION", 45, 54]]], ["Consequently, there is a pressing need for the discovery and development of small molecule therapeutics for the treatment and prophylaxis of norovirus infection [10e13] .IntroductionNorovirus is an RNA virus that belongs to the Norovirus genus of the Caliciviridae family.", [["norovirus infection", "DISEASE", 141, 160], ["Norovirus", "DISEASE", 182, 191], ["norovirus", "ORGANISM", 141, 150], ["Norovirus", "ORGANISM", 182, 191], ["Norovirus genus", "ORGANISM", 228, 243], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 251, 264], ["small molecule therapeutics", "TREATMENT", 76, 103], ["the treatment", "TREATMENT", 108, 121], ["norovirus infection", "PROBLEM", 141, 160], ["IntroductionNorovirus", "PROBLEM", 170, 191], ["an RNA virus", "PROBLEM", 195, 207], ["small", "OBSERVATION_MODIFIER", 76, 81], ["Norovirus", "OBSERVATION", 182, 191]]], ["It carries a positive sense single stranded RNA genome (7.7 Kb) that consists of three open reading frames (ORF1-3).", [["positive sense single stranded RNA genome", "DNA", 13, 54], ["open reading frames", "DNA", 87, 106], ["ORF1", "DNA", 108, 112], ["a positive sense single stranded RNA genome", "PROBLEM", 11, 54], ["ORF1", "TEST", 108, 112], ["positive", "OBSERVATION_MODIFIER", 13, 21], ["stranded", "OBSERVATION_MODIFIER", 35, 43], ["RNA genome", "OBSERVATION", 44, 54]]], ["ORF1 encodes a 200 kDa precursor polyprotein which is processed by a virus-encoded cysteine endopeptidase to generate at least six mature non-structural proteins [14e16] .", [["cysteine", "CHEMICAL", 83, 91], ["ORF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["cysteine endopeptidase", "GENE_OR_GENE_PRODUCT", 83, 105], ["ORF1", "DNA", 0, 4], ["200 kDa precursor polyprotein", "PROTEIN", 15, 44], ["virus-encoded cysteine endopeptidase", "PROTEIN", 69, 105], ["mature non-structural proteins", "PROTEIN", 131, 161], ["14e16", "PROTEIN", 163, 168], ["a 200 kDa precursor polyprotein", "TREATMENT", 13, 44], ["a virus", "PROBLEM", 67, 74], ["encoded cysteine endopeptidase", "TREATMENT", 75, 105]]], ["Polyprotein processing by norovirus 3C-like protease (3CLpro) is vital for the replication of the virus, consequently, norovirus 3CLpro has emerged as an attractive target for the discovery and development of antiviral agents against norovirus infections [10e11,17] .IntroductionNorovirus 3CLpro is a chymotrypsin-like cysteine protease with an active site consisting of the catalytic triad of Cys139, His30 and Glu54 and located in a groove that is sandwiched between a bsheet domain and a b-barrel domain [17e21] .", [["Polyprotein", "CHEMICAL", 0, 11], ["3CLpro", "CHEMICAL", 129, 135], ["norovirus infections", "DISEASE", 234, 254], ["cysteine", "CHEMICAL", 319, 327], ["Cys139", "CHEMICAL", 394, 400], ["His30", "CHEMICAL", 402, 407], ["Glu54", "CHEMICAL", 412, 417], ["Polyprotein", "GENE_OR_GENE_PRODUCT", 0, 11], ["norovirus 3C-like protease", "GENE_OR_GENE_PRODUCT", 26, 52], ["3CLpro", "GENE_OR_GENE_PRODUCT", 54, 60], ["norovirus 3CLpro", "ORGANISM", 119, 135], ["norovirus", "ORGANISM", 234, 243], ["Norovirus 3CLpro", "ORGANISM", 279, 295], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 301, 313], ["Cys139", "GENE_OR_GENE_PRODUCT", 394, 400], ["His30", "AMINO_ACID", 402, 407], ["Glu54", "AMINO_ACID", 412, 417], ["Polyprotein", "PROTEIN", 0, 11], ["norovirus 3C-like protease", "PROTEIN", 26, 52], ["3CLpro", "PROTEIN", 54, 60], ["Norovirus 3CLpro", "PROTEIN", 279, 295], ["chymotrypsin-like cysteine protease", "PROTEIN", 301, 336], ["catalytic triad", "PROTEIN", 375, 390], ["Cys139", "PROTEIN", 394, 400], ["His30", "PROTEIN", 402, 407], ["Glu54", "PROTEIN", 412, 417], ["bsheet domain", "PROTEIN", 471, 484], ["b-barrel domain", "PROTEIN", 491, 506], ["17e21", "PROTEIN", 508, 513], ["norovirus 3CLpro", "SPECIES", 119, 135], ["Polyprotein processing", "TREATMENT", 0, 22], ["norovirus 3C", "TREATMENT", 26, 38], ["protease (3CLpro)", "TREATMENT", 44, 61], ["the virus", "PROBLEM", 94, 103], ["norovirus 3CLpro", "TREATMENT", 119, 135], ["antiviral agents", "TREATMENT", 209, 225], ["norovirus infections", "PROBLEM", 234, 254], ["IntroductionNorovirus 3CLpro", "TREATMENT", 267, 295], ["a chymotrypsin-like cysteine protease", "TREATMENT", 299, 336], ["groove", "ANATOMY_MODIFIER", 435, 441]]], ["The b-barrel domain accounts for most of the binding interactions involved between a peptide substrate and 3CLpro.", [["b-barrel domain", "PROTEIN", 4, 19], ["3CLpro", "PROTEIN", 107, 113], ["a peptide substrate", "TREATMENT", 83, 102], ["3CLpro", "TREATMENT", 107, 113]]], ["A hallmark of norovirus 3CLpro, as well as other related 3C or 3CL viral proteases, is that its primary substrate specificity is dictated by the presence of a P 1 glutamine (and less frequently glutamic acid), at the S 1 subsite [22] .", [["glutamine", "CHEMICAL", 163, 172], ["glutamic acid", "CHEMICAL", 194, 207], ["glutamine", "CHEMICAL", 163, 172], ["glutamic acid", "CHEMICAL", 194, 207], ["norovirus 3CLpro", "ORGANISM", 14, 30], ["3CL", "GENE_OR_GENE_PRODUCT", 63, 66], ["glutamine", "AMINO_ACID", 163, 172], ["glutamic acid", "AMINO_ACID", 194, 207], ["norovirus 3CLpro", "PROTEIN", 14, 30], ["3CL viral proteases", "PROTEIN", 63, 82], ["norovirus 3CLpro", "SPECIES", 14, 30], ["norovirus 3CLpro", "TREATMENT", 14, 30], ["3CL viral proteases", "TREATMENT", 63, 82], ["a P 1 glutamine", "TREATMENT", 157, 172], ["less frequently glutamic acid", "TREATMENT", 178, 207], ["norovirus", "OBSERVATION", 14, 23]]], ["Furthermore, previous studies involving the mapping of the substrate specificity of 3CLpro have revealed that the protease prefers small hydrophobic amino acids such as a leucine residue at P 2 and that the plasticity of its S 3 subsite allows the protease to accommodate His, Gln or Glu [16, 18, 19] .IntroductionIn continuing our studies in this area [12, 13, 17, 23] , we describe herein the structure-based design of cell-permeable macrocyclic transition state inhibitors (I) and (II) (Fig. 1 ) of norovirus 3CLpro [23, 24] , as well as relevant structural, biochemical, spectroscopic, and cell-based studies.Inhibitor designInspection of crystal structures of norovirus 3CLpro with peptidyl inhibitors reveals that peptidyl inhibitors of norovirus 3CLpro bind to the enzyme via a network of backbone hydrogen bonds that mimic an antiparallel b-sheet [25, 26] .", [["cell", "ANATOMY", 421, 425], ["cell", "ANATOMY", 594, 598], ["amino acids", "CHEMICAL", 149, 160], ["leucine", "CHEMICAL", 171, 178], ["Gln", "CHEMICAL", 277, 280], ["Glu", "CHEMICAL", 284, 287], ["3CLpro", "CHEMICAL", 753, 759], ["amino acids", "CHEMICAL", 149, 160], ["leucine", "CHEMICAL", 171, 178], ["His", "CHEMICAL", 272, 275], ["Gln", "CHEMICAL", 277, 280], ["Glu", "CHEMICAL", 284, 287], ["(II)", "CHEMICAL", 484, 488], ["hydrogen", "CHEMICAL", 805, 813], ["3CLpro", "GENE_OR_GENE_PRODUCT", 84, 90], ["amino acids", "AMINO_ACID", 149, 160], ["leucine", "AMINO_ACID", 171, 178], ["S 3", "GENE_OR_GENE_PRODUCT", 225, 228], ["His", "GENE_OR_GENE_PRODUCT", 272, 275], ["Gln", "AMINO_ACID", 277, 280], ["Glu", "AMINO_ACID", 284, 287], ["cell", "CELL", 421, 425], ["macrocyclic transition state inhibitors", "SIMPLE_CHEMICAL", 436, 475], ["norovirus", "ORGANISM", 502, 511], ["cell", "CELL", 594, 598], ["norovirus 3CLpro", "ORGANISM", 665, 681], ["peptidyl inhibitors", "SIMPLE_CHEMICAL", 687, 706], ["peptidyl inhibitors", "SIMPLE_CHEMICAL", 720, 739], ["norovirus 3CLpro", "ORGANISM", 743, 759], ["3CLpro", "PROTEIN", 84, 90], ["protease", "PROTEIN", 114, 122], ["P 2", "PROTEIN", 190, 193], ["S 3 subsite", "PROTEIN", 225, 236], ["protease", "PROTEIN", 248, 256], ["norovirus 3CLpro", "PROTEIN", 743, 759], ["enzyme", "PROTEIN", 772, 778], ["previous studies", "TEST", 13, 29], ["the mapping", "TEST", 40, 51], ["the protease", "TREATMENT", 110, 122], ["small hydrophobic amino acids", "TREATMENT", 131, 160], ["a leucine residue", "PROBLEM", 169, 186], ["the protease", "TREATMENT", 244, 256], ["our studies", "TEST", 328, 339], ["cell-permeable macrocyclic transition state inhibitors", "TREATMENT", 421, 475], ["norovirus 3CLpro", "TREATMENT", 502, 518], ["cell-based studies", "TEST", 594, 612], ["Inhibitor designInspection of crystal structures", "TREATMENT", 613, 661], ["norovirus 3CLpro", "TREATMENT", 665, 681], ["peptidyl inhibitors", "TREATMENT", 687, 706], ["peptidyl inhibitors", "TREATMENT", 720, 739], ["norovirus 3CLpro bind", "TREATMENT", 743, 764], ["the enzyme", "TEST", 768, 778], ["backbone hydrogen bonds", "TREATMENT", 796, 819], ["norovirus", "OBSERVATION", 665, 674]]], ["Among these hydrogen bonds, the backbone NH and carbonyl O of the Ala160 residue forms two hydrogen bonds with the backbone carbonyl O and NH of the P 3 residue of the inhibitor ( Fig. 2A) .", [["NH", "CHEMICAL", 41, 43], ["carbonyl O", "CHEMICAL", 48, 58], ["Ala160", "CHEMICAL", 66, 72], ["carbonyl O", "CHEMICAL", 124, 134], ["hydrogen", "CHEMICAL", 12, 20], ["NH", "CHEMICAL", 41, 43], ["carbonyl", "CHEMICAL", 48, 56], ["O", "CHEMICAL", 57, 58], ["Ala160", "CHEMICAL", 66, 72], ["hydrogen", "CHEMICAL", 91, 99], ["carbonyl", "CHEMICAL", 124, 132], ["O", "CHEMICAL", 133, 134], ["NH", "CHEMICAL", 139, 141], ["backbone NH", "SIMPLE_CHEMICAL", 32, 43], ["carbonyl O", "SIMPLE_CHEMICAL", 48, 58], ["Ala160", "AMINO_ACID", 66, 72], ["backbone carbonyl O", "SIMPLE_CHEMICAL", 115, 134], ["the backbone NH", "TREATMENT", 28, 43], ["the Ala160 residue", "TREATMENT", 62, 80], ["the backbone carbonyl O", "TREATMENT", 111, 134], ["the inhibitor", "TREATMENT", 164, 177], ["hydrogen bonds", "OBSERVATION", 12, 26], ["hydrogen bonds", "OBSERVATION", 91, 105]]], ["In addition, a third hydrogen bond exists between the backbone O of the Ala158 residue and the backbone NH of the P 1 residue of the inhibitor.", [["hydrogen", "CHEMICAL", 21, 29], ["O", "CHEMICAL", 63, 64], ["Ala158", "CHEMICAL", 72, 78], ["NH", "CHEMICAL", 104, 106], ["Ala158", "AMINO_ACID", 72, 78], ["P 1 residue", "PROTEIN", 114, 125], ["a third hydrogen bond", "PROBLEM", 13, 34], ["the Ala158 residue", "TREATMENT", 68, 86], ["the inhibitor", "TREATMENT", 129, 142]]], ["This hydrogen bonding arrangement resembles the hydrogen bonding pattern found in antiparallel b-sheets and serves to correctly orient and position the inhibitor (or substrate) backbone to the active site.Inhibitor designThe hydrogen bonding associated with an antiparallel b-sheet is more feasible when an inhibitor (or substrate) binds to the active site of a protease in a b-strand conformation, the extended \"saw tooth\" conformation of a peptide (f \u00bc \u00c0120 \u00b1 20 0 and j \u00bc \u00fe120 \u00b1 20 0 ) where the backbone NHs are exposed to the environment [27] .", [["tooth", "ANATOMY", 417, 422], ["hydrogen", "CHEMICAL", 225, 233], ["hydrogen", "CHEMICAL", 5, 13], ["hydrogen", "CHEMICAL", 48, 56], ["hydrogen", "CHEMICAL", 225, 233], ["hydrogen", "SIMPLE_CHEMICAL", 225, 233], ["antiparallel b-sheets", "PROTEIN", 82, 103], ["protease", "PROTEIN", 362, 370], ["This hydrogen bonding arrangement", "TREATMENT", 0, 33], ["the hydrogen bonding pattern", "PROBLEM", 44, 72], ["antiparallel b-sheets", "TREATMENT", 82, 103], ["the inhibitor", "TREATMENT", 148, 161], ["substrate) backbone", "TREATMENT", 166, 185], ["Inhibitor designThe hydrogen bonding", "TREATMENT", 205, 241], ["an antiparallel b-sheet", "TREATMENT", 258, 281], ["an inhibitor", "TREATMENT", 304, 316], ["a protease", "PROBLEM", 360, 370], ["a peptide", "TEST", 440, 449], ["hydrogen bonding", "OBSERVATION", 48, 64], ["active site", "OBSERVATION", 193, 204], ["hydrogen bonding", "OBSERVATION", 225, 241]]], ["As a consequence, the aforementioned binding mode permits proteases to universally recognize their ligands in the b-strand conformation [25, 26] .Inhibitor designBased on the forgoing, we recently reported the results of preliminary studies related to the design of triazole-based macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus and coronavirus [24] .", [["triazole", "CHEMICAL", 266, 274], ["triazole", "CHEMICAL", 266, 274], ["triazole", "SIMPLE_CHEMICAL", 266, 274], ["3C", "SIMPLE_CHEMICAL", 307, 309], ["3C", "GENE_OR_GENE_PRODUCT", 314, 316], ["picornavirus", "ORGANISM", 335, 347], ["norovirus", "ORGANISM", 349, 358], ["coronavirus", "ORGANISM", 363, 374], ["proteases", "PROTEIN", 58, 67], ["3C and 3C-like proteases", "PROTEIN", 307, 331], ["coronavirus", "SPECIES", 363, 374], ["Inhibitor", "TREATMENT", 146, 155], ["preliminary studies", "TEST", 221, 240], ["triazole", "TREATMENT", 266, 274], ["macrocyclic inhibitors", "TREATMENT", 281, 303], ["3C", "PROBLEM", 307, 309], ["3C", "TEST", 314, 316], ["picornavirus", "PROBLEM", 335, 347], ["norovirus", "PROBLEM", 349, 358], ["coronavirus", "PROBLEM", 363, 374]]], ["Macrocyclization of linear peptidyl inhibitors was accomplished by tethering the P 1 and P 3 residues of the linear inhibitor by a suitable linker, thereby pre-organizing the macrocycle in a b-strand conformation prior to binding to the enzyme active site (Fig. 2B) [27, 28] .", [["P 1 and P 3 residues", "PROTEIN", 81, 101], ["enzyme active site", "PROTEIN", 237, 255], ["Macrocyclization", "TREATMENT", 0, 16], ["linear peptidyl inhibitors", "TREATMENT", 20, 46], ["the linear inhibitor", "TREATMENT", 105, 125], ["a suitable linker", "TREATMENT", 129, 146], ["the macrocycle", "TREATMENT", 171, 185], ["linear", "OBSERVATION_MODIFIER", 20, 26], ["peptidyl inhibitors", "OBSERVATION", 27, 46]]], ["This approach results in the formation of a pre-organized and semi-rigid entity that displays the amino acid side chains in a well-defined vector relationship for optimal binding and enhances the affinity of the inhibitor to the target enzyme by minimizing the entropy loss upon binding.", [["amino acid", "CHEMICAL", 98, 108], ["amino acid", "CHEMICAL", 98, 108], ["amino acid", "AMINO_ACID", 98, 108], ["amino acid side chains", "PROTEIN", 98, 120], ["a pre-organized and semi-rigid entity", "PROBLEM", 42, 79], ["the amino acid side chains", "TREATMENT", 94, 120], ["the inhibitor", "TREATMENT", 208, 221], ["the target enzyme", "TEST", 225, 242], ["the entropy loss upon binding", "PROBLEM", 257, 286], ["entropy loss", "OBSERVATION", 261, 273]]], ["Additional potential advantages of macrocyclic inhibitors include high stability to metabolizing enzymes, high selectivity and, frequently, increased cellular permeability [29e32] .", [["cellular", "ANATOMY", 150, 158], ["cellular", "CELL", 150, 158], ["metabolizing enzymes", "PROTEIN", 84, 104], ["macrocyclic inhibitors", "TREATMENT", 35, 57], ["metabolizing enzymes", "TEST", 84, 104], ["increased cellular permeability", "PROBLEM", 140, 171], ["high selectivity", "OBSERVATION_MODIFIER", 106, 122], ["increased", "OBSERVATION_MODIFIER", 140, 149], ["cellular permeability", "OBSERVATION", 150, 171]]], ["We describe herein the structurebased design of macrocyclic inhibitors of norovirus 3CLpro where the side chain of the P 1 Gln primary substrate specificity residue is tethered to the P 3 residue via a triazole linker to yield macrocycles (I) (Fig. 1) and explore the effect of ring size on conformation and its impact on pharmacological activity using high field NMR and X-ray crystallographic studies.", [["Gln", "CHEMICAL", 123, 126], ["triazole", "CHEMICAL", 202, 210], ["Gln", "CHEMICAL", 123, 126], ["triazole", "CHEMICAL", 202, 210], ["norovirus", "ORGANISM", 74, 83], ["3CLpro", "SIMPLE_CHEMICAL", 84, 90], ["P 3 residue", "PROTEIN", 184, 195], ["macrocyclic inhibitors", "TREATMENT", 48, 70], ["norovirus 3CLpro", "TREATMENT", 74, 90], ["Gln primary substrate specificity residue", "PROBLEM", 123, 164], ["a triazole linker to yield macrocycles", "TREATMENT", 200, 238], ["ring size on conformation", "TREATMENT", 278, 303], ["pharmacological activity", "TREATMENT", 322, 346], ["high field NMR", "TEST", 353, 367], ["X-ray crystallographic studies", "TEST", 372, 402], ["size", "OBSERVATION_MODIFIER", 283, 287]]], ["We also report the first examples of macrocyclic inhibitors of norovirus 3CLpro that are cellurarly permeable.ChemistryThe synthesis of macrocyclic compounds 1e11 (Table 1) was accomplished by first constructing key intermediates 15aec, 18aee, 19aee, and 20aeb using well-established methodologies (Scheme 1).", [["norovirus", "ORGANISM", 63, 72], ["3CLpro", "SIMPLE_CHEMICAL", 73, 79], ["15aec", "SIMPLE_CHEMICAL", 230, 235], ["18aee", "SIMPLE_CHEMICAL", 237, 242], ["19aee", "SIMPLE_CHEMICAL", 244, 249], ["20aeb", "SIMPLE_CHEMICAL", 255, 260], ["norovirus 3CLpro", "SPECIES", 63, 79], ["macrocyclic inhibitors", "TREATMENT", 37, 59], ["norovirus 3CLpro", "TREATMENT", 63, 79], ["macrocyclic compounds", "TEST", 136, 157]]], ["The commercially available N-Boc protected L-propargylglycine was reacted with L-leucine methylester, L-cyclohexylalanine methyl ester or L-phenylalanine methyl ester, in the presence of EDCI and HOBt to provide the corresponding dipeptide esters.", [["N-Boc", "CHEMICAL", 27, 32], ["-propargylglycine", "CHEMICAL", 44, 61], ["L-leucine methylester", "CHEMICAL", 79, 100], ["L-cyclohexylalanine methyl ester", "CHEMICAL", 102, 134], ["L-phenylalanine methyl ester", "CHEMICAL", 138, 166], ["EDCI", "CHEMICAL", 187, 191], ["HOBt", "CHEMICAL", 196, 200], ["N-Boc", "CHEMICAL", 27, 32], ["L-propargylglycine", "CHEMICAL", 43, 61], ["L-leucine methylester", "CHEMICAL", 79, 100], ["L-cyclohexylalanine methyl ester", "CHEMICAL", 102, 134], ["L-phenylalanine methyl ester", "CHEMICAL", 138, 166], ["EDCI", "CHEMICAL", 187, 191], ["HOBt", "CHEMICAL", 196, 200], ["dipeptide esters", "CHEMICAL", 230, 246], ["N-Boc", "SIMPLE_CHEMICAL", 27, 32], ["L-propargylglycine", "SIMPLE_CHEMICAL", 43, 61], ["L-leucine methylester", "SIMPLE_CHEMICAL", 79, 100], ["L-cyclohexylalanine methyl ester", "SIMPLE_CHEMICAL", 102, 134], ["L-phenylalanine methyl ester", "SIMPLE_CHEMICAL", 138, 166], ["EDCI", "SIMPLE_CHEMICAL", 187, 191], ["HOBt", "SIMPLE_CHEMICAL", 196, 200], ["dipeptide esters", "SIMPLE_CHEMICAL", 230, 246], ["N-Boc protected L-propargylglycine", "TREATMENT", 27, 61], ["L-leucine methylester", "TREATMENT", 79, 100], ["L-cyclohexylalanine methyl ester", "TREATMENT", 102, 134], ["L-phenylalanine methyl ester", "TREATMENT", 138, 166]]], ["Deblocking of the resulting esters was accomplished by treatment with 4 M HCl in dioxane.", [["4 M HCl", "CHEMICAL", 70, 77], ["dioxane", "CHEMICAL", 81, 88], ["esters", "CHEMICAL", 28, 34], ["HCl", "CHEMICAL", 74, 77], ["dioxane", "CHEMICAL", 81, 88], ["esters", "SIMPLE_CHEMICAL", 28, 34], ["4 M HCl", "SIMPLE_CHEMICAL", 70, 77], ["dioxane", "SIMPLE_CHEMICAL", 81, 88], ["dioxane", "TREATMENT", 81, 88], ["esters", "OBSERVATION_MODIFIER", 28, 34]]], ["The resulting amine hydrochlorides were reacted with benzylchloroformate followed by LiOH to yield the corresponding N-Cbz protected dipeptide acid intermediates 15aec.", [["amine hydrochlorides", "CHEMICAL", 14, 34], ["benzylchloroformate", "CHEMICAL", 53, 72], ["LiOH", "CHEMICAL", 85, 89], ["N-Cbz", "CHEMICAL", 117, 122], ["amine hydrochlorides", "CHEMICAL", 14, 34], ["benzylchloroformate", "CHEMICAL", 53, 72], ["LiOH", "CHEMICAL", 85, 89], ["N-Cbz", "CHEMICAL", 117, 122], ["dipeptide acid", "CHEMICAL", 133, 147], ["amine hydrochlorides", "SIMPLE_CHEMICAL", 14, 34], ["benzylchloroformate", "SIMPLE_CHEMICAL", 53, 72], ["LiOH", "SIMPLE_CHEMICAL", 85, 89], ["N-Cbz protected dipeptide acid", "SIMPLE_CHEMICAL", 117, 147], ["15aec", "SIMPLE_CHEMICAL", 162, 167], ["The resulting amine hydrochlorides", "TREATMENT", 0, 34], ["benzylchloroformate", "TREATMENT", 53, 72], ["Cbz protected dipeptide acid intermediates", "TREATMENT", 119, 161]]], ["Preparation of the HCl salts of amino azides 18aee was effected by sequential reaction of commercially available N-Boc protected amino alcohols with methanesulfonyl chloride and sodium azide followed by deprotection with 4 M HCl in dioxane.", [["HCl salts", "CHEMICAL", 19, 28], ["amino azides 18aee", "CHEMICAL", 32, 50], ["N-Boc", "CHEMICAL", 113, 118], ["amino alcohols", "CHEMICAL", 129, 143], ["methanesulfonyl chloride", "CHEMICAL", 149, 173], ["sodium azide", "CHEMICAL", 178, 190], ["4 M HCl", "CHEMICAL", 221, 228], ["dioxane", "CHEMICAL", 232, 239], ["HCl", "CHEMICAL", 19, 22], ["amino azides", "CHEMICAL", 32, 44], ["N-Boc", "CHEMICAL", 113, 118], ["amino alcohols", "CHEMICAL", 129, 143], ["methanesulfonyl chloride", "CHEMICAL", 149, 173], ["sodium azide", "CHEMICAL", 178, 190], ["HCl", "CHEMICAL", 225, 228], ["dioxane", "CHEMICAL", 232, 239], ["HCl salts", "SIMPLE_CHEMICAL", 19, 28], ["amino azides 18aee", "SIMPLE_CHEMICAL", 32, 50], ["N-Boc protected amino alcohols", "SIMPLE_CHEMICAL", 113, 143], ["methanesulfonyl chloride", "SIMPLE_CHEMICAL", 149, 173], ["sodium azide", "SIMPLE_CHEMICAL", 178, 190], ["4 M HCl", "SIMPLE_CHEMICAL", 221, 228], ["dioxane", "SIMPLE_CHEMICAL", 232, 239], ["the HCl salts", "TREATMENT", 15, 28], ["amino azides", "TREATMENT", 32, 44], ["Boc protected amino alcohols", "TREATMENT", 115, 143], ["methanesulfonyl chloride", "TREATMENT", 149, 173], ["sodium azide", "TREATMENT", 178, 190], ["deprotection", "TREATMENT", 203, 215], ["dioxane", "TREATMENT", 232, 239]]], ["Coupling of N-Boc protected glutamic acid with the corresponding HCl salts of amino azides 18aee in the presence of EDCI and HOBt gave intermediates 19aee, in good yields.ChemistryThe macrocyclization step was effected in two different ways.", [["N-Boc", "CHEMICAL", 12, 17], ["glutamic acid", "CHEMICAL", 28, 41], ["HCl salts", "CHEMICAL", 65, 74], ["amino azides 18aee", "CHEMICAL", 78, 96], ["EDCI", "CHEMICAL", 116, 120], ["HOBt", "CHEMICAL", 125, 129], ["19aee", "CHEMICAL", 149, 154], ["N-Boc", "CHEMICAL", 12, 17], ["glutamic acid", "CHEMICAL", 28, 41], ["HCl", "CHEMICAL", 65, 68], ["amino azides", "CHEMICAL", 78, 90], ["EDCI", "CHEMICAL", 116, 120], ["HOBt", "CHEMICAL", 125, 129], ["N-Boc", "SIMPLE_CHEMICAL", 12, 17], ["glutamic acid", "SIMPLE_CHEMICAL", 28, 41], ["HCl salts", "SIMPLE_CHEMICAL", 65, 74], ["amino azides 18aee", "SIMPLE_CHEMICAL", 78, 96], ["EDCI", "SIMPLE_CHEMICAL", 116, 120], ["HOBt", "SIMPLE_CHEMICAL", 125, 129], ["19aee", "SIMPLE_CHEMICAL", 149, 154], ["Boc protected glutamic acid", "TREATMENT", 14, 41], ["the corresponding HCl salts", "TREATMENT", 47, 74], ["amino azides", "TREATMENT", 78, 90], ["Chemistry", "TEST", 171, 180], ["The macrocyclization step", "TREATMENT", 180, 205]]], ["Specifically, the synthesis of macrocycles 2e3 entailed click chemistry-mediated macrocyclization using intermediates 15aec and 20aeb (Scheme 2), while compounds 1 and 4e11 were obtained through macrolactamization starting with key intermediates 15aec and 19aee (Scheme 3).", [["macrocycles 2e3", "CHEMICAL", 31, 46], ["compounds 1 and 4e11", "CHEMICAL", 152, 172], ["2e3", "CHEMICAL", 43, 46], ["macrocycles 2e3", "SIMPLE_CHEMICAL", 31, 46], ["15aec", "SIMPLE_CHEMICAL", 118, 123], ["20aeb", "SIMPLE_CHEMICAL", 128, 133], ["4e11", "SIMPLE_CHEMICAL", 168, 172], ["macrocycles", "TEST", 31, 42], ["click chemistry", "TEST", 56, 71], ["mediated macrocyclization", "TREATMENT", 72, 97]]], ["In general, the macrolactamization methodology was found to be superior, particularly in terms of ease of purification of the resultant cyclized products.", [["the macrolactamization methodology", "TEST", 12, 46], ["the resultant cyclized products", "TREATMENT", 122, 153], ["cyclized products", "OBSERVATION", 136, 153]]], ["Intermediates 15a and 20aeb were coupled in the presence of EDCI and HOBt to yield the corresponding linear precursors 24a and 24b of the macrocyclic esters 25a and 25b.", [["EDCI", "CHEMICAL", 60, 64], ["HOBt", "CHEMICAL", 69, 73], ["EDCI", "CHEMICAL", 60, 64], ["HOBt", "CHEMICAL", 69, 73], ["esters", "CHEMICAL", 150, 156], ["20aeb", "SIMPLE_CHEMICAL", 22, 27], ["EDCI", "SIMPLE_CHEMICAL", 60, 64], ["HOBt", "SIMPLE_CHEMICAL", 69, 73], ["macrocyclic esters 25a", "SIMPLE_CHEMICAL", 138, 160], ["the macrocyclic esters", "TEST", 134, 156]]], ["Intramolecular click reactions of the linear precursors 24aeb were carried out using a CuI/DBU mixture in dichloromethane under a nitrogen atmosphere at room temperature for 24 h to provide macrocyclic esters 25aeb in fairly good yields (45e50%).", [["CuI", "CHEMICAL", 87, 90], ["DBU", "CHEMICAL", 91, 94], ["dichloromethane", "CHEMICAL", 106, 121], ["macrocyclic esters 25aeb", "CHEMICAL", 190, 214], ["CuI", "CHEMICAL", 87, 90], ["DBU", "CHEMICAL", 91, 94], ["dichloromethane", "CHEMICAL", 106, 121], ["nitrogen", "CHEMICAL", 130, 138], ["macrocyclic esters 25aeb", "CHEMICAL", 190, 214], ["24aeb", "SIMPLE_CHEMICAL", 56, 61], ["CuI", "SIMPLE_CHEMICAL", 87, 90], ["DBU", "SIMPLE_CHEMICAL", 91, 94], ["dichloromethane", "SIMPLE_CHEMICAL", 106, 121], ["macrocyclic esters 25aeb", "SIMPLE_CHEMICAL", 190, 214], ["Intramolecular click reactions", "PROBLEM", 0, 30], ["the linear precursors", "PROBLEM", 34, 55], ["a CuI/DBU mixture", "TREATMENT", 85, 102], ["dichloromethane", "TREATMENT", 106, 121], ["a nitrogen atmosphere", "TREATMENT", 128, 149], ["macrocyclic esters", "TEST", 190, 208], ["click", "OBSERVATION", 15, 20], ["linear", "OBSERVATION_MODIFIER", 38, 44]]], ["Intermediates 15aec and 19aee were coupled using intermolecular click reaction in the presence of CuSO 4 and sodium ascorbate in THF/H 2 O solution to obtain the corresponding linear precursors 27aei of macrocyclic esters 28aei.", [["15aec and 19aee", "CHEMICAL", 14, 29], ["CuSO 4", "CHEMICAL", 98, 104], ["sodium ascorbate", "CHEMICAL", 109, 125], ["THF", "CHEMICAL", 129, 132], ["H", "CHEMICAL", 133, 134], ["27aei of macrocyclic esters 28aei", "CHEMICAL", 194, 227], ["CuSO 4", "CHEMICAL", 98, 104], ["sodium ascorbate", "CHEMICAL", 109, 125], ["THF", "CHEMICAL", 129, 132], ["H 2 O", "CHEMICAL", 133, 138], ["esters", "CHEMICAL", 215, 221], ["15aec", "SIMPLE_CHEMICAL", 14, 19], ["19aee", "SIMPLE_CHEMICAL", 24, 29], ["CuSO 4", "SIMPLE_CHEMICAL", 98, 104], ["sodium ascorbate", "SIMPLE_CHEMICAL", 109, 125], ["THF/H 2 O solution", "SIMPLE_CHEMICAL", 129, 147], ["27aei", "SIMPLE_CHEMICAL", 194, 199], ["macrocyclic esters 28aei", "SIMPLE_CHEMICAL", 203, 227], ["intermolecular click reaction", "PROBLEM", 49, 78], ["sodium ascorbate in THF/H 2 O solution", "TREATMENT", 109, 147]]], ["Macrolactamization of compounds 27aei was carried out using EDCI and HOBt in DMF at room temperature for 24 h to yield macrocyclic esters 28aei in good yields (~60%).", [["EDCI", "CHEMICAL", 60, 64], ["HOBt", "CHEMICAL", 69, 73], ["DMF", "CHEMICAL", 77, 80], ["macrocyclic esters 28aei", "CHEMICAL", 119, 143], ["EDCI", "CHEMICAL", 60, 64], ["HOBt", "CHEMICAL", 69, 73], ["DMF", "CHEMICAL", 77, 80], ["macrocyclic esters 28aei", "CHEMICAL", 119, 143], ["27aei", "SIMPLE_CHEMICAL", 32, 37], ["EDCI", "SIMPLE_CHEMICAL", 60, 64], ["HOBt", "SIMPLE_CHEMICAL", 69, 73], ["DMF", "SIMPLE_CHEMICAL", 77, 80], ["macrocyclic esters 28aei", "SIMPLE_CHEMICAL", 119, 143], ["Macrolactamization of compounds", "PROBLEM", 0, 31], ["macrocyclic esters", "TEST", 119, 137]]], ["In both cyclization methods, the dilution factor of the reaction mixture was critical in controlling the intramolecular cyclization reaction over the intermolecular reaction.", [["both cyclization methods", "TREATMENT", 3, 27], ["the dilution factor", "TREATMENT", 29, 48], ["the reaction mixture", "TREATMENT", 52, 72], ["the intramolecular cyclization reaction", "PROBLEM", 101, 140], ["the intermolecular reaction", "PROBLEM", 146, 173], ["intramolecular cyclization", "OBSERVATION", 105, 131]]], ["Reduction of macrocyclic esters using LiBH 4 followed by DesseMartin periodinane oxidation provided the corresponding macrocyclic aldehydes 1e11 in fairly good yields (~50%).ChemistryThe orientation of the triazole ring and its effect on pharmacological activity and conformation was probed by synthesizing macrocycle 12, via intermediates 21 and 23, as illustrated in Scheme 4.", [["macrocyclic esters", "CHEMICAL", 13, 31], ["LiBH 4", "CHEMICAL", 38, 44], ["DesseMartin", "CHEMICAL", 57, 68], ["aldehydes 1e11", "CHEMICAL", 130, 144], ["triazole", "CHEMICAL", 206, 214], ["esters", "CHEMICAL", 25, 31], ["LiBH 4", "CHEMICAL", 38, 44], ["DesseMartin periodinane", "CHEMICAL", 57, 80], ["aldehydes", "CHEMICAL", 130, 139], ["triazole", "CHEMICAL", 206, 214], ["macrocyclic esters", "SIMPLE_CHEMICAL", 13, 31], ["LiBH 4", "SIMPLE_CHEMICAL", 38, 44], ["DesseMartin periodinane", "SIMPLE_CHEMICAL", 57, 80], ["macrocyclic aldehydes 1e11", "SIMPLE_CHEMICAL", 118, 144], ["Reduction of macrocyclic esters", "TREATMENT", 0, 31], ["LiBH", "TREATMENT", 38, 42], ["DesseMartin periodinane oxidation", "TREATMENT", 57, 90], ["the corresponding macrocyclic aldehydes", "TREATMENT", 100, 139], ["the triazole ring", "TREATMENT", 202, 219], ["macrocyclic esters", "OBSERVATION", 13, 31], ["macrocyclic aldehydes", "OBSERVATION", 118, 139], ["triazole ring", "OBSERVATION", 206, 219]]], ["The acyclic variant of macrocycle 3 was synthesized according to Scheme 5 in order to determine the effect of macrocyclization on antiviral activity.", [["macrocycle", "CHEMICAL", 23, 33], ["macrocycle 3", "CHEMICAL", 23, 35], ["macrocycle 3", "SIMPLE_CHEMICAL", 23, 35], ["macrocycle 3", "TREATMENT", 23, 35], ["macrocyclization", "TREATMENT", 110, 126], ["antiviral activity", "TREATMENT", 130, 148], ["antiviral activity", "OBSERVATION", 130, 148]]], ["As dictated by the primary substrate specificity of norovirus 3CLpro, the P 1 Gln residue remained invariant in all synthesized inhibitors.", [["Gln", "CHEMICAL", 78, 81], ["Gln", "CHEMICAL", 78, 81], ["norovirus 3CLpro", "ORGANISM", 52, 68], ["norovirus 3CLpro", "PROTEIN", 52, 68], ["norovirus 3CLpro", "SPECIES", 52, 68], ["norovirus 3CLpro", "TREATMENT", 52, 68], ["the P 1 Gln residue", "TREATMENT", 70, 89], ["all synthesized inhibitors", "TREATMENT", 112, 138]]], ["Furthermore, norovirus 3CLpro prefers a P 2 Leu or Cha [12,23a-c] , consequently, the convergent nature of the synthetic plan allowed for variations in the P 2 residue via the judicious selection of appropriate natural or unnatural amino acid esters, thereby permitting the targeting of related viral proteases in the and Coronaviridae families.Biochemical studiesThe inhibitory activity of compounds 1e12 against norovirus 3CLpro in vitro and norovirus in a cell-based replicon system was evaluated as previously described [12, 13] and the results are summarized in Table 1 .X-ray crystallographyIn order to establish the precise mechanism of action of inhibitors (I) and gain insight and understanding into the structural determinants that impact potency and permeability that can be used to facilitate the structure-guided optimization of pharmacological activity, high-resolution X-ray crystal structures of NV 3CLpro with bound inhibitors 1, 3, and 10 were determined.", [["cell", "ANATOMY", 459, 463], ["P 2 Leu", "CHEMICAL", 40, 47], ["amino acid esters", "CHEMICAL", 232, 249], ["compounds 1e12", "CHEMICAL", 391, 405], ["3CLpro", "CHEMICAL", 424, 430], ["norovirus", "DISEASE", 444, 453], ["Leu", "CHEMICAL", 44, 47], ["Cha [12,23a-c]", "CHEMICAL", 51, 65], ["amino acid esters", "CHEMICAL", 232, 249], ["norovirus 3CLpro", "ORGANISM", 13, 29], ["amino acid esters", "SIMPLE_CHEMICAL", 232, 249], ["1e12", "SIMPLE_CHEMICAL", 401, 405], ["norovirus 3CLpro", "ORGANISM", 414, 430], ["norovirus", "ORGANISM", 444, 453], ["cell", "CELL", 459, 463], ["3", "GENE_OR_GENE_PRODUCT", 947, 948], ["viral proteases", "PROTEIN", 295, 310], ["Coronaviridae families", "PROTEIN", 322, 344], ["NV 3CLpro", "PROTEIN", 912, 921], ["norovirus 3CLpro", "SPECIES", 13, 29], ["norovirus", "PROBLEM", 13, 22], ["the P 2 residue", "PROBLEM", 152, 167], ["unnatural amino acid esters", "TREATMENT", 222, 249], ["viral proteases", "TREATMENT", 295, 310], ["Biochemical studies", "TEST", 345, 364], ["norovirus 3CLpro", "TREATMENT", 414, 430], ["norovirus", "PROBLEM", 444, 453], ["a cell-based replicon system", "TREATMENT", 457, 485], ["ray crystallography", "TEST", 578, 597], ["action of inhibitors", "TREATMENT", 644, 664], ["pharmacological activity", "TREATMENT", 842, 866], ["high-resolution X-ray crystal structures", "TREATMENT", 868, 908], ["NV 3CLpro with bound inhibitors", "TREATMENT", 912, 943], ["norovirus", "OBSERVATION", 13, 22], ["viral proteases", "OBSERVATION", 295, 310], ["norovirus", "OBSERVATION", 444, 453]]], ["Attempts to obtain crystal structures of permeable inhibitors 7 and 8 were unsuccessful, precluding a structural comparison between the permeable and non-permeable macrocyclic inhibitors that might perhaps illuminate the structural determinants responsible for the observed differences in potency and cellular permeability.", [["cellular", "ANATOMY", 301, 309], ["cellular", "CELL", 301, 309], ["permeable inhibitors", "TREATMENT", 41, 61], ["non-permeable macrocyclic inhibitors", "TREATMENT", 150, 186], ["cellular permeability", "OBSERVATION", 301, 322]]], ["Examination of the active site revealed the presence of an antiparallel b-sheet-like hydrogen bonding network associated with the backbone of all three inhibitors, covalently bound to the catalytic Cys139 residue (Fig. 3) .", [["hydrogen", "CHEMICAL", 85, 93], ["Cys139", "CHEMICAL", 198, 204], ["antiparallel b-sheet", "PROTEIN", 59, 79], ["catalytic Cys139 residue", "PROTEIN", 188, 212], ["Examination of the active site", "TEST", 0, 30], ["an antiparallel b-sheet-like hydrogen bonding network", "TREATMENT", 56, 109], ["all three inhibitors", "TREATMENT", 142, 162], ["hydrogen bonding", "OBSERVATION", 85, 101]]], ["The coordinates of the Ramachandran plot (see Fig. S8 in Supporting information) of six f and j angle pairs of the corresponding P 2 and P 3 residues, extracted from the X-ray crystal structures, lie in the upper left quadrant of the plot, indicating that bound inhibitors 1, 3, and 10 assume an extended b-strand conformation.", [["3", "GENE_OR_GENE_PRODUCT", 276, 277], ["S8", "PROTEIN", 51, 53], ["P 2 and P 3 residues", "DNA", 129, 149], ["1, 3, and 10", "PROTEIN", 273, 285], ["P 3 residues", "PROBLEM", 137, 149], ["bound inhibitors", "TREATMENT", 256, 272], ["j angle", "OBSERVATION_MODIFIER", 94, 101], ["upper", "ANATOMY_MODIFIER", 207, 212], ["left", "ANATOMY_MODIFIER", 213, 217], ["quadrant", "ANATOMY_MODIFIER", 218, 226]]], ["The pseudo f angles of the P 1 residue covalently bound to the Cys139 residue range from \u00c0129.5 to \u00c0137.8 .", [["Cys139", "CHEMICAL", 63, 69], ["P 1 residue", "DNA", 27, 38], ["the P 1 residue covalently bound", "PROBLEM", 23, 55], ["pseudo f angles", "OBSERVATION_MODIFIER", 4, 19]]], ["The electron density maps for the three bound inhibitors are shown in Fig. 4AeC .", [["4AeC", "CHEMICAL", 75, 79], ["electron", "SIMPLE_CHEMICAL", 4, 12], ["4AeC", "SIMPLE_CHEMICAL", 75, 79], ["4AeC", "PROTEIN", 75, 79], ["The electron density maps", "TREATMENT", 0, 25], ["the three bound inhibitors", "TREATMENT", 30, 56]]], ["As expected, the backbones of all three inhibitors are structurally more rigid compared to the atoms forming the macrocyclic linker, which is more flexible.", [["structurally more rigid", "PROBLEM", 55, 78], ["the macrocyclic linker", "TREATMENT", 109, 131], ["backbones", "ANATOMY_MODIFIER", 17, 26], ["more", "OBSERVATION_MODIFIER", 68, 72], ["rigid", "OBSERVATION", 73, 78], ["macrocyclic linker", "OBSERVATION", 113, 131], ["flexible", "OBSERVATION_MODIFIER", 147, 155]]], ["This is evident from an analysis of the B-factors for the inhibitors in each structure, which are slightly lower in the backbone region as shown in the right panels of Fig. 4AeC .", [["4AeC", "CHEMICAL", 173, 177], ["B-factors", "GENE_OR_GENE_PRODUCT", 40, 49], ["4AeC", "SIMPLE_CHEMICAL", 173, 177], ["B-factors", "PROTEIN", 40, 49], ["4AeC", "PROTEIN", 173, 177], ["an analysis", "TEST", 21, 32], ["the inhibitors", "TREATMENT", 54, 68], ["slightly", "OBSERVATION_MODIFIER", 98, 106], ["lower", "OBSERVATION_MODIFIER", 107, 112], ["backbone", "ANATOMY_MODIFIER", 120, 128], ["region", "ANATOMY_MODIFIER", 129, 135], ["right", "ANATOMY_MODIFIER", 152, 157]]], ["The electron density for the \"cap\" phenyl ring was not observed for 1 and 3 due to disorder and could not be modeled, while inhibitor 10 has somewhat weak electron density that permitted modeling of the phenyl ring.", [["phenyl", "CHEMICAL", 35, 41], ["disorder", "DISEASE", 83, 91], ["phenyl", "CHEMICAL", 35, 41], ["phenyl", "CHEMICAL", 203, 209], ["electron", "SIMPLE_CHEMICAL", 4, 12], ["electron", "SIMPLE_CHEMICAL", 155, 163], ["phenyl ring", "SIMPLE_CHEMICAL", 203, 214], ["the \"cap\" phenyl ring", "TREATMENT", 25, 46], ["disorder", "PROBLEM", 83, 91], ["somewhat weak electron density", "PROBLEM", 141, 171], ["the phenyl ring", "TREATMENT", 199, 214], ["electron density", "OBSERVATION", 4, 20], ["density", "OBSERVATION", 164, 171], ["phenyl ring", "OBSERVATION", 203, 214]]], ["The triazole ring of inhibitor 3 has reasonable electron density, however, it is more disordered and its exact orientation is not clearly discernible (Fig. 4) .", [["triazole", "CHEMICAL", 4, 12], ["triazole", "CHEMICAL", 4, 12], ["electron", "SIMPLE_CHEMICAL", 48, 56], ["The triazole ring of inhibitor", "TREATMENT", 0, 30], ["triazole ring", "OBSERVATION", 4, 17], ["electron density", "OBSERVATION_MODIFIER", 48, 64]]], ["The observed degree of inhibition prompted us to delineate the structural determinants associated with binding in order to gain insight and understanding into the relative potency of the inhibitors.", [["the inhibitors", "TREATMENT", 183, 197]]], ["Toward that end, superposition with GESAMT [33] of the high-resolution X-ray crystal structure of the NV 3CLpro:10 complex (largest ring size) with the NV 3CLPro:1 complex (smallest ring size) shows that the enzyme structures in both complexes are similar, with an RMSD between Ca atoms of 0.76 \u00c5 (167 residues), except for the flexible loop spanning Lys121 to Glu140 (Fig. 5A ).", [["Ca", "CHEMICAL", 278, 280], ["Ca", "CHEMICAL", 278, 280], ["Lys121", "CHEMICAL", 351, 357], ["Glu140", "CHEMICAL", 361, 367], ["Lys121", "AMINO_ACID", 351, 357], ["NV 3CLpro:10 complex", "PROTEIN", 102, 122], ["NV 3CLPro:1 complex", "PROTEIN", 152, 171], ["Glu140", "PROTEIN", 361, 367], ["Fig. 5A", "PROTEIN", 369, 376], ["the high-resolution X-ray crystal structure", "TREATMENT", 51, 94], ["the enzyme structures", "TEST", 204, 225], ["Ca atoms", "TEST", 278, 286], ["the flexible loop", "TREATMENT", 324, 341], ["size", "OBSERVATION_MODIFIER", 137, 141], ["size", "OBSERVATION_MODIFIER", 187, 191], ["both", "ANATOMY_MODIFIER", 229, 233], ["complexes", "ANATOMY_MODIFIER", 234, 243], ["similar", "OBSERVATION_MODIFIER", 248, 255], ["RMSD", "OBSERVATION", 265, 269], ["flexible loop", "OBSERVATION", 328, 341]]], ["The binding of inhibitor 10 (larger ring size) to the active site is accompanied by the movement of the flexible loop away from the inhibitor resulting in the loss of a hydrogen bond between the P 1 side chain (Gln C]O) of the inhibitor with Thr134 (backbone NH) which forms the S 1 pocket.", [["Gln", "CHEMICAL", 211, 214], ["Thr134", "CHEMICAL", 242, 248], ["hydrogen", "CHEMICAL", 169, 177], ["Gln C]O", "CHEMICAL", 211, 218], ["Thr", "CHEMICAL", 242, 245], ["NH", "CHEMICAL", 259, 261], ["Gln C]O", "SIMPLE_CHEMICAL", 211, 218], ["Thr134", "SIMPLE_CHEMICAL", 242, 248], ["backbone NH", "SIMPLE_CHEMICAL", 250, 261], ["P 1 side chain", "PROTEIN", 195, 209], ["S 1 pocket", "PROTEIN", 279, 289], ["The binding of inhibitor", "TREATMENT", 0, 24], ["larger ring size)", "TREATMENT", 29, 46], ["the inhibitor", "TREATMENT", 128, 141], ["the loss of a hydrogen bond", "PROBLEM", 155, 182], ["the inhibitor", "TREATMENT", 223, 236], ["Thr", "TREATMENT", 242, 245], ["size", "OBSERVATION_MODIFIER", 41, 45], ["active", "OBSERVATION_MODIFIER", 54, 60], ["site", "OBSERVATION", 61, 65], ["flexible loop", "OBSERVATION", 104, 117], ["loss", "OBSERVATION", 159, 163]]], ["His157, which is the other constituent of the S 1 pocket but is not a part of the flexible loop, maintains a hydrogen bond interaction with the P 1 Gln C]O (Fig. 5B ).", [["His", "CHEMICAL", 0, 3], ["hydrogen", "CHEMICAL", 109, 117], ["P 1 Gln C]O", "CHEMICAL", 144, 155], ["S 1 pocket", "PROTEIN", 46, 56], ["flexible loop", "PROTEIN", 82, 95], ["a hydrogen bond interaction", "PROBLEM", 107, 134], ["Gln C]O (Fig. 5B )", "TEST", 148, 166]]], ["It should be noted that the interaction of NV 3CLpro with acyclic dipeptidyl and tripeptidyl inhibitors involves the formation of two crucial hydrogen bonds between the carbonyl oxygen of the glutamine surrogate C]O in the inhibitor and the Thr134 and His157 residues [12] .", [["NV 3CLpro", "CHEMICAL", 43, 52], ["oxygen", "CHEMICAL", 178, 184], ["glutamine", "CHEMICAL", 192, 201], ["NV 3CLpro", "CHEMICAL", 43, 52], ["tripeptidyl", "CHEMICAL", 81, 92], ["hydrogen", "CHEMICAL", 142, 150], ["carbonyl", "CHEMICAL", 169, 177], ["oxygen", "CHEMICAL", 178, 184], ["glutamine", "CHEMICAL", 192, 201], ["C]O", "CHEMICAL", 212, 215], ["Thr134", "CHEMICAL", 241, 247], ["His157", "CHEMICAL", 252, 258], ["NV 3CLpro", "SIMPLE_CHEMICAL", 43, 52], ["acyclic dipeptidyl", "SIMPLE_CHEMICAL", 58, 76], ["tripeptidyl inhibitors", "SIMPLE_CHEMICAL", 81, 103], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 169, 184], ["glutamine surrogate C]O", "SIMPLE_CHEMICAL", 192, 215], ["Thr134", "GENE_OR_GENE_PRODUCT", 241, 247], ["glutamine surrogate C]O", "PROTEIN", 192, 215], ["NV 3CLpro", "TREATMENT", 43, 52], ["acyclic dipeptidyl", "TREATMENT", 58, 76], ["tripeptidyl inhibitors", "TREATMENT", 81, 103], ["two crucial hydrogen bonds", "TREATMENT", 130, 156], ["the carbonyl oxygen", "TREATMENT", 165, 184], ["the glutamine surrogate C", "TREATMENT", 188, 213], ["the inhibitor", "TREATMENT", 219, 232], ["hydrogen bonds", "OBSERVATION", 142, 156]]], ["These two hydrogen bonding interactions, as well as the flexible backbone of the T123-G133 loop [34] , appear to play a critical role in enzyme-substrate recognition and are conserved in all norovirus proteases.", [["hydrogen", "CHEMICAL", 10, 18], ["hydrogen", "CHEMICAL", 10, 18], ["T123", "PROTEIN", 81, 85], ["enzyme", "PROTEIN", 137, 143], ["norovirus proteases", "PROTEIN", 191, 210], ["all norovirus proteases", "PROBLEM", 187, 210], ["hydrogen bonding", "OBSERVATION", 10, 26], ["norovirus", "OBSERVATION", 191, 200]]], ["Thus, in the NV 3CLpro:1 complex, the movement of the flexible loop and the shorter linker length of the inhibitor which positions the carbonyl oxygen of the P 1 Gln side chain away from His157 and Thr134, results in the loss of the Thr134 P 1 Gln C]O hydrogen bond (Fig. 5C) .", [["oxygen", "CHEMICAL", 144, 150], ["P 1 Gln", "CHEMICAL", 158, 165], ["Thr134", "CHEMICAL", 198, 204], ["carbonyl", "CHEMICAL", 135, 143], ["oxygen", "CHEMICAL", 144, 150], ["Gln", "CHEMICAL", 162, 165], ["His", "CHEMICAL", 187, 190], ["Thr", "CHEMICAL", 198, 201], ["Thr", "CHEMICAL", 233, 236], ["Gln C]O", "CHEMICAL", 244, 251], ["hydrogen", "CHEMICAL", 252, 260], ["3CLpro:1 complex", "GENE_OR_GENE_PRODUCT", 16, 32], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 135, 150], ["His157", "AMINO_ACID", 187, 193], ["Thr134", "AMINO_ACID", 198, 204], ["NV 3CLpro:1 complex", "PROTEIN", 13, 32], ["flexible loop", "PROTEIN", 54, 67], ["P 1 Gln side chain", "PROTEIN", 158, 176], ["the flexible loop", "TREATMENT", 50, 67], ["the shorter linker length of the inhibitor", "TREATMENT", 72, 114], ["the carbonyl oxygen", "TREATMENT", 131, 150], ["Gln side chain", "TEST", 162, 176], ["Thr", "TEST", 198, 201], ["Gln C]O hydrogen bond (Fig. 5C", "TREATMENT", 244, 274], ["flexible loop", "OBSERVATION", 54, 67]]], ["Conversely, the binding of inhibitor 1 allows the flexible loop to move closer to the inhibitor such that a contact can be formed (3.3 \u00c5) between Pro136 and the carbonyl oxygen of the warhead (Fig. 5B ).", [["Pro136", "CHEMICAL", 146, 152], ["oxygen", "CHEMICAL", 170, 176], ["Pro136", "CHEMICAL", 146, 152], ["carbonyl", "CHEMICAL", 161, 169], ["oxygen", "CHEMICAL", 170, 176], ["Pro136", "SIMPLE_CHEMICAL", 146, 152], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 161, 176], ["inhibitor", "TREATMENT", 27, 36], ["the flexible loop", "TREATMENT", 46, 63], ["the inhibitor", "TREATMENT", 82, 95], ["Pro136", "TREATMENT", 146, 152], ["the carbonyl oxygen", "TREATMENT", 157, 176]]], ["The compact nature of the inhibitor positions the NH group of the P 1 Gln side chain within hydrogen bonding distance (3.2 \u00c5) of the carbonyl oxygen of the Ala160 residue (see Fig. S1 in Supporting information for distance information related to the hydrogen bonds).", [["Gln", "CHEMICAL", 70, 73], ["oxygen", "CHEMICAL", 142, 148], ["NH", "CHEMICAL", 50, 52], ["Gln", "CHEMICAL", 70, 73], ["hydrogen", "CHEMICAL", 92, 100], ["carbonyl", "CHEMICAL", 133, 141], ["oxygen", "CHEMICAL", 142, 148], ["Ala160", "CHEMICAL", 156, 162], ["hydrogen", "CHEMICAL", 250, 258], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 133, 148], ["Ala160", "SIMPLE_CHEMICAL", 156, 162], ["NH group", "PROTEIN", 50, 58], ["P 1 Gln side chain", "PROTEIN", 66, 84], ["S1", "PROTEIN", 181, 183], ["the inhibitor positions", "TREATMENT", 22, 45], ["the P 1 Gln side chain", "TREATMENT", 62, 84], ["the carbonyl oxygen", "TREATMENT", 129, 148], ["the Ala160 residue", "PROBLEM", 152, 170], ["hydrogen bonding", "OBSERVATION", 92, 108], ["carbonyl oxygen", "OBSERVATION", 133, 148]]], ["The subtle structural shifts associated with the P1 Gln side chain may account for the lower inhibitory activity observed with this series of macrocyclic triazole compounds, as compared to previously reported triazole-based macrocyclic calpain inhibitors [35] specifically and macrocyclic inhibitors generally [29e31].", [["Gln", "CHEMICAL", 52, 55], ["triazole", "CHEMICAL", 209, 217], ["Gln", "CHEMICAL", 52, 55], ["triazole", "CHEMICAL", 154, 162], ["triazole", "CHEMICAL", 209, 217], ["macrocyclic triazole compounds", "SIMPLE_CHEMICAL", 142, 172], ["triazole-based macrocyclic calpain inhibitors [35]", "SIMPLE_CHEMICAL", 209, 259], ["macrocyclic inhibitors", "SIMPLE_CHEMICAL", 277, 299], ["The subtle structural shifts", "PROBLEM", 0, 28], ["the P1 Gln side chain", "TREATMENT", 45, 66], ["the lower inhibitory activity", "PROBLEM", 83, 112], ["macrocyclic triazole compounds", "TREATMENT", 142, 172], ["triazole-based macrocyclic calpain inhibitors", "TREATMENT", 209, 254], ["macrocyclic inhibitors", "TREATMENT", 277, 299], ["subtle", "OBSERVATION_MODIFIER", 4, 10], ["structural shifts", "OBSERVATION", 11, 28], ["may account for", "UNCERTAINTY", 67, 82]]], ["In the former case, potency is solely dependent on the combined effect of hydrophobic interactions and the network of hydrogen bonding interactions between the inhibitor backbone and the enzyme active site which is facilitated by the b-strand conformation of the inhibitor.X-ray crystallographyThe enhancement in the IC 50 values associated with the replacement of the P 2 isobutyl side chain with a cyclohexyl group observed with linear dipeptidyl inhibitors [12] is diminished in compound 10 (IC 50 6.1 mM) and is partly due to the loss of the key hydrogen bonding interaction with Thr134, as revealed by the X-ray crystal structure and the larger flexible ring (see discussion of NMR studies).", [["P 2 isobutyl", "CHEMICAL", 369, 381], ["cyclohexyl", "CHEMICAL", 400, 410], ["Thr134", "CHEMICAL", 584, 590], ["hydrogen", "CHEMICAL", 118, 126], ["isobutyl", "CHEMICAL", 373, 381], ["cyclohexyl", "CHEMICAL", 400, 410], ["hydrogen", "CHEMICAL", 550, 558], ["Thr", "CHEMICAL", 584, 587], ["hydrogen", "SIMPLE_CHEMICAL", 118, 126], ["cyclohexyl", "SIMPLE_CHEMICAL", 400, 410], ["dipeptidyl inhibitors [12]", "SIMPLE_CHEMICAL", 438, 464], ["Thr134", "AMINO_ACID", 584, 590], ["enzyme active site", "PROTEIN", 187, 205], ["hydrophobic interactions", "PROBLEM", 74, 98], ["hydrogen bonding interactions", "PROBLEM", 118, 147], ["the inhibitor backbone", "TREATMENT", 156, 178], ["the enzyme active site", "PROBLEM", 183, 205], ["the inhibitor", "TREATMENT", 259, 272], ["X-ray crystallography", "TEST", 273, 294], ["the replacement of the P 2 isobutyl side chain", "TREATMENT", 346, 392], ["a cyclohexyl group", "TREATMENT", 398, 416], ["linear dipeptidyl inhibitors", "TREATMENT", 431, 459], ["diminished in compound", "PROBLEM", 468, 490], ["the larger flexible ring", "TREATMENT", 639, 663], ["NMR studies", "TEST", 683, 694], ["hydrogen bonding", "OBSERVATION", 118, 134], ["enhancement", "OBSERVATION_MODIFIER", 298, 309], ["replacement", "OBSERVATION", 350, 361], ["diminished", "OBSERVATION_MODIFIER", 468, 478], ["hydrogen bonding", "OBSERVATION", 550, 566], ["larger", "OBSERVATION_MODIFIER", 643, 649], ["flexible ring", "OBSERVATION", 650, 663]]], ["On the other hand, as mentioned above, the compact, rigid ring structure and the additional hydrogen bond with Ala160, discernible from the X-ray crystal structure, may account for the 4fold decrease in the IC 50 value (1.6 mM) of compound 1 as compared to compound 10.", [["Ala160", "CHEMICAL", 111, 117], ["hydrogen", "CHEMICAL", 92, 100], ["Ala", "CHEMICAL", 111, 114], ["Ala160", "SIMPLE_CHEMICAL", 111, 117], ["the compact, rigid ring structure", "PROBLEM", 39, 72], ["Ala", "TEST", 111, 114], ["the X-ray crystal structure", "TEST", 136, 163], ["the 4fold decrease", "PROBLEM", 181, 199], ["rigid ring", "OBSERVATION", 52, 62], ["hydrogen bond", "OBSERVATION", 92, 105], ["may account for", "UNCERTAINTY", 165, 180], ["decrease", "OBSERVATION_MODIFIER", 191, 199]]], ["The in vitro inhibitory activity of compounds 1 and 3 which form the same number of direct hydrogen bonds with the enzyme (7 hydrogen bonds) was found to be 1.6 mM and 2.4 mM, respectively.", [["hydrogen", "CHEMICAL", 91, 99], ["hydrogen", "CHEMICAL", 125, 133], ["3", "GENE_OR_GENE_PRODUCT", 52, 53], ["the enzyme", "TEST", 111, 121]]], ["Interestingly, compound 34, the acyclic variant of compound 3, was devoid of any inhibitory activity.", [["compound 34", "CHEMICAL", 15, 26], ["compound 34", "SIMPLE_CHEMICAL", 15, 26]]], ["Finally, the 18membered macrocycle 12 ( Fig. 1 ) in which the triazole ring was constructed in a reverse fashion and presumably assumes a different orientation than inhibitors 1e11, was effective against In summary, the interaction of macrocyclic inhibitors (I) with NV 3CLpro induces conformational changes in the flexible loop and active site of the enzyme which are dependent on macrocycle ring size and structure.", [["triazole", "CHEMICAL", 62, 70], ["3CLpro", "CHEMICAL", 270, 276], ["triazole", "CHEMICAL", 62, 70], ["1e11", "SIMPLE_CHEMICAL", 176, 180], ["macrocyclic inhibitors", "SIMPLE_CHEMICAL", 235, 257], ["NV 3CLpro", "SIMPLE_CHEMICAL", 267, 276], ["enzyme", "PROTEIN", 352, 358], ["the 18membered macrocycle", "TREATMENT", 9, 34], ["the triazole ring", "TREATMENT", 58, 75], ["a different orientation than inhibitors", "TREATMENT", 136, 175], ["macrocyclic inhibitors", "TREATMENT", 235, 257], ["NV 3CLpro", "TREATMENT", 267, 276], ["conformational changes in the flexible loop", "PROBLEM", 285, 328], ["the enzyme", "TEST", 348, 358], ["flexible loop", "OBSERVATION", 315, 328], ["active", "OBSERVATION_MODIFIER", 333, 339], ["site", "OBSERVATION_MODIFIER", 340, 344], ["macrocycle ring", "OBSERVATION", 382, 397], ["size", "OBSERVATION_MODIFIER", 398, 402]]], ["These changes result in sub-optimal angles and distances in forming the critical intermolecular hydrogen bonds between the P1 Gln side chain and the active site His157 and Thr134 residues, consequently, maximal binding potency and effective compensation for the energy penalty required to desolvate the molecule, are not attained.NMR studiesIn order to gain further insight into the solution conformation and binding of the synthesized macrocyclic inhibitors, as well as confirm the absence of alternate structures, NMR studies were carried out using the precursor cyclic esters.", [["Gln", "CHEMICAL", 126, 129], ["cyclic esters", "CHEMICAL", 565, 578], ["hydrogen", "CHEMICAL", 96, 104], ["Gln", "CHEMICAL", 126, 129], ["His", "CHEMICAL", 161, 164], ["Thr", "CHEMICAL", 172, 175], ["cyclic esters", "CHEMICAL", 565, 578], ["His157", "AMINO_ACID", 161, 167], ["Thr134 residues", "AMINO_ACID", 172, 187], ["cyclic esters", "SIMPLE_CHEMICAL", 565, 578], ["P1 Gln side chain", "PROTEIN", 123, 140], ["the P1 Gln side chain", "TREATMENT", 119, 140], ["maximal binding potency", "PROBLEM", 203, 226], ["the energy penalty", "PROBLEM", 258, 276], ["NMR studies", "TEST", 330, 341], ["the solution conformation", "TREATMENT", 379, 404], ["the synthesized macrocyclic inhibitors", "TREATMENT", 420, 458], ["NMR studies", "TEST", 516, 527], ["the precursor cyclic esters", "TEST", 551, 578], ["sub", "OBSERVATION_MODIFIER", 24, 27], ["intermolecular hydrogen bonds", "OBSERVATION", 81, 110], ["active", "OBSERVATION_MODIFIER", 149, 155], ["site", "OBSERVATION_MODIFIER", 156, 160]]], ["Assignment of the proton resonances was done using 1 H, COSY, ROESY and HMBC spectral details.", [["1 H", "CHEMICAL", 51, 54], ["the proton resonances", "TEST", 14, 35]]], ["The ROESY spectra of the compounds show H ia to NH (i \u00fe 1) type correlation, where the Gln and Leu NH show correlation to the Leu Ha and carbamate Ha, respectively (see Figs.", [["H", "CHEMICAL", 40, 41], ["Gln", "CHEMICAL", 87, 90], ["Leu", "CHEMICAL", 95, 98], ["Leu Ha", "CHEMICAL", 126, 132], ["carbamate", "CHEMICAL", 137, 146], ["H", "CHEMICAL", 40, 41], ["NH", "CHEMICAL", 48, 50], ["Gln", "CHEMICAL", 87, 90], ["Leu", "CHEMICAL", 95, 98], ["NH", "CHEMICAL", 99, 101], ["Leu", "CHEMICAL", 126, 129], ["carbamate", "CHEMICAL", 137, 146], ["H ia", "SIMPLE_CHEMICAL", 40, 44], ["Gln", "AMINO_ACID", 87, 90], ["Leu NH", "SIMPLE_CHEMICAL", 95, 101], ["Leu Ha", "SIMPLE_CHEMICAL", 126, 132], ["carbamate Ha", "SIMPLE_CHEMICAL", 137, 149], ["the Gln and Leu NH", "TEST", 83, 101], ["the Leu Ha and carbamate Ha", "TREATMENT", 122, 149]]], ["S1eS5 in Supporting information).", [["S1eS5", "PROTEIN", 0, 5]]], ["This observation is indicative of a prearranged structure within the macrocycle [28] .", [["This observation", "TEST", 0, 16], ["a prearranged structure within the macrocycle", "PROBLEM", 34, 79], ["indicative of", "UNCERTAINTY", 20, 33]]], ["The temperature dependence of amide NH chemical shifts experiments were performed using compounds 28a (ring size: 17), 28e (ring size: 20) and 28g (ring size: 21), revealing important information about the solution structures of the macrocycles.", [["amide NH", "CHEMICAL", 30, 38], ["amide", "CHEMICAL", 30, 35], ["NH", "CHEMICAL", 36, 38], ["The temperature dependence of amide NH chemical shifts experiments", "PROBLEM", 0, 66]]], ["Solvent shielded NH protons typically have Dd/T values less than 4 ppb/K while solvent exposed NH protons have Dd/T values greater than 4 ppb/K [28] .", [["NH", "CHEMICAL", 17, 19], ["NH", "CHEMICAL", 95, 97], ["NH protons", "SIMPLE_CHEMICAL", 17, 27], ["NH protons", "SIMPLE_CHEMICAL", 95, 105], ["Dd", "PROTEIN", 43, 45], ["Dd", "PROTEIN", 111, 113], ["Solvent shielded NH protons", "TREATMENT", 0, 27], ["Dd/T values", "TEST", 43, 54], ["NH protons", "TREATMENT", 95, 105], ["Dd/T values", "TEST", 111, 122]]], ["According to the results, the Gln, Leu, and propargylglycine NH protons have Dd/T values greater than 4 ppb/K in all cases (Table 3) .", [["Gln", "CHEMICAL", 30, 33], ["Leu", "CHEMICAL", 35, 38], ["propargylglycine", "CHEMICAL", 44, 60], ["Gln", "CHEMICAL", 30, 33], ["Leu", "CHEMICAL", 35, 38], ["propargylglycine", "CHEMICAL", 44, 60], ["NH", "CHEMICAL", 61, 63], ["Gln, Leu", "SIMPLE_CHEMICAL", 30, 38], ["propargylglycine NH protons", "SIMPLE_CHEMICAL", 44, 71], ["Dd", "PROTEIN", 77, 79], ["the Gln, Leu", "TREATMENT", 26, 38], ["propargylglycine NH protons", "TREATMENT", 44, 71], ["Dd/T values", "TEST", 77, 88]]], ["At larger ring sizes, the carbamate NH shows a higher temperature dependence (\u00c07.0 and 6.4 ppb/K for ring sizes 20 and 21, respectively), indicating greater solvent exposure.", [["carbamate", "CHEMICAL", 26, 35], ["carbamate NH", "CHEMICAL", 26, 38], ["carbamate NH", "SIMPLE_CHEMICAL", 26, 38], ["the carbamate NH", "TEST", 22, 38], ["a higher temperature dependence", "PROBLEM", 45, 76], ["ring sizes", "TEST", 101, 111], ["larger", "OBSERVATION_MODIFIER", 3, 9], ["ring", "OBSERVATION_MODIFIER", 10, 14], ["sizes", "OBSERVATION_MODIFIER", 15, 20], ["higher temperature", "OBSERVATION_MODIFIER", 47, 65], ["greater", "OBSERVATION_MODIFIER", 149, 156], ["solvent exposure", "OBSERVATION", 157, 173]]], ["However, for smaller ring size it shows comparatively low temperature dependence (4.2 ppb/K at 17 ring size), indicating less solvent exposure.", [["smaller ring size", "PROBLEM", 13, 30], ["comparatively low temperature dependence", "PROBLEM", 40, 80], ["smaller", "OBSERVATION_MODIFIER", 13, 20], ["ring", "OBSERVATION_MODIFIER", 21, 25], ["size", "OBSERVATION_MODIFIER", 26, 30], ["comparatively", "OBSERVATION_MODIFIER", 40, 53], ["low temperature", "OBSERVATION_MODIFIER", 54, 69], ["size", "OBSERVATION_MODIFIER", 103, 107], ["less", "OBSERVATION_MODIFIER", 121, 125], ["solvent exposure", "OBSERVATION", 126, 142]]], ["This is further supported by the observed line broadening of the carbamate NH proton at elevated temperatures for compounds 28e and 28g, and the lower line broadening observed for 28a ( Fig. S6 in Supporting information).", [["carbamate NH", "CHEMICAL", 65, 77], ["carbamate", "CHEMICAL", 65, 74], ["NH", "CHEMICAL", 75, 77], ["carbamate NH proton", "SIMPLE_CHEMICAL", 65, 84], ["S6", "PROTEIN", 191, 193], ["the carbamate NH proton", "TREATMENT", 61, 84], ["elevated temperatures", "PROBLEM", 88, 109], ["the lower line broadening", "TREATMENT", 141, 166], ["lower line", "OBSERVATION", 145, 155]]], ["Previous studies have shown that amide signals exchanging with water impurity present in DMSO solvent show considerable broadening of the line width at elevated temperatures due to the enhanced exchange rate at higher temperatures [28] .", [["DMSO", "CHEMICAL", 89, 93], ["amide", "CHEMICAL", 33, 38], ["DMSO", "CHEMICAL", 89, 93], ["water", "SIMPLE_CHEMICAL", 63, 68], ["DMSO", "SIMPLE_CHEMICAL", 89, 93], ["Previous studies", "TEST", 0, 16], ["amide signals", "PROBLEM", 33, 46], ["water impurity", "TREATMENT", 63, 77], ["DMSO solvent", "TREATMENT", 89, 101], ["the line width", "PROBLEM", 134, 148], ["elevated temperatures", "PROBLEM", 152, 173], ["the enhanced exchange rate", "PROBLEM", 181, 207], ["considerable", "OBSERVATION_MODIFIER", 107, 119], ["broadening", "OBSERVATION_MODIFIER", 120, 130], ["line", "OBSERVATION_MODIFIER", 138, 142], ["width", "OBSERVATION_MODIFIER", 143, 148]]], ["At smaller ring size, all three NH protons show less temperature dependence, indicating solvent shielding which is partly due to the compact nature of the compound.", [["NH", "CHEMICAL", 32, 34], ["NH protons", "SIMPLE_CHEMICAL", 32, 42], ["less temperature dependence", "PROBLEM", 48, 75], ["solvent shielding", "PROBLEM", 88, 105], ["smaller", "OBSERVATION_MODIFIER", 3, 10], ["ring", "OBSERVATION_MODIFIER", 11, 15], ["size", "OBSERVATION_MODIFIER", 16, 20], ["less temperature", "OBSERVATION_MODIFIER", 48, 64], ["dependence", "OBSERVATION_MODIFIER", 65, 75], ["solvent shielding", "OBSERVATION", 88, 105], ["partly due to", "UNCERTAINTY", 115, 128], ["compound", "OBSERVATION_MODIFIER", 155, 163]]], ["The absence of very low temperature dependent NH protons (~2 ppb/K) would appear to rule out the presence of alternative turn structures, such as g-turns.", [["NH", "CHEMICAL", 46, 48], ["NH", "CHEMICAL", 46, 48], ["NH protons", "SIMPLE_CHEMICAL", 46, 56], ["very low temperature dependent NH protons", "PROBLEM", 15, 56], ["alternative turn structures", "PROBLEM", 109, 136]]], ["Finally, the conformations of the peptide backbone of macrocycles 28a and 28h were determined based on 1D 3 J NH-CHa coupling constants ( Table 4 ).", [["NH-CHa", "CHEMICAL", 110, 116], ["the peptide backbone of macrocycles", "TREATMENT", 30, 65]]], ["The coupling constant 3 J NH-CHa correlates with the dihedral angle (j) according to the Karplus equation [28] .", [["NH-CHa", "CHEMICAL", 26, 32]]], ["For unstructured random coil conformations the coupling constant is around 7 Hz while unusually high coupling constants (>9 Hz) are observed for well-structured b-strands.", [["unstructured random coil conformations", "TREATMENT", 4, 42], ["unusually high coupling constants", "PROBLEM", 86, 119]]], ["According to the results shown in Table 4 , the expected b-strand conformation was observed only for the 17-membered ring.ConclusionThe studies described herein demonstrate the feasibility of generating cell-permeable triazole-based macrocyclic inhibitors of norovirus 3CL protease.", [["cell", "ANATOMY", 203, 207], ["triazole", "CHEMICAL", 218, 226], ["triazole", "CHEMICAL", 218, 226], ["cell", "CELL", 203, 207], ["triazole", "SIMPLE_CHEMICAL", 218, 226], ["norovirus", "ORGANISM", 259, 268], ["3CL protease", "GENE_OR_GENE_PRODUCT", 269, 281], ["norovirus 3CL protease", "PROTEIN", 259, 281], ["the 17-membered ring", "TREATMENT", 101, 121], ["The studies", "TEST", 132, 143], ["generating cell-permeable triazole", "TREATMENT", 192, 226], ["macrocyclic inhibitors", "TREATMENT", 233, 255], ["norovirus 3CL protease", "TREATMENT", 259, 281]]], ["Valuable insights into the mechanism of action, conformation, and pharmacological activity were gained using an array of structural, spectroscopic, and antiviral techniques and methodologies.", [["antiviral techniques", "TREATMENT", 152, 172]]], ["The interaction of inhibitor (I) with NV 3CLpro results in subtle structural shifts in the active site topography that impair hydrogen bonding interactions between the P1 Gln residue in the inhibitor and key amino acid residues and contribute to lower pharmacological activity.", [["Gln", "CHEMICAL", 171, 174], ["amino acid", "CHEMICAL", 208, 218], ["hydrogen", "CHEMICAL", 126, 134], ["Gln", "CHEMICAL", 171, 174], ["amino acid", "CHEMICAL", 208, 218], ["NV 3CLpro", "SIMPLE_CHEMICAL", 38, 47], ["hydrogen", "SIMPLE_CHEMICAL", 126, 134], ["amino acid", "AMINO_ACID", 208, 218], ["NV 3CLpro", "TREATMENT", 38, 47], ["subtle structural shifts", "PROBLEM", 59, 83], ["hydrogen bonding interactions", "PROBLEM", 126, 155], ["the P1 Gln residue", "TREATMENT", 164, 182], ["the inhibitor", "TREATMENT", 186, 199], ["key amino acid residues", "TREATMENT", 204, 227], ["lower pharmacological activity", "PROBLEM", 246, 276], ["subtle", "OBSERVATION_MODIFIER", 59, 65], ["structural shifts", "OBSERVATION", 66, 83], ["hydrogen bonding", "OBSERVATION", 126, 142], ["Gln residue", "OBSERVATION", 171, 182], ["amino acid", "OBSERVATION", 208, 218], ["lower", "OBSERVATION_MODIFIER", 246, 251], ["pharmacological activity", "OBSERVATION", 252, 276]]], ["The results of ongoing studies are likely to illuminate further the interplay of ring size, conformation, and cellular permeability, and will reported in due course.GeneralReagents and dry solvents were purchased from various chemical suppliers (Aldrich, Acros Organics, ChemImpex, TCI America, and Bachem) and were used as obtained.", [["cellular", "ANATOMY", 110, 118], ["cellular", "CELL", 110, 118], ["GeneralReagents", "SIMPLE_CHEMICAL", 165, 180], ["ongoing studies", "TEST", 15, 30], ["dry solvents", "TREATMENT", 185, 197], ["Aldrich", "TREATMENT", 246, 253], ["Acros Organics", "TREATMENT", 255, 269], ["ChemImpex", "TREATMENT", 271, 280], ["TCI America", "TREATMENT", 282, 293], ["ring", "OBSERVATION_MODIFIER", 81, 85], ["size", "OBSERVATION_MODIFIER", 86, 90], ["cellular permeability", "OBSERVATION", 110, 131]]], ["Silica gel (230e450 mesh) used for flash chromatography was purchased from Sorbent Technologies (Atlanta, GA).", [["Silica gel", "CHEMICAL", 0, 10], ["Silica gel", "CHEMICAL", 0, 10], ["Silica", "SIMPLE_CHEMICAL", 0, 6], ["Silica gel (230e450 mesh)", "TREATMENT", 0, 25], ["flash chromatography", "PROBLEM", 35, 55]]], ["Thin layer chromatography was performed using Analtech silica gel plates.", [["silica", "CHEMICAL", 55, 61], ["Thin layer chromatography", "TEST", 0, 25], ["Analtech silica gel plates", "TREATMENT", 46, 72]]], ["Visualization was accomplished using UV light and/or iodine.", [["iodine", "CHEMICAL", 53, 59], ["iodine", "CHEMICAL", 53, 59], ["iodine", "SIMPLE_CHEMICAL", 53, 59], ["Visualization", "TEST", 0, 13], ["UV light", "TREATMENT", 37, 45], ["iodine", "TREATMENT", 53, 59]]], ["The 1 H NMR were recorded in CDCl 3 or DMSO-d 6 using a Varian XL-400 spectrometer and are reported relative to TMS (d H \u00bc 0.00 ppm).", [["DMSO", "CHEMICAL", 39, 43], ["1 H", "CHEMICAL", 4, 7], ["CDCl 3", "CHEMICAL", 29, 35], ["DMSO", "CHEMICAL", 39, 43], ["The 1 H NMR", "TEST", 0, 11], ["a Varian XL", "TREATMENT", 54, 65]]], ["Chemical shifts are reported in ppm and spin multiplicities are represented by the following signals: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet) and m (multiplet).", [["d (doublet)", "TREATMENT", 115, 126], ["dd (doublet of doublets)", "TREATMENT", 128, 152], ["t (triplet)", "TREATMENT", 154, 165]]], ["Melting points were Table 2 Crystallographic data for norovirus 3CL protease:Inhibitor structures.GeneralNV 3CLpro:1 NV 3CLpro:3 NV 3CLpro:10Generalis the intensity measured for the ith reflection and is the average intensity of all reflections with indices hkl. c R factor \u00bc S hkl jjF obs (hkl) j \u00c0 jF calc (hkl) jj/S hkl jF obs (hkl)j; Rfree is calculated in an identical manner using 5% of randomly selected reflections that were not included in the refinement. d R meas \u00bc redundancy-independent (multiplicity-weighted) R merge [46] .", [["norovirus", "ORGANISM", 54, 63], ["3CL protease", "GENE_OR_GENE_PRODUCT", 64, 76], ["c R factor", "GENE_OR_GENE_PRODUCT", 263, 273], ["norovirus 3CL protease", "PROTEIN", 54, 76], ["c R factor", "PROTEIN", 263, 273], ["S hkl", "PROTEIN", 276, 281], ["jjF", "PROTEIN", 282, 285], ["hkl", "PROTEIN", 291, 294], ["jF", "PROTEIN", 300, 302], ["hkl", "PROTEIN", 309, 312], ["jj", "PROTEIN", 314, 316], ["S", "PROTEIN", 317, 318], ["jF", "PROTEIN", 323, 325], ["hkl", "PROTEIN", 331, 334], ["Rfree", "PROTEIN", 338, 343], ["norovirus 3CL", "SPECIES", 54, 67], ["Melting points", "PROBLEM", 0, 14], ["Crystallographic data", "TEST", 28, 49], ["norovirus 3CL protease", "TREATMENT", 54, 76], ["Inhibitor structures", "TREATMENT", 77, 97], ["R factor", "TEST", 265, 273], ["hkl", "TEST", 278, 281], ["jjF obs", "TEST", 282, 289], ["hkl", "TEST", 291, 294], ["jF calc", "TEST", 300, 307], ["hkl", "TEST", 309, 312], ["jj/S", "TEST", 314, 318], ["d R meas \u00bc redundancy", "PROBLEM", 465, 486], ["average", "OBSERVATION_MODIFIER", 208, 215], ["intensity", "OBSERVATION_MODIFIER", 216, 225], ["all", "OBSERVATION_MODIFIER", 229, 232], ["reflections", "OBSERVATION", 233, 244], ["jF", "ANATOMY", 300, 302]]], ["R pim \u00bc precision-indicating (multiplicity-weighted) R merge [47, 48] . e CC 1/2 is the correlation coefficient of the mean intensities between two random half-sets of data [49\u00c050].Generalrecorded on a Mel-Temp apparatus and are uncorrected.", [["CC", "CHEMICAL", 74, 76], ["R pim", "GENE_OR_GENE_PRODUCT", 0, 5], ["the mean intensities", "TEST", 115, 135]]], ["High resolution mass spectrometry (HRMS) was performed at the University of Kansas Mass Spectrometry lab using an LCT Premier mass spectrometer (Waters, Milford, MA) equipped with a time of flight mass analyzer and an electrospray ion source.", [["High resolution mass spectrometry", "PROBLEM", 0, 33], ["an LCT Premier mass spectrometer", "TREATMENT", 111, 143], ["flight mass analyzer", "TEST", 190, 210], ["an electrospray ion source", "TREATMENT", 215, 241]]], ["The purity of the compounds was established using HPLC and was >95%.General procedure A. Peptide coupling reactionTo a solution of N-protected amino acid derivative (1.0 eq) in dry DMF was added EDCI (1.22 eq), HOBt (eq) and the reaction mixture was stirred at room temperature for 40 min (Solution A).", [["amino acid", "CHEMICAL", 143, 153], ["DMF", "CHEMICAL", 181, 184], ["EDCI", "CHEMICAL", 195, 199], ["HOBt", "CHEMICAL", 211, 215], ["N", "CHEMICAL", 131, 132], ["amino acid", "CHEMICAL", 143, 153], ["DMF", "CHEMICAL", 181, 184], ["EDCI", "CHEMICAL", 195, 199], ["HOBt", "CHEMICAL", 211, 215], ["N-protected amino acid", "SIMPLE_CHEMICAL", 131, 153], ["DMF", "SIMPLE_CHEMICAL", 181, 184], ["EDCI", "SIMPLE_CHEMICAL", 195, 199], ["HOBt", "SIMPLE_CHEMICAL", 211, 215], ["HPLC", "TEST", 50, 54], ["General procedure", "TREATMENT", 68, 85], ["a solution of N-protected amino acid derivative", "TREATMENT", 117, 164], ["EDCI", "TREATMENT", 195, 199], ["the reaction mixture", "PROBLEM", 225, 245]]], ["In the meantime, O-protected amino acid/amine (1.0 eq) in dry DMF kept at 0 C was added DIEA (4 eq) and stirred for 25 min (Solution B).", [["amino acid", "CHEMICAL", 29, 39], ["amine", "CHEMICAL", 40, 45], ["DMF", "CHEMICAL", 62, 65], ["DIEA", "CHEMICAL", 88, 92], ["amino acid", "CHEMICAL", 29, 39], ["amine", "CHEMICAL", 40, 45], ["DMF", "CHEMICAL", 62, 65], ["DIEA", "CHEMICAL", 88, 92], ["O-protected amino acid", "SIMPLE_CHEMICAL", 17, 39], ["amine", "SIMPLE_CHEMICAL", 40, 45], ["DMF", "SIMPLE_CHEMICAL", 62, 65], ["DIEA", "SIMPLE_CHEMICAL", 88, 92], ["O-protected amino acid/amine", "TREATMENT", 17, 45]]], ["The solvent was removed on the rotary evaporator and residue was taken up with ethyl acetate, washed sequentially with saturated sodium bicarbonate, 5% HCl and brine.", [["ethyl acetate", "CHEMICAL", 79, 92], ["sodium bicarbonate", "CHEMICAL", 129, 147], ["HCl", "CHEMICAL", 152, 155], ["ethyl acetate", "CHEMICAL", 79, 92], ["sodium bicarbonate", "CHEMICAL", 129, 147], ["HCl", "CHEMICAL", 152, 155], ["ethyl acetate", "SIMPLE_CHEMICAL", 79, 92], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 129, 147], ["HCl", "SIMPLE_CHEMICAL", 152, 155], ["The solvent", "TREATMENT", 0, 11], ["the rotary evaporator", "TREATMENT", 27, 48], ["ethyl acetate", "TREATMENT", 79, 92], ["saturated sodium bicarbonate", "TREATMENT", 119, 147]]], ["The organic layer was dried over anhydrous sodium sulfate, filtered and the solvent was removed on the rotary evaporator.", [["sodium sulfate", "CHEMICAL", 43, 57], ["sodium sulfate", "CHEMICAL", 43, 57], ["anhydrous sodium sulfate", "SIMPLE_CHEMICAL", 33, 57], ["The organic layer", "TREATMENT", 0, 17], ["anhydrous sodium sulfate", "TREATMENT", 33, 57], ["the solvent", "TREATMENT", 72, 83], ["the rotary evaporator", "TREATMENT", 99, 120], ["organic", "OBSERVATION_MODIFIER", 4, 11], ["layer", "OBSERVATION_MODIFIER", 12, 17]]], ["See individual experiments for details.General procedure B. Hydrolysis of methyl estersA solution of compound methyl ester (1.0 eq) in dry THF kept in an ice bath was treated with a solution of 1 M lithium hydroxide (3.5 eq) and stirred for 4 h at 0 C until the starting material disappeared (as shown by TLC).", [["methyl estersA solution of compound methyl ester", "CHEMICAL", 74, 122], ["THF", "CHEMICAL", 139, 142], ["lithium hydroxide", "CHEMICAL", 198, 215], ["methyl estersA", "CHEMICAL", 74, 88], ["methyl ester", "CHEMICAL", 110, 122], ["THF", "CHEMICAL", 139, 142], ["lithium hydroxide", "CHEMICAL", 198, 215], ["methyl estersA", "SIMPLE_CHEMICAL", 74, 88], ["compound methyl ester", "SIMPLE_CHEMICAL", 101, 122], ["lithium hydroxide", "SIMPLE_CHEMICAL", 198, 215], ["General procedure", "TREATMENT", 39, 56], ["methyl estersA solution of compound methyl ester", "TREATMENT", 74, 122], ["dry THF", "TREATMENT", 135, 142], ["an ice bath", "TREATMENT", 151, 162], ["a solution of 1 M lithium hydroxide", "TREATMENT", 180, 215]]], ["The solvent was removed and the residue was diluted with water.", [["The solvent", "TREATMENT", 0, 11], ["the residue", "PROBLEM", 28, 39]]], ["The pH of the aqueous solution was adjusted to~2 with 5% HCl and acidified solution was extracted with ethyl acetate and washed with brine.", [["HCl", "CHEMICAL", 57, 60], ["ethyl acetate", "CHEMICAL", 103, 116], ["HCl", "CHEMICAL", 57, 60], ["ethyl acetate", "CHEMICAL", 103, 116], ["HCl", "SIMPLE_CHEMICAL", 57, 60], ["ethyl acetate", "SIMPLE_CHEMICAL", 103, 116], ["The pH", "TEST", 0, 6], ["the aqueous solution", "TREATMENT", 10, 30], ["5% HCl", "TREATMENT", 54, 60], ["acidified solution", "TREATMENT", 65, 83], ["ethyl acetate", "TREATMENT", 103, 116], ["brine", "TREATMENT", 133, 138]]], ["Organic extract was dried using anhydrous sodium sulfate, filtered and solvent was removed on the rotary evaporator.", [["sodium sulfate", "CHEMICAL", 42, 56], ["sodium sulfate", "CHEMICAL", 42, 56], ["anhydrous sodium sulfate", "SIMPLE_CHEMICAL", 32, 56], ["Organic extract", "TREATMENT", 0, 15], ["anhydrous sodium sulfate", "TREATMENT", 32, 56], ["solvent", "TREATMENT", 71, 78], ["the rotary evaporator", "TREATMENT", 94, 115]]], ["For details, see individual experiments.General procedure C. Removal of N-Boc protectionA solution of N-Boc protected compound (1.0 eq) in dry DCM was treated with 4 M HCl in dioxane (10 eq) and stirred at room temperature for 3 h while monitoring the disappearance of the starting material by TLC.", [["N-Boc", "CHEMICAL", 72, 77], ["N-Boc", "CHEMICAL", 102, 107], ["DCM", "DISEASE", 143, 146], ["dioxane", "CHEMICAL", 175, 182], ["N-Boc", "CHEMICAL", 72, 77], ["N-Boc", "CHEMICAL", 102, 107], ["HCl", "CHEMICAL", 168, 171], ["dioxane", "CHEMICAL", 175, 182], ["N-Boc", "SIMPLE_CHEMICAL", 72, 77], ["N-Boc", "SIMPLE_CHEMICAL", 102, 107], ["dioxane", "SIMPLE_CHEMICAL", 175, 182], ["General procedure C. Removal", "TREATMENT", 40, 68], ["N-Boc protectionA solution", "TREATMENT", 72, 98], ["N-Boc protected compound", "TREATMENT", 102, 126], ["4 M HCl in dioxane", "TREATMENT", 164, 182]]], ["Solvent was removed on the rotary evaporator, residue was treated with ether and concentrated.", [["ether", "CHEMICAL", 71, 76], ["ether", "SIMPLE_CHEMICAL", 71, 76], ["Solvent", "TREATMENT", 0, 7], ["the rotary evaporator", "TREATMENT", 23, 44]]], ["See individual experiments for details.General procedure D. Conversion of N-Boc protected alcohol to mesylateTo a solution of N-Boc protected alcohol (60 mmol) and TEA (60 mmol) in dry DCM (100 mL) kept in an ice bath (0 C) was slowly added methane sulfonyl chloride (60 mmol)) and reaction mixture was stirred for 30 min at 0 C. The ice bath was removed and reaction mixture was further allowed to stir at room temperature for 5 h (Completion of the reaction was monitored by TLC).", [["N-Boc", "CHEMICAL", 74, 79], ["alcohol", "CHEMICAL", 90, 97], ["mesylate", "CHEMICAL", 101, 109], ["N-Boc", "CHEMICAL", 126, 131], ["alcohol", "CHEMICAL", 142, 149], ["TEA", "CHEMICAL", 164, 167], ["DCM", "CHEMICAL", 185, 188], ["methane sulfonyl chloride", "CHEMICAL", 241, 266], ["N-Boc", "CHEMICAL", 74, 79], ["alcohol", "CHEMICAL", 90, 97], ["mesylate", "CHEMICAL", 101, 109], ["N-Boc protected alcohol", "CHEMICAL", 126, 149], ["TEA", "CHEMICAL", 164, 167], ["methane sulfonyl chloride", "CHEMICAL", 241, 266], ["N-Boc", "SIMPLE_CHEMICAL", 74, 79], ["alcohol", "SIMPLE_CHEMICAL", 90, 97], ["mesylate", "SIMPLE_CHEMICAL", 101, 109], ["N-Boc", "SIMPLE_CHEMICAL", 126, 131], ["alcohol", "SIMPLE_CHEMICAL", 142, 149], ["TEA", "SIMPLE_CHEMICAL", 164, 167], ["methane sulfonyl chloride", "SIMPLE_CHEMICAL", 241, 266], ["mesylate", "TREATMENT", 101, 109], ["a solution of N-Boc protected alcohol", "TREATMENT", 112, 149], ["TEA", "TREATMENT", 164, 167], ["an ice bath", "TREATMENT", 206, 217], ["slowly added methane sulfonyl chloride", "TREATMENT", 228, 266], ["The ice bath", "TREATMENT", 330, 342], ["reaction mixture", "PROBLEM", 359, 375], ["the reaction", "PROBLEM", 447, 459]]], ["Then water (50 mL) was added with stirring, the resulting solution was transferred to a reparatory funnel, organic layer was separated and aqueous layer was extracted with DCM (2 \u00c2 75 mL).", [["aqueous layer", "ANATOMY", 139, 152], ["DCM", "CHEMICAL", 172, 175], ["aqueous layer", "ORGANISM_SUBSTANCE", 139, 152], ["a reparatory funnel, organic layer", "TREATMENT", 86, 120], ["aqueous layer", "TREATMENT", 139, 152], ["DCM", "TREATMENT", 172, 175]]], ["The combined organic layers were washed with brine (50 mL) dried over anhydrous sodium sulfate and concentrated on rotary evaporator.", [["sodium sulfate", "CHEMICAL", 80, 94], ["sodium sulfate", "CHEMICAL", 80, 94], ["anhydrous sodium sulfate", "SIMPLE_CHEMICAL", 70, 94], ["The combined organic layers", "TREATMENT", 0, 27], ["anhydrous sodium sulfate", "TREATMENT", 70, 94], ["rotary evaporator", "TREATMENT", 115, 132], ["organic", "OBSERVATION_MODIFIER", 13, 20], ["layers", "OBSERVATION_MODIFIER", 21, 27]]], ["See individual experiments for more details.General procedure E. Conversion of N-Boc protected mesylate to azideTo a solution of compound N-Boc protected mesylate (60 mmol) in dry DMF (150 mL) was added in small portions NaN 3 (180 mmol) with stirring over 30 min.", [["N-Boc", "CHEMICAL", 79, 84], ["mesylate", "CHEMICAL", 95, 103], ["azideTo", "CHEMICAL", 107, 114], ["compound N-Boc", "CHEMICAL", 129, 143], ["mesylate", "CHEMICAL", 154, 162], ["DMF", "CHEMICAL", 180, 183], ["N-Boc", "CHEMICAL", 79, 84], ["mesylate", "CHEMICAL", 95, 103], ["azideTo", "CHEMICAL", 107, 114], ["N-Boc protected mesylate", "CHEMICAL", 138, 162], ["DMF", "CHEMICAL", 180, 183], ["NaN 3", "CHEMICAL", 221, 226], ["N-Boc", "SIMPLE_CHEMICAL", 79, 84], ["mesylate", "SIMPLE_CHEMICAL", 95, 103], ["azideTo", "SIMPLE_CHEMICAL", 107, 114], ["N-Boc", "SIMPLE_CHEMICAL", 138, 143], ["mesylate", "SIMPLE_CHEMICAL", 154, 162], ["DMF", "SIMPLE_CHEMICAL", 180, 183], ["General procedure", "TREATMENT", 44, 61], ["Boc protected mesylate", "TREATMENT", 81, 103], ["a solution of compound N-Boc protected mesylate", "TREATMENT", 115, 162]]], ["Then water (50 mL) was added with stirring, solvent was removed and residue was extracted with ethyl acetate (2 \u00c2 175 mL).", [["ethyl acetate", "CHEMICAL", 95, 108], ["ethyl acetate", "CHEMICAL", 95, 108], ["ethyl acetate", "SIMPLE_CHEMICAL", 95, 108], ["solvent", "TREATMENT", 44, 51], ["ethyl acetate", "TREATMENT", 95, 108]]], ["The combined organic layers were washed sequentially with water (2 \u00c2 50 mL), brine (2 \u00c2 50 mL) and solvent was dried over anhydrous sodium sulfate and evaporated on rotary evaporator.", [["sodium sulfate", "CHEMICAL", 132, 146], ["sodium sulfate", "CHEMICAL", 132, 146], ["anhydrous sodium sulfate", "SIMPLE_CHEMICAL", 122, 146], ["The combined organic layers", "TREATMENT", 0, 27], ["solvent", "TREATMENT", 99, 106], ["anhydrous sodium sulfate", "TREATMENT", 122, 146], ["rotary evaporator", "TREATMENT", 165, 182], ["organic layers", "OBSERVATION", 13, 27]]], ["See individual experiments for more details.General procedure F. Intermolecular click reactionsTo a stirred solution of alkyne (5 mmol) in a mixture of water and THF (1:1, 25 mL) was added corresponding azide (5 mmol) followed by addition of sodium ascorbate (0.5 mmol) and CuSO 4 .5H 2 O (0.25 mmol).", [["alkyne", "CHEMICAL", 120, 126], ["THF", "CHEMICAL", 162, 165], ["azide", "CHEMICAL", 203, 208], ["sodium ascorbate", "CHEMICAL", 242, 258], ["CuSO 4 .5H 2 O", "CHEMICAL", 274, 288], ["alkyne", "CHEMICAL", 120, 126], ["THF", "CHEMICAL", 162, 165], ["azide", "CHEMICAL", 203, 208], ["sodium ascorbate", "CHEMICAL", 242, 258], ["CuSO 4 .5H 2 O", "CHEMICAL", 274, 288], ["alkyne", "SIMPLE_CHEMICAL", 120, 126], ["water", "SIMPLE_CHEMICAL", 152, 157], ["THF", "SIMPLE_CHEMICAL", 162, 165], ["azide", "SIMPLE_CHEMICAL", 203, 208], ["sodium ascorbate", "SIMPLE_CHEMICAL", 242, 258], ["CuSO 4 .5H 2 O", "SIMPLE_CHEMICAL", 274, 288], ["General procedure", "TREATMENT", 44, 61], ["Intermolecular click reactions", "PROBLEM", 65, 95], ["a stirred solution of alkyne", "TREATMENT", 98, 126], ["THF", "TREATMENT", 162, 165], ["sodium ascorbate", "TREATMENT", 242, 258], ["CuSO", "TREATMENT", 274, 278], ["Intermolecular click", "OBSERVATION", 65, 85]]], ["See individual experiments for more details.General procedure G. Intramolecular click reactionTo a solution of macrocycle precursor (0.512 mmol) in dry DCM (1.2 M) under N 2 atmosphere, was added DBU (1.53 mmol) while solution was stirring vigorously at room temperature.", [["DCM", "CHEMICAL", 152, 155], ["DBU", "CHEMICAL", 196, 199], ["DBU", "CHEMICAL", 196, 199], ["DBU", "SIMPLE_CHEMICAL", 196, 199], ["General procedure", "TREATMENT", 44, 61], ["Intramolecular click", "PROBLEM", 65, 85], ["a solution of macrocycle precursor", "TREATMENT", 97, 131], ["dry DCM", "PROBLEM", 148, 155], ["DBU", "TREATMENT", 196, 199], ["Intramolecular click", "OBSERVATION", 65, 85]]], ["After 15 min Cu(I)Br (0.512 mmol) was added and reaction mixture was stirred for 12 h at room temperature.", [["Cu", "CHEMICAL", 13, 15], ["Br", "CHEMICAL", 18, 20], ["Cu(I)Br", "CHEMICAL", 13, 20], ["Cu(I)Br", "SIMPLE_CHEMICAL", 13, 20]]], ["After that it was quenched by adding 3 M HCl (100 mL), aqueous layer was separated and extracted with DCM (2 \u00c2 500 mL).", [["aqueous layer", "ANATOMY", 55, 68], ["HCl", "CHEMICAL", 41, 44], ["DCM", "CHEMICAL", 102, 105], ["HCl", "CHEMICAL", 41, 44], ["HCl", "SIMPLE_CHEMICAL", 41, 44], ["aqueous layer", "TREATMENT", 55, 68], ["DCM", "TREATMENT", 102, 105]]], ["The combined organic layers were washed sequentially with water (300 mL), brine (300 mL), dried over anhydrous sodium sulfate, filtered and concentrated on rotary evaporator.", [["sodium sulfate", "CHEMICAL", 111, 125], ["sodium sulfate", "CHEMICAL", 111, 125], ["anhydrous sodium sulfate", "SIMPLE_CHEMICAL", 101, 125], ["The combined organic layers", "TREATMENT", 0, 27], ["anhydrous sodium sulfate", "TREATMENT", 101, 125], ["rotary evaporator", "TREATMENT", 156, 173], ["organic layers", "OBSERVATION", 13, 27]]], ["See individual experiments for more details.General procedure H. Macrolactamization reactionTo a solution of macrocycle precursor (1 mmol) in dry DMF (2 M) was added DIEA (4 mmol) and stirred for 30 min.", [["DMF", "CHEMICAL", 146, 149], ["DIEA", "CHEMICAL", 166, 170], ["DMF", "CHEMICAL", 146, 149], ["DIEA", "CHEMICAL", 166, 170], ["macrocycle precursor", "SIMPLE_CHEMICAL", 109, 129], ["DMF", "SIMPLE_CHEMICAL", 146, 149], ["DIEA", "SIMPLE_CHEMICAL", 166, 170], ["General procedure", "TREATMENT", 44, 61], ["a solution of macrocycle precursor", "TREATMENT", 95, 129]]], ["After that, was added EDCI (1.25 mmol) followed by HOBt (1.25 mmol) and resulting solution was stirred for 20 h at room temperature.", [["EDCI", "CHEMICAL", 22, 26], ["HOBt", "CHEMICAL", 51, 55], ["EDCI", "CHEMICAL", 22, 26], ["HOBt", "CHEMICAL", 51, 55], ["EDCI", "SIMPLE_CHEMICAL", 22, 26], ["HOBt", "SIMPLE_CHEMICAL", 51, 55], ["EDCI", "TREATMENT", 22, 26]]], ["The solvent was removed on the rotary evaporator and residue was taken up with DCM, washed sequentially with saturated sodium bicarbonate, 5% HCl and brine.", [["DCM", "DISEASE", 79, 82], ["sodium bicarbonate", "CHEMICAL", 119, 137], ["HCl", "CHEMICAL", 142, 145], ["sodium bicarbonate", "CHEMICAL", 119, 137], ["HCl", "CHEMICAL", 142, 145], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 119, 137], ["HCl", "SIMPLE_CHEMICAL", 142, 145], ["The solvent", "TREATMENT", 0, 11], ["the rotary evaporator", "TREATMENT", 27, 48], ["DCM", "PROBLEM", 79, 82], ["saturated sodium bicarbonate", "TREATMENT", 109, 137]]], ["The organic layer was dried over anhydrous sodium sulfate, filtered and the solvent was removed on the rotary evaporator.", [["sodium sulfate", "CHEMICAL", 43, 57], ["sodium sulfate", "CHEMICAL", 43, 57], ["anhydrous sodium sulfate", "SIMPLE_CHEMICAL", 33, 57], ["The organic layer", "TREATMENT", 0, 17], ["anhydrous sodium sulfate", "TREATMENT", 33, 57], ["the solvent", "TREATMENT", 72, 83], ["the rotary evaporator", "TREATMENT", 99, 120], ["organic", "OBSERVATION_MODIFIER", 4, 11], ["layer", "OBSERVATION_MODIFIER", 12, 17]]], ["See individual experiments for details.General procedure I. Reduction of macrocycle estersTo a solution of compound macrocycle ester (1 mmol) in dry THF (6 mL) was added a solution of 2 M LiBH 4 (3.0 mmol) drop wise followed by drop wise addition of absolute ethanol (11 mL) and was stirred at room temperature for 16 h while monitoring the disappearance of the starting material by TLC.", [["macrocycle esters", "CHEMICAL", 73, 90], ["macrocycle ester", "CHEMICAL", 116, 132], ["THF", "CHEMICAL", 149, 152], ["LiBH", "CHEMICAL", 188, 192], ["ethanol", "CHEMICAL", 259, 266], ["macrocycle esters", "CHEMICAL", 73, 90], ["macrocycle ester", "CHEMICAL", 116, 132], ["THF", "CHEMICAL", 149, 152], ["LiBH 4", "CHEMICAL", 188, 194], ["ethanol", "CHEMICAL", 259, 266], ["macrocycle esters", "SIMPLE_CHEMICAL", 73, 90], ["compound macrocycle ester", "SIMPLE_CHEMICAL", 107, 132], ["THF", "SIMPLE_CHEMICAL", 149, 152], ["ethanol", "SIMPLE_CHEMICAL", 259, 266], ["General procedure", "TREATMENT", 39, 56], ["Reduction of macrocycle esters", "TREATMENT", 60, 90], ["a solution of compound macrocycle ester", "TREATMENT", 93, 132], ["dry THF", "TREATMENT", 145, 152], ["a solution of 2 M LiBH", "TREATMENT", 170, 192], ["absolute ethanol", "TREATMENT", 250, 266]]], ["After that solvent was removed on the rotary evaporator and residue was partitioned between ethyl acetate and 1 M KHSO 4 .", [["ethyl acetate", "CHEMICAL", 92, 105], ["ethyl acetate", "CHEMICAL", 92, 105], ["KHSO 4", "CHEMICAL", 114, 120], ["ethyl acetate", "SIMPLE_CHEMICAL", 92, 105], ["the rotary evaporator", "TREATMENT", 34, 55], ["ethyl acetate", "TREATMENT", 92, 105]]], ["The aqueous phase was extracted twice more chloroform and each organic extract was washed with brine separately, dried over anhydrous sodium sulfate and evaporated to give corresponding alcohol.", [["chloroform", "CHEMICAL", 43, 53], ["sodium sulfate", "CHEMICAL", 134, 148], ["alcohol", "CHEMICAL", 186, 193], ["chloroform", "CHEMICAL", 43, 53], ["sodium sulfate", "CHEMICAL", 134, 148], ["alcohol", "CHEMICAL", 186, 193], ["aqueous", "ORGANISM_SUBSTANCE", 4, 11], ["chloroform", "SIMPLE_CHEMICAL", 43, 53], ["anhydrous sodium sulfate", "SIMPLE_CHEMICAL", 124, 148], ["alcohol", "SIMPLE_CHEMICAL", 186, 193], ["anhydrous sodium sulfate", "TREATMENT", 124, 148], ["aqueous phase", "OBSERVATION_MODIFIER", 4, 17]]], ["See individual experiments for more details.General procedure J. Oxidation of macrocyclic alcoholsCorresponding macrocycle alcohol (0.36 mmol) was suspended in dry DCM (40 mL) under N 2 atmosphere and was added Dessemartin periodinane (1.08 mmol).", [["macrocyclic alcohols", "CHEMICAL", 78, 98], ["macrocycle alcohol", "CHEMICAL", 112, 130], ["DCM", "CHEMICAL", 164, 167], ["Dessemartin periodinane", "CHEMICAL", 211, 234], ["macrocyclic alcohols", "CHEMICAL", 78, 98], ["macrocycle alcohol", "CHEMICAL", 112, 130], ["Dessemartin periodinane", "CHEMICAL", 211, 234], ["macrocyclic alcohols", "SIMPLE_CHEMICAL", 78, 98], ["macrocycle alcohol", "SIMPLE_CHEMICAL", 112, 130], ["Dessemartin periodinane", "SIMPLE_CHEMICAL", 211, 234], ["macrocyclic alcohols", "TREATMENT", 78, 98], ["Dessemartin periodinane", "TREATMENT", 211, 234]]], ["Reaction mixture was stirred for 4 h at room temperature and quenched with saturated sodium bicarbonate solution containing 10% Sodium thiosulfate (10 mL).", [["sodium bicarbonate", "CHEMICAL", 85, 103], ["Sodium thiosulfate", "CHEMICAL", 128, 146], ["sodium bicarbonate", "CHEMICAL", 85, 103], ["Sodium thiosulfate", "CHEMICAL", 128, 146], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 85, 103], ["Sodium thiosulfate", "SIMPLE_CHEMICAL", 128, 146], ["saturated sodium bicarbonate solution", "TREATMENT", 75, 112], ["10% Sodium thiosulfate", "TREATMENT", 124, 146]]], ["Organic layer was separated and aqueous layer was extracted with DCM (2 \u00c2 60 mL), combined organic layers were washed with brine (40 mL), dried over anhydrous sodium sulfate and solvent was evaporated on rotary evaporator.", [["aqueous layer", "ANATOMY", 32, 45], ["DCM", "CHEMICAL", 65, 68], ["sodium sulfate", "CHEMICAL", 159, 173], ["sodium sulfate", "CHEMICAL", 159, 173], ["aqueous layer", "ORGANISM_SUBSTANCE", 32, 45], ["anhydrous sodium sulfate", "SIMPLE_CHEMICAL", 149, 173], ["Organic layer", "TREATMENT", 0, 13], ["aqueous layer", "TREATMENT", 32, 45], ["DCM", "TREATMENT", 65, 68], ["combined organic layers", "TREATMENT", 82, 105], ["brine", "TREATMENT", 123, 128], ["anhydrous sodium sulfate", "TREATMENT", 149, 173], ["solvent", "TREATMENT", 178, 185], ["rotary evaporator", "TREATMENT", 204, 221], ["layer", "OBSERVATION_MODIFIER", 8, 13], ["aqueous", "OBSERVATION_MODIFIER", 32, 39], ["layer", "OBSERVATION_MODIFIER", 40, 45]]], ["See individual experiments for more details.Methyl ((S)-2-((tert-butoxycarbonyl)amino)pent-4-ynoyl)-Lleucinate 13aBoc-L-Propargylglycine (6.39 g; 30 mmol) in dry DMF (70 mL) was reacted with L-Leu-OMe(HCl) (30 mmol) according to general procedure A and crude product was purified using flash chromatography (silica gel; hexane/ethyl acetate 75:25) to give 13a as a white solid (9.0 g; 89% yield); M.p.", [["Methyl", "CHEMICAL", 44, 50], ["(S)-2-((tert-butoxycarbonyl)amino)pent-4-ynoyl)-Lleucinate 13aBoc-L-Propargylglycine", "CHEMICAL", 52, 136], ["DMF", "CHEMICAL", 162, 165], ["L-Leu-OMe", "CHEMICAL", 191, 200], ["HCl", "CHEMICAL", 201, 204], ["silica gel", "CHEMICAL", 308, 318], ["hexane/ethyl acetate", "CHEMICAL", 320, 340], ["Methyl ((S)-2-((tert-butoxycarbonyl)amino)pent-4-ynoyl)-Lleucinate 13aBoc-L-Propargylglycine", "CHEMICAL", 44, 136], ["DMF", "CHEMICAL", 162, 165], ["L-Leu-OMe", "CHEMICAL", 191, 200], ["HCl", "CHEMICAL", 201, 204], ["silica gel", "CHEMICAL", 308, 318], ["hexane", "CHEMICAL", 320, 326], ["ethyl acetate", "CHEMICAL", 327, 340], ["Methyl ((S)-2-((tert-butoxycarbonyl)amino)pent-4-ynoyl)-Lleucinate 13aBoc-L-Propargylglycine", "SIMPLE_CHEMICAL", 44, 136], ["DMF", "SIMPLE_CHEMICAL", 162, 165], ["L-Leu-OMe", "SIMPLE_CHEMICAL", 191, 200], ["HCl", "SIMPLE_CHEMICAL", 201, 204], ["silica", "SIMPLE_CHEMICAL", 308, 314], ["hexane", "SIMPLE_CHEMICAL", 320, 326], ["ethyl acetate 75:25", "SIMPLE_CHEMICAL", 327, 346], ["13a", "SIMPLE_CHEMICAL", 356, 359], ["Methyl ((S)", "TREATMENT", 44, 55], ["tert-butoxycarbonyl)amino)", "TREATMENT", 60, 86], ["Lleucinate", "TREATMENT", 100, 110], ["Propargylglycine", "TREATMENT", 120, 136], ["L-Leu-OMe(HCl)", "TREATMENT", 191, 205], ["general procedure A and crude product", "TREATMENT", 229, 266], ["flash chromatography (silica gel", "TREATMENT", 286, 318], ["hexane/ethyl acetate", "TREATMENT", 320, 340]]], ["76e78 C; 1 Compounds 13b and 13c were prepared using a similar procedure as the one described above.Methyl (S)-2-((S)-2-((tert-butoxycarbonyl)amino)pent-4ynamido)-3-cyclohexylpropanoate 13bWhite solid (9.2 g; 81% yield); M.p 85e87 C; 1 Compound 13a (6.8 g; 20 mmol) in dry CH 2 Cl 2 (30 mL) was treated with 1 M HCl in dioxane to remove Boc protection according to general procedure C and solvent was removed after the reaction, under high vacuum to dryness.", [["Methyl (S)-2-((S)-2-((tert-butoxycarbonyl)amino)pent-4ynamido)-3-cyclohexylpropanoate 13bWhite", "CHEMICAL", 100, 194], ["M.p 85e87 C", "CHEMICAL", 221, 232], ["CH 2 Cl", "CHEMICAL", 273, 280], ["HCl", "CHEMICAL", 312, 315], ["Boc", "CHEMICAL", 337, 340], ["Methyl (S)-2-((S)-2-((tert-butoxycarbonyl)amino)pent-4ynamido)-3-cyclohexylpropanoate", "CHEMICAL", 100, 185], ["M.p 85e87 C", "CHEMICAL", 221, 232], ["CH 2 Cl 2", "CHEMICAL", 273, 282], ["HCl", "CHEMICAL", 312, 315], ["dioxane", "CHEMICAL", 319, 326], ["Boc", "CHEMICAL", 337, 340], ["13c", "SIMPLE_CHEMICAL", 29, 32], ["Methyl (S)-2-((S)-2-((tert-butoxycarbonyl)amino)pent-4ynamido)-3-cyclohexylpropanoate", "SIMPLE_CHEMICAL", 100, 185], ["M.p 85e87 C", "SIMPLE_CHEMICAL", 221, 232], ["Compound 13a", "SIMPLE_CHEMICAL", 236, 248], ["dioxane", "SIMPLE_CHEMICAL", 319, 326], ["Boc", "SIMPLE_CHEMICAL", 337, 340], ["a similar procedure", "TREATMENT", 53, 72], ["Methyl (S)", "TREATMENT", 100, 110], ["(tert-butoxycarbonyl)amino)", "TREATMENT", 121, 148], ["dioxane", "TREATMENT", 319, 326], ["Boc protection", "TREATMENT", 337, 351], ["general procedure C and solvent", "TREATMENT", 365, 396], ["the reaction", "PROBLEM", 415, 427], ["dryness", "PROBLEM", 450, 457]]], ["To a solution of resulting HCl salt of the amine in dry THF (70 mL) was added DIEA (12.9 g; 100 mmol) and stirred for 30 min.", [["HCl salt", "CHEMICAL", 27, 35], ["amine", "CHEMICAL", 43, 48], ["THF", "CHEMICAL", 56, 59], ["DIEA", "CHEMICAL", 78, 82], ["HCl", "CHEMICAL", 27, 30], ["amine", "CHEMICAL", 43, 48], ["THF", "CHEMICAL", 56, 59], ["DIEA", "CHEMICAL", 78, 82], ["HCl salt", "SIMPLE_CHEMICAL", 27, 35], ["amine", "SIMPLE_CHEMICAL", 43, 48], ["THF", "SIMPLE_CHEMICAL", 56, 59], ["DIEA", "SIMPLE_CHEMICAL", 78, 82], ["resulting HCl salt of the amine in dry THF", "TREATMENT", 17, 59]]], ["After that, benzyl chloroformate (3.75 g; 22 mmol) was added and the resulting solution was further reacted for 16 h at room temperature.", [["benzyl chloroformate", "CHEMICAL", 12, 32], ["benzyl chloroformate", "CHEMICAL", 12, 32], ["benzyl chloroformate", "SIMPLE_CHEMICAL", 12, 32], ["benzyl chloroformate", "TREATMENT", 12, 32], ["the resulting solution", "TREATMENT", 65, 87]]], ["The solvent was removed on the rotary evaporator and the residue was taken up in ethyl acetate (150 mL) and washed sequentially with saturated NaHCO 3 (50 mL), 5% HCl (2 \u00c2 50 mL) and brine (50 mL).", [["ethyl acetate", "CHEMICAL", 81, 94], ["NaHCO", "CHEMICAL", 143, 148], ["HCl", "CHEMICAL", 163, 166], ["ethyl acetate", "CHEMICAL", 81, 94], ["NaHCO 3", "CHEMICAL", 143, 150], ["HCl", "CHEMICAL", 163, 166], ["ethyl acetate", "SIMPLE_CHEMICAL", 81, 94], ["HCl", "SIMPLE_CHEMICAL", 163, 166], ["The solvent", "TREATMENT", 0, 11], ["the rotary evaporator", "TREATMENT", 27, 48], ["the residue", "PROBLEM", 53, 64], ["ethyl acetate", "TREATMENT", 81, 94], ["saturated NaHCO", "TREATMENT", 133, 148]]], ["The organic layer was dried over anhydrous sodium sulfate, filtered and solvent was removed on the rotary evaporator to give 14a as a white solid (6.7 g: 90% yield); M.p 79e80 C. 1 Compounds 14b and 14c were prepared according to the same procedure as above.Methyl (S)-2-((S)-2-(((benzyloxy)carbonyl)amino)pent-4ynamido)-3-cyclohexylpropanoate 14bWhite solid (7.6 g: 92% yield); M.p 86e88 C. 1Methyl ((S)-2-(((benzyloxy)carbonyl)amino)pent-4-ynoyl)-L-phenylalaninate 14cWhite solid (6.9 g: 85% yield); M.p 106e108 C. 1((S)-2-(((benzyloxy)carbonyl)amino)pent-4-ynoyl)-Lleucine 15aA solution of compound 14a (5.6 g; 15 mmol) in dry THF (60 mL) was hydrolyzed according to general procedure B. The crude product was purified by Flash chromatography (Silica gel; Hexane/ Ethyl acetate 50:50) to give 15a as a colorless oil (4.5 g; 84% yield); Compounds 15b and 15c were prepared using the same procedure as described above.(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)pent-4ynamido)-3-cyclohexylpropanoic acid 15bColorless oil (Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aA solution of 2-(Boc-amino)-1-ethanol (9.6 g: 60 mmol) in dry DCM (100 mL) was converted in to mesylate according to general procedure D to yield 16b as a colorless oil (13.4 g; 94% yield).Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aCompound 16a (11.9 g; 50 mmol) was dissolve in dry DMF (120 mL) and converted in to azide according to general procedure E to yield 17a as a light yellow oil (7.2 g; 78% yield).Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aA solution of compound 17a (6.8 g; 37 mmol) in dry CH 2 Cl 2 (30 mL) was treated with 1 M HCl in dioxane to remove Boc protection according to general procedure C and solvent was removed after the reaction under high vacuum to dryness resulting compound 18a.Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aBoceGlueOMe (9.67 g; 37 mmol) in dry DMF (100 mL) was reacted with compound 18a (4.5 g: 37 mmol) according to general procedure A and the crude product was purified by flash chromatography (silica gel; hexane/ethyl acetate 70:30) to give 19a as a colorless oil (9.5 g; 78% yield); 1 Compounds 19bee were prepared using the same procedure as described above.Methyl N 5 -(3-azidopropyl)-N 2 -(tert-butoxycarbonyl)-Lglutaminate 19bColorless oil ( Compound 20b was prepared using the same procedure as described above.Methyl N 5 -(4-azidobutyl)-L-glutaminate hydrochloride 20bYellow oil ( To a solution of sodium azide (2.27 g; 35 mmol) suspended in anhydrous acetonitrile (35 mL) at 0 C was added triflic anhydride (8.18 g; 29 mmol) dropwise over 10 min and the cooled solution was stirred for 2 h.", [["colorless oil", "ANATOMY", 1242, 1255], ["sodium sulfate", "CHEMICAL", 43, 57], ["Methyl (S)-2-((S)-2-(((benzyloxy)carbonyl)amino)pent-4ynamido)-3-cyclohexylpropanoate", "CHEMICAL", 258, 343], ["M.p 86e88 C. 1Methyl ((S)-2-(((benzyloxy)carbonyl)amino)pent-4-ynoyl)-L-phenylalaninate 14cWhite", "CHEMICAL", 379, 475], ["M.p 106e108 C. 1((S)-2-(((benzyloxy)carbonyl)amino)pent-4-ynoyl)-Lleucine 15aA solution of compound 14a", "CHEMICAL", 502, 605], ["THF", "CHEMICAL", 630, 633], ["Silica gel", "CHEMICAL", 747, 757], ["Hexane/ Ethyl acetate", "CHEMICAL", 759, 780], ["15a", "CHEMICAL", 796, 799], ["S)-2-((S)-2-(((benzyloxy)carbonyl)amino)pent-4ynamido)-3-cyclohexylpropanoic acid", "CHEMICAL", 920, 1001], ["Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aA", "CHEMICAL", 1020, 1088], ["2-(Boc-amino)-1-ethanol", "CHEMICAL", 1101, 1124], ["DCM", "CHEMICAL", 1149, 1152], ["mesylate", "CHEMICAL", 1182, 1190], ["Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aCompound 16a", "CHEMICAL", 1276, 1355], ["DMF", "CHEMICAL", 1394, 1397], ["azide", "CHEMICAL", 1427, 1432], ["Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aA", "CHEMICAL", 1520, 1588], ["compound 17a", "CHEMICAL", 1601, 1613], ["CH 2 Cl 2", "CHEMICAL", 1638, 1647], ["HCl", "CHEMICAL", 1677, 1680], ["dioxane", "CHEMICAL", 1684, 1691], ["Boc", "CHEMICAL", 1702, 1705], ["Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aBoceGlueOMe", "CHEMICAL", 1845, 1923], ["DMF", "CHEMICAL", 1949, 1952], ["compound 18a", "CHEMICAL", 1979, 1991], ["silica gel", "CHEMICAL", 2102, 2112], ["hexane/ethyl acetate", "CHEMICAL", 2114, 2134], ["19a", "CHEMICAL", 2150, 2153], ["Methyl N 5 -(3-azidopropyl)-N 2 -(tert-butoxycarbonyl)-Lglutaminate", "CHEMICAL", 2269, 2336], ["Compound 20b", "CHEMICAL", 2356, 2368], ["Methyl N 5 -(4-azidobutyl)-L-glutaminate hydrochloride", "CHEMICAL", 2426, 2480], ["sodium azide", "CHEMICAL", 2514, 2526], ["anhydrous acetonitrile", "CHEMICAL", 2558, 2580], ["triflic anhydride", "CHEMICAL", 2606, 2623], ["sodium sulfate", "CHEMICAL", 43, 57], ["Methyl (S)-2-((S)-2-(((benzyloxy)carbonyl)amino)pent-4ynamido)-3-cyclohexylpropanoate", "CHEMICAL", 258, 343], ["(S)-2-(((benzyloxy)carbonyl)amino)pent-4-ynoyl)-L-phenylalaninate 14cWhite", "CHEMICAL", 401, 475], ["(S)-2-(((benzyloxy)carbonyl)amino)pent-4-ynoyl)-Lleucine 15aA", "CHEMICAL", 519, 580], ["THF", "CHEMICAL", 630, 633], ["Silica gel", "CHEMICAL", 747, 757], ["Hexane", "CHEMICAL", 759, 765], ["Ethyl acetate", "CHEMICAL", 767, 780], ["(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)pent-4ynamido)-3-cyclohexylpropanoic acid", "CHEMICAL", 919, 1001], ["Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aA", "CHEMICAL", 1020, 1088], ["2-(Boc-amino)-1-ethanol", "CHEMICAL", 1101, 1124], ["mesylate", "CHEMICAL", 1182, 1190], ["Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate", "CHEMICAL", 1276, 1339], ["DMF", "CHEMICAL", 1394, 1397], ["azide", "CHEMICAL", 1427, 1432], ["Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aA", "CHEMICAL", 1520, 1588], ["CH 2 Cl 2", "CHEMICAL", 1638, 1647], ["HCl", "CHEMICAL", 1677, 1680], ["dioxane", "CHEMICAL", 1684, 1691], ["Boc", "CHEMICAL", 1702, 1705], ["Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate", "CHEMICAL", 1845, 1908], ["BoceGlueOMe", "CHEMICAL", 1912, 1923], ["DMF", "CHEMICAL", 1949, 1952], ["silica gel", "CHEMICAL", 2102, 2112], ["hexane", "CHEMICAL", 2114, 2120], ["ethyl acetate", "CHEMICAL", 2121, 2134], ["Methyl N 5 -(3-azidopropyl)-N 2 -(tert-butoxycarbonyl)-Lglutaminate", "CHEMICAL", 2269, 2336], ["Methyl N 5 -(4-azidobutyl)-L-glutaminate hydrochloride", "CHEMICAL", 2426, 2480], ["sodium azide", "CHEMICAL", 2514, 2526], ["anhydrous acetonitrile", "CHEMICAL", 2558, 2580], ["triflic anhydride", "CHEMICAL", 2606, 2623], ["anhydrous sodium sulfate", "SIMPLE_CHEMICAL", 33, 57], ["14c", "SIMPLE_CHEMICAL", 199, 202], ["Methyl (S)-2-((S)-2-(((benzyloxy)carbonyl)amino)pent-4ynamido)-3-cyclohexylpropanoate", "SIMPLE_CHEMICAL", 258, 343], ["M.p 86e88 C. 1Methyl ((S)-2-(((benzyloxy)carbonyl)amino)pent-4-ynoyl)-L-phenylalaninate", "SIMPLE_CHEMICAL", 379, 466], ["M.p 106e108 C. 1((S)-2-(((benzyloxy)carbonyl)amino)pent-4-ynoyl)-Lleucine 15aA", "SIMPLE_CHEMICAL", 502, 580], ["compound 14a", "SIMPLE_CHEMICAL", 593, 605], ["THF", "SIMPLE_CHEMICAL", 630, 633], ["Silica", "SIMPLE_CHEMICAL", 747, 753], ["Hexane", "SIMPLE_CHEMICAL", 759, 765], ["Ethyl acetate 50:50", "SIMPLE_CHEMICAL", 767, 786], ["15a", "SIMPLE_CHEMICAL", 796, 799], ["oil", "ORGANISM_SUBSTANCE", 815, 818], ["15c", "SIMPLE_CHEMICAL", 857, 860], ["(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)pent-4ynamido)-3-cyclohexylpropanoic acid 15bColorless oil", "SIMPLE_CHEMICAL", 919, 1018], ["Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aA", "SIMPLE_CHEMICAL", 1020, 1088], ["2-(Boc-amino)-1-ethanol", "SIMPLE_CHEMICAL", 1101, 1124], ["mesylate", "SIMPLE_CHEMICAL", 1182, 1190], ["16b", "SIMPLE_CHEMICAL", 1233, 1236], ["oil", "ORGANISM_SUBSTANCE", 1252, 1255], ["Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aCompound 16a", "SIMPLE_CHEMICAL", 1276, 1355], ["DMF", "SIMPLE_CHEMICAL", 1394, 1397], ["azide", "SIMPLE_CHEMICAL", 1427, 1432], ["oil", "ORGANISM_SUBSTANCE", 1497, 1500], ["Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aA", "SIMPLE_CHEMICAL", 1520, 1588], ["compound 17a", "SIMPLE_CHEMICAL", 1601, 1613], ["dioxane", "SIMPLE_CHEMICAL", 1684, 1691], ["Boc", "SIMPLE_CHEMICAL", 1702, 1705], ["Methyl N5-(3-azidoropyl)-N2-(tert-butyoxycarbonyl)-Lglutaminate 19aBoceGlueOMe", "SIMPLE_CHEMICAL", 1845, 1923], ["DMF", "SIMPLE_CHEMICAL", 1949, 1952], ["18a", "SIMPLE_CHEMICAL", 1988, 1991], ["silica", "SIMPLE_CHEMICAL", 2102, 2108], ["hexane", "SIMPLE_CHEMICAL", 2114, 2120], ["ethyl acetate 70:30", "SIMPLE_CHEMICAL", 2121, 2140], ["19a", "SIMPLE_CHEMICAL", 2150, 2153], ["oil", "ORGANISM_SUBSTANCE", 2169, 2172], ["Methyl N 5 -(3-azidopropyl)-N 2 -(tert-butoxycarbonyl)-Lglutaminate 19bColorless oil", "SIMPLE_CHEMICAL", 2269, 2353], ["Compound 20b", "SIMPLE_CHEMICAL", 2356, 2368], ["Methyl N 5 -(4-azidobutyl)-L-glutaminate", "SIMPLE_CHEMICAL", 2426, 2466], ["20bYellow oil", "SIMPLE_CHEMICAL", 2481, 2494], ["sodium azide", "SIMPLE_CHEMICAL", 2514, 2526], ["anhydrous acetonitrile", "SIMPLE_CHEMICAL", 2558, 2580], ["triflic anhydride", "SIMPLE_CHEMICAL", 2606, 2623], ["The organic layer", "TREATMENT", 0, 17], ["anhydrous sodium sulfate", "TREATMENT", 33, 57], ["solvent", "TREATMENT", 72, 79], ["the rotary evaporator", "TREATMENT", 95, 116], ["the same procedure", "TREATMENT", 230, 248], ["Methyl (S)", "TREATMENT", 258, 268], ["((benzyloxy)carbonyl)amino)pent-4ynamido)", "TREATMENT", 279, 320], ["cyclohexylpropanoate 14bWhite solid", "TREATMENT", 323, 358], ["((benzyloxy)carbonyl)amino)", "TREATMENT", 408, 435], ["L-phenylalaninate 14cWhite solid", "TREATMENT", 449, 481], ["((benzyloxy)carbonyl)amino)pent", "TREATMENT", 526, 557], ["Lleucine 15aA solution", "TREATMENT", 567, 589], ["general procedure", "TREATMENT", 670, 687], ["The crude product", "TREATMENT", 691, 708], ["Flash chromatography (Silica gel", "TREATMENT", 725, 757], ["Hexane/ Ethyl acetate", "TREATMENT", 759, 780], ["a colorless oil", "TREATMENT", 803, 818], ["the same procedure", "TREATMENT", 881, 899], ["((benzyloxy)carbonyl)amino)pent", "TREATMENT", 933, 964], ["4ynamido)", "TREATMENT", 965, 974], ["cyclohexylpropanoic acid", "TREATMENT", 977, 1001], ["Methyl N5", "TREATMENT", 1020, 1029], ["azidoropyl", "TREATMENT", 1033, 1043], ["N2", "TREATMENT", 1045, 1047], ["tert-butyoxycarbonyl)", "TREATMENT", 1049, 1070], ["Lglutaminate 19aA solution", "TREATMENT", 1071, 1097], ["a colorless oil", "TREATMENT", 1240, 1255], ["Methyl N5", "TREATMENT", 1276, 1285], ["azidoropyl", "TREATMENT", 1289, 1299], ["N2-(tert-butyoxycarbonyl)", "TREATMENT", 1301, 1326], ["Lglutaminate", "TREATMENT", 1327, 1339], ["Methyl N5", "TREATMENT", 1520, 1529], ["azidoropyl", "TREATMENT", 1533, 1543], ["N2", "TREATMENT", 1545, 1547], ["tert-butyoxycarbonyl)", "TREATMENT", 1549, 1570], ["Lglutaminate 19aA solution of compound", "TREATMENT", 1571, 1609], ["dioxane", "TREATMENT", 1684, 1691], ["Boc protection", "TREATMENT", 1702, 1716], ["general procedure C and solvent", "TREATMENT", 1730, 1761], ["the reaction", "PROBLEM", 1780, 1792], ["high vacuum to dryness", "PROBLEM", 1799, 1821], ["Methyl N5", "TREATMENT", 1845, 1854], ["azidoropyl)", "TREATMENT", 1858, 1869], ["N2", "TREATMENT", 1870, 1872], ["tert-butyoxycarbonyl)", "TREATMENT", 1874, 1895], ["Lglutaminate 19aBoceGlueOMe", "TREATMENT", 1896, 1923], ["general procedure", "TREATMENT", 2022, 2039], ["the crude product", "TREATMENT", 2046, 2063], ["flash chromatography (silica gel", "TREATMENT", 2080, 2112], ["hexane/ethyl acetate", "TREATMENT", 2114, 2134], ["a colorless oil", "TREATMENT", 2157, 2172], ["the same procedure", "TREATMENT", 2231, 2249], ["Methyl N", "TREATMENT", 2269, 2277], ["azidopropyl)", "TREATMENT", 2284, 2296], ["tert-butoxycarbonyl)", "TREATMENT", 2303, 2323], ["Lglutaminate 19bColorless oil", "TREATMENT", 2324, 2353], ["Compound 20b", "TREATMENT", 2356, 2368], ["the same procedure", "TREATMENT", 2388, 2406], ["Methyl N", "TREATMENT", 2426, 2434], ["azidobutyl)", "TREATMENT", 2441, 2452], ["L-glutaminate hydrochloride 20bYellow oil", "TREATMENT", 2453, 2494], ["a solution of sodium azide", "TREATMENT", 2500, 2526], ["anhydrous acetonitrile", "TREATMENT", 2558, 2580], ["triflic anhydride", "TREATMENT", 2606, 2623], ["the cooled solution", "TREATMENT", 2667, 2686], ["organic", "OBSERVATION_MODIFIER", 4, 11], ["layer", "OBSERVATION_MODIFIER", 12, 17], ["high vacuum", "OBSERVATION_MODIFIER", 1799, 1810]]], ["The mixture was filtered through cotton wool to give a crude triflic azide solution.", [["triflic azide", "CHEMICAL", 61, 74], ["triflic azide", "CHEMICAL", 61, 74], ["triflic azide", "SIMPLE_CHEMICAL", 61, 74], ["cotton wool", "TREATMENT", 33, 44], ["a crude triflic azide solution", "TREATMENT", 53, 83]]], ["To a vigorously stirred suspension of Z-L-ornithine (6.39 g; 24 mmol) in acetonitrile (100 mL) and water (40 mL) mixture was added trimethylamine (7.38 g; 73 mmol) and CuSO 4 (24 mmol).", [["Z-L-ornithine", "CHEMICAL", 38, 51], ["acetonitrile", "CHEMICAL", 73, 85], ["trimethylamine", "CHEMICAL", 131, 145], ["CuSO 4", "CHEMICAL", 168, 174], ["Z-L-ornithine", "CHEMICAL", 38, 51], ["acetonitrile", "CHEMICAL", 73, 85], ["trimethylamine", "CHEMICAL", 131, 145], ["CuSO 4", "CHEMICAL", 168, 174], ["Z-L-ornithine", "SIMPLE_CHEMICAL", 38, 51], ["acetonitrile", "SIMPLE_CHEMICAL", 73, 85], ["water", "SIMPLE_CHEMICAL", 99, 104], ["trimethylamine", "SIMPLE_CHEMICAL", 131, 145], ["CuSO 4", "SIMPLE_CHEMICAL", 168, 174], ["Z-L-ornithine", "TREATMENT", 38, 51], ["acetonitrile", "TREATMENT", 73, 85], ["trimethylamine", "TREATMENT", 131, 145]]], ["The resulting solution was cooled to 0 C and the triflic azide solution was added dropwise.", [["triflic azide", "CHEMICAL", 49, 62], ["triflic azide", "CHEMICAL", 49, 62], ["triflic azide", "SIMPLE_CHEMICAL", 49, 62], ["The resulting solution", "TREATMENT", 0, 22], ["the triflic azide solution", "TREATMENT", 45, 71]]], ["After 30 min, cooling was removed and the reaction mixture was stirred at room temperature overnight.", [["cooling", "TREATMENT", 14, 21], ["the reaction mixture", "PROBLEM", 38, 58]]], ["The solvent was removed on the rotary evaporator and the aqueous solution was washed with ethyl acetate (2 \u00c2 100 mL).", [["ethyl acetate", "CHEMICAL", 90, 103], ["ethyl acetate", "CHEMICAL", 90, 103], ["ethyl acetate", "SIMPLE_CHEMICAL", 90, 103], ["The solvent", "TREATMENT", 0, 11], ["the rotary evaporator", "TREATMENT", 27, 48], ["the aqueous solution", "TREATMENT", 53, 73], ["ethyl acetate", "TREATMENT", 90, 103]]], ["The aqueous phase was then acidified with 2 M HCl followed by concentrated HCl and extracted with ethyl acetate (3 \u00c2 100 mL).", [["HCl", "CHEMICAL", 75, 78], ["ethyl acetate", "CHEMICAL", 98, 111], ["HCl", "CHEMICAL", 46, 49], ["HCl", "CHEMICAL", 75, 78], ["ethyl acetate", "CHEMICAL", 98, 111], ["HCl", "SIMPLE_CHEMICAL", 75, 78], ["ethyl acetate", "SIMPLE_CHEMICAL", 98, 111], ["2 M HCl", "TREATMENT", 42, 49], ["concentrated HCl", "TREATMENT", 62, 78], ["ethyl acetate", "TREATMENT", 98, 111], ["aqueous phase", "OBSERVATION_MODIFIER", 4, 17]]], ["The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to yield a crude product.", [["sodium sulfate", "CHEMICAL", 43, 57], ["sodium sulfate", "CHEMICAL", 43, 57], ["anhydrous sodium sulfate", "SIMPLE_CHEMICAL", 33, 57], ["The organic layer", "TREATMENT", 0, 17], ["anhydrous sodium sulfate", "TREATMENT", 33, 57], ["organic", "OBSERVATION_MODIFIER", 4, 11], ["layer", "OBSERVATION_MODIFIER", 12, 17]]], ["After that chloroform was added and the solution was refrigerated and the precipitate was filtered off.", [["chloroform", "CHEMICAL", 11, 21], ["chloroform", "CHEMICAL", 11, 21], ["chloroform", "SIMPLE_CHEMICAL", 11, 21], ["chloroform", "TREATMENT", 11, 21], ["the solution", "TREATMENT", 36, 48]]], ["The solvent was removed on the rotary evaporator and the crude product was purified using flash chromatography to obtain compound 21 as a light yellow oil (2.14 g; 30% yield); 1 To a solution of BoceGlueOMe (5.2 g; 20 mmol) in dry DMF (60 mL) was added EDCI (4.67 g; 24.4 mmol), HOBt (3.7 g; 24.4 mmol) and the reaction mixture was stirred at room temperature for 30 min.", [["BoceGlueOMe", "CHEMICAL", 195, 206], ["DMF", "CHEMICAL", 231, 234], ["EDCI", "CHEMICAL", 253, 257], ["HOBt", "CHEMICAL", 279, 283], ["BoceGlueOMe", "CHEMICAL", 195, 206], ["DMF", "CHEMICAL", 231, 234], ["HOBt", "CHEMICAL", 279, 283], ["oil", "ORGANISM_SUBSTANCE", 151, 154], ["BoceGlueOMe", "SIMPLE_CHEMICAL", 195, 206], ["DMF", "SIMPLE_CHEMICAL", 231, 234], ["EDCI", "SIMPLE_CHEMICAL", 253, 257], ["HOBt", "SIMPLE_CHEMICAL", 279, 283], ["The solvent", "TREATMENT", 0, 11], ["the rotary evaporator", "TREATMENT", 27, 48], ["flash chromatography", "TEST", 90, 110], ["a light yellow oil", "TEST", 136, 154], ["a solution of BoceGlueOMe", "TREATMENT", 181, 206], ["EDCI", "TEST", 253, 257], ["HOBt", "TEST", 279, 283], ["the reaction mixture", "PROBLEM", 307, 327]]], ["Propargylamine (1.1 g; 20 mmol) was added to the mixture and the reaction mixture was stirred overnight at room temperature.", [["Propargylamine", "CHEMICAL", 0, 14], ["Propargylamine", "CHEMICAL", 0, 14], ["Propargylamine", "SIMPLE_CHEMICAL", 0, 14], ["Propargylamine", "TREATMENT", 0, 14], ["the reaction mixture", "PROBLEM", 61, 81]]], ["The solvent was removed on the rotary evaporator and residue was taken up with DCM (400 mL) and washed sequentially with 10% aqueous citric acid (150 mL) and brine (150 mL).", [["DCM", "CHEMICAL", 79, 82], ["citric acid", "CHEMICAL", 133, 144], ["citric acid", "CHEMICAL", 133, 144], ["aqueous citric acid", "SIMPLE_CHEMICAL", 125, 144], ["The solvent", "TREATMENT", 0, 11], ["the rotary evaporator", "TREATMENT", 27, 48], ["DCM", "TREATMENT", 79, 82], ["10% aqueous citric acid", "TREATMENT", 121, 144]]], ["The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to yield a crude product which was purified by flash chromatography (silica gel; hexane/ethyl acetate 50:50) to give 22 as a colorless oil (3.8 g; 64% yield); 1Methyl N 5 -(3-azidopropyl)-N 2 -(((S)-2-(((benzyloxy) carbonyl)amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24aA solution of compound 15a (11.7 g; 31 mmol) in dry DMF (100 mL) was coupled with compound 20a according to general procedure A and the crude product was purified using flash chromatography (silica gel; DCM/methanol 95:5) to obtain compound 24a as a white solid (8.3 g; 46% yield); M.p 110e111 C. 1 Compound 24b was prepared using the same procedure as described above.Methyl N 5 -(4-azidobutyl)-N 2 -(((S)-2-(((benzyloxy)carbonyl) amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24bWhite solid (9.6 g; 58% yield); M.p 106e108 C. 1 6S,9S ,Z)-3-(((benzyloxy)carbonyl)amino)-6isobutyl-4,7,12-trioxo-1 1 H-5,8,13-triaza-1(4,1)triazolacyclohexadecaphane-9-carboxylate 25a A solution of compound 24a (0.3 g: 0.512 mmol) in dry DCM (420 mL) was cyclized according to general procedure G and the crude product was purified using flash chromatography (silica gel; DCM/methanol 95:5) to give compound 25a as a white solid (0.14 g; 45% yield); M.p 210e211 C. 1 Compound 25b was prepared using the same procedure as described above.Methyl N 5 -(4-azidobutyl)-N 2 -(((S)-2-(((benzyloxy)carbonyl) amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24b4.1.33.", [["sodium sulfate", "CHEMICAL", 43, 57], ["silica gel", "CHEMICAL", 155, 165], ["hexane/ethyl acetate", "CHEMICAL", 167, 187], ["1Methyl N 5 -(3-azidopropyl)-N 2 -(((S)-2-(((benzyloxy) carbonyl)amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24aA", "CHEMICAL", 245, 358], ["compound 15a", "CHEMICAL", 371, 383], ["DMF", "CHEMICAL", 409, 412], ["compound 20a", "CHEMICAL", 439, 451], ["silica gel", "CHEMICAL", 548, 558], ["DCM/methanol 95:5", "CHEMICAL", 560, 577], ["compound 24a", "CHEMICAL", 589, 601], ["M.p 110e111 C. 1 Compound 24b", "CHEMICAL", 639, 668], ["Methyl N 5 -(4-azidobutyl)-N 2 -(((S)-2-(((benzyloxy)carbonyl) amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24bWhite", "CHEMICAL", 726, 841], ["M.p 106e108 C. 1 6S,9S ,Z)-3-(((benzyloxy)carbonyl)amino)-6isobutyl-4,7,12-trioxo-1 1 H-5,8,13-triaza-1(4,1)triazolacyclohexadecaphane-9-carboxylate 25a A solution of compound 24a", "CHEMICAL", 868, 1047], ["DCM", "CHEMICAL", 1075, 1078], ["silica gel", "CHEMICAL", 1197, 1207], ["DCM/methanol 95:5", "CHEMICAL", 1209, 1226], ["compound 25a", "CHEMICAL", 1236, 1248], ["M.p 210e211 C. 1 Compound 25b", "CHEMICAL", 1287, 1316], ["Methyl N 5 -(4-azidobutyl)-N 2 -(((S)-2-(((benzyloxy)carbonyl) amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24b4.1.33", "CHEMICAL", 1374, 1490], ["sodium sulfate", "CHEMICAL", 43, 57], ["silica gel", "CHEMICAL", 155, 165], ["hexane", "CHEMICAL", 167, 173], ["ethyl acetate", "CHEMICAL", 174, 187], ["1Methyl N 5 -(3-azidopropyl)-N 2 -(((S)-2-(((benzyloxy) carbonyl)amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24aA", "CHEMICAL", 245, 358], ["DMF", "CHEMICAL", 409, 412], ["silica gel", "CHEMICAL", 548, 558], ["methanol", "CHEMICAL", 564, 572], ["Methyl N 5 -(4-azidobutyl)-N 2 -(((S)-2-(((benzyloxy)carbonyl) amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24bWhite", "CHEMICAL", 726, 841], ["6S,9S ,Z)-3-(((benzyloxy)carbonyl)amino)-6isobutyl-4,7,12-trioxo-1 1 H-5,8,13-triaza-1(4,1)triazolacyclohexadecaphane-9-carboxylate 25a A", "CHEMICAL", 885, 1022], ["silica gel", "CHEMICAL", 1197, 1207], ["methanol", "CHEMICAL", 1213, 1221], ["Methyl N 5 -(4-azidobutyl)-N 2 -(((S)-2-(((benzyloxy)carbonyl) amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24b4.1.33", "CHEMICAL", 1374, 1490], ["anhydrous sodium sulfate", "SIMPLE_CHEMICAL", 33, 57], ["silica", "SIMPLE_CHEMICAL", 155, 161], ["hexane", "SIMPLE_CHEMICAL", 167, 173], ["ethyl acetate 50:50", "SIMPLE_CHEMICAL", 174, 193], ["oil", "ORGANISM_SUBSTANCE", 221, 224], ["1Methyl N 5 -(3-azidopropyl)-N 2 -(((S)-2-(((benzyloxy) carbonyl)amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24aA", "SIMPLE_CHEMICAL", 245, 358], ["compound 15a", "SIMPLE_CHEMICAL", 371, 383], ["DMF", "SIMPLE_CHEMICAL", 409, 412], ["silica", "SIMPLE_CHEMICAL", 548, 554], ["24a", "SIMPLE_CHEMICAL", 598, 601], ["Methyl N 5 -(4-azidobutyl)-N 2 -(((S)-2-(((benzyloxy)carbonyl) amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate", "SIMPLE_CHEMICAL", 726, 832], ["1 6S,9S ,Z)-3-(((benzyloxy)carbonyl)amino)-6isobutyl-4,7,12-trioxo-1 1 H-5,8,13-triaza-1(4,1)triazolacyclohexadecaphane-9-carboxylate 25a A", "SIMPLE_CHEMICAL", 883, 1022], ["compound 24a", "SIMPLE_CHEMICAL", 1035, 1047], ["silica", "SIMPLE_CHEMICAL", 1197, 1203], ["25a", "SIMPLE_CHEMICAL", 1245, 1248], ["Methyl N 5 -(4-azidobutyl)-N 2 -(((S)-2-(((benzyloxy)carbonyl) amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24b4.1.33", "SIMPLE_CHEMICAL", 1374, 1490], ["The organic layer", "TREATMENT", 0, 17], ["anhydrous sodium sulfate", "TREATMENT", 33, 57], ["a crude product", "TREATMENT", 95, 110], ["flash chromatography (silica gel", "TREATMENT", 133, 165], ["hexane/ethyl acetate", "TREATMENT", 167, 187], ["a colorless oil", "TREATMENT", 209, 224], ["1Methyl N", "TREATMENT", 245, 254], ["azidopropyl)", "TREATMENT", 261, 273], ["((benzyloxy) carbonyl)amino)pent", "TREATMENT", 288, 320], ["L-leucyl", "TREATMENT", 330, 338], ["L-glutaminate 24aA solution of compound 15a", "TREATMENT", 340, 383], ["general procedure", "TREATMENT", 465, 482], ["the crude product", "TREATMENT", 489, 506], ["flash chromatography (silica gel", "TREATMENT", 526, 558], ["DCM/methanol", "TREATMENT", 560, 572], ["the same procedure", "TREATMENT", 688, 706], ["Methyl N", "TREATMENT", 726, 734], ["azidobutyl)", "TREATMENT", 741, 752], ["((benzyloxy)carbonyl) amino)pent", "TREATMENT", 767, 799], ["L-leucyl", "TREATMENT", 809, 817], ["L-glutaminate 24bWhite solid", "TREATMENT", 819, 847], ["((benzyloxy)carbonyl)amino", "TREATMENT", 898, 924], ["6isobutyl", "TEST", 926, 935], ["trioxo", "TREATMENT", 943, 949], ["triaza", "TREATMENT", 963, 969], ["triazolacyclohexadecaphane-9-carboxylate", "TREATMENT", 976, 1016], ["general procedure G", "TREATMENT", 1114, 1133], ["the crude product", "TREATMENT", 1138, 1155], ["flash chromatography (silica gel", "TREATMENT", 1175, 1207], ["DCM/methanol", "TREATMENT", 1209, 1221], ["the same procedure", "TREATMENT", 1336, 1354], ["Methyl N", "TREATMENT", 1374, 1382], ["azidobutyl)", "TREATMENT", 1389, 1400], ["((benzyloxy)carbonyl) amino)pent", "TREATMENT", 1415, 1447], ["L-leucyl", "TREATMENT", 1457, 1465], ["L-glutaminate", "TREATMENT", 1467, 1480], ["layer", "OBSERVATION_MODIFIER", 12, 17]]], ["Methyl (3S,6S,9S,Z)-3-(((benzyloxy)carbonyl)amino)-6isobutyl-4,7,12-trioxo-1 1 H-5,8,13-triaza-1(4,1)triazolacycloheptadecaphane-9-carboxylate 25bMethyl N 5 -(4-azidobutyl)-N 2 -(((S)-2-(((benzyloxy)carbonyl) amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24bWhite solid (0.15 g; 50% yield); M.p 213e215 C. 1 Compound 27b-27i was prepared using the same procedure as described above.", [["Methyl (3S,6S,9S,Z)-3-(((benzyloxy)carbonyl)amino)-6isobutyl-4,7,12-trioxo-1 1 H-5,8,13-triaza-1(4,1)triazolacycloheptadecaphane-9-carboxylate", "CHEMICAL", 0, 142], ["25bMethyl N 5 -(4-azidobutyl)-N 2 -(((S)-2-(((benzyloxy)carbonyl) amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24bWhite", "CHEMICAL", 143, 261], ["M.p 213e215 C. 1 Compound 27b-27i", "CHEMICAL", 289, 322], ["Methyl (3S,6S,9S,Z)-3-(((benzyloxy)carbonyl)amino)-6isobutyl-4,7,12-trioxo-1 1 H-5,8,13-triaza-1(4,1)triazolacycloheptadecaphane-9-carboxylate 25bMethyl N 5 -(4-azidobutyl)-N 2 -(((S)-2-(((benzyloxy)carbonyl) amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24bWhite", "CHEMICAL", 0, 261], ["Methyl (3S,6S,9S,Z)-3-(((benzyloxy)carbonyl)amino)-6isobutyl-4,7,12-trioxo-1 1 H-5,8,13-triaza-1(4,1)triazolacycloheptadecaphane-9-carboxylate 25bMethyl N 5 -(4-azidobutyl)-N 2 -(((S)-2-(((benzyloxy)carbonyl) amino)pent-4-ynoyl)-L-leucyl)-L-glutaminate 24bWhite solid", "SIMPLE_CHEMICAL", 0, 267], ["27b-27i", "SIMPLE_CHEMICAL", 315, 322], ["Methyl (3S,6S,9S,Z)", "TREATMENT", 0, 19], ["((benzyloxy)carbonyl)amino)", "TREATMENT", 23, 50], ["6isobutyl", "TREATMENT", 51, 60], ["trioxo", "TREATMENT", 68, 74], ["triaza", "TREATMENT", 88, 94], ["triazolacycloheptadecaphane-9-carboxylate 25bMethyl N", "TREATMENT", 101, 154], ["((benzyloxy)carbonyl) amino)pent", "TREATMENT", 187, 219], ["L-leucyl", "TREATMENT", 229, 237], ["L-glutaminate 24bWhite solid", "TREATMENT", 239, 267], ["the same procedure", "TREATMENT", 342, 360]]], ["White solid (3.4 g; 84%); M.p 51e53 C. 1(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-(1-(4-((S)-4-((tert-butoxycarbonyl)amino)-5-methoxy-5-oxopentanamido) butyl)-1H-1,2,3-triazol-4-yl)propanamido)-3-cyclohexylpropanoic acid 27dWhite solid (3.3 g; 82% yield); M.p 58e60 C. 1 Compound 28be28i was prepared using the same procedure as described above.", [["M.p 51e53 C. 1(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-(1-(4-((S)-4-((tert-butoxycarbonyl)amino)-5-methoxy-5-oxopentanamido) butyl)-1H-1,2,3-triazol-4-yl)propanamido)-3-cyclohexylpropanoic acid 27dWhite", "CHEMICAL", 26, 231], ["(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-(1-(4-((S)-4-((tert-butoxycarbonyl)amino)-5-methoxy-5-oxopentanamido) butyl)-1H-1,2,3-triazol-4-yl)propanamido)-3-cyclohexylpropanoic acid", "CHEMICAL", 40, 222], ["M.p 51e53 C. 1(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-(1-(4-((S)-4-((tert-butoxycarbonyl)amino)-5-methoxy-5-oxopentanamido) butyl)-1H-1,2,3-triazol-4-yl)propanamido)-3-cyclohexylpropanoic acid", "SIMPLE_CHEMICAL", 26, 222], ["White solid", "TEST", 0, 11], ["M.p", "TEST", 26, 29], ["benzyloxy)carbonyl)amino)", "TEST", 56, 81], ["tert-butoxycarbonyl)amino)", "TREATMENT", 99, 125], ["methoxy", "TREATMENT", 128, 135], ["oxopentanamido) butyl", "TREATMENT", 138, 159], ["triazol", "TREATMENT", 170, 177], ["propanamido", "TREATMENT", 183, 194], ["cyclohexylpropanoic acid 27dWhite solid", "TREATMENT", 198, 237], ["the same procedure", "TREATMENT", 309, 327]]], ["White solid (0.37 g; 62% yield); M.p > 230 C. 1 A solution of compound 25a (0.57 g; 1 mmol) in dry THF (6 mL) was reduced using 2 M LiBH 4 solution according to general procedure I and the crude product was purified using flash chromatography (silica gel; DCM/methanol 95:5) to give compound 26a as a white solid (0.47; 84% yield); M.p 112e114 C. 1 Compound 26b, 29ae29i and 32 were prepared using the same procedure as described above.Enzyme assays and inhibition studiesThe IC 50 (50% inhibitory concentration in enzyme assay) values of protease inhibitors against 3CLpro were determined as described previously by our lab [13] .", [["compound 25a", "CHEMICAL", 62, 74], ["dry THF", "CHEMICAL", 95, 102], ["silica gel", "CHEMICAL", 244, 254], ["DCM/methanol 95:5", "CHEMICAL", 256, 273], ["THF", "CHEMICAL", 99, 102], ["LiBH 4", "CHEMICAL", 132, 138], ["silica gel", "CHEMICAL", 244, 254], ["methanol", "CHEMICAL", 260, 268], ["25a", "SIMPLE_CHEMICAL", 71, 74], ["THF", "SIMPLE_CHEMICAL", 99, 102], ["silica", "SIMPLE_CHEMICAL", 244, 250], ["29ae29i", "SIMPLE_CHEMICAL", 363, 370], ["3CLpro", "SIMPLE_CHEMICAL", 567, 573], ["White solid", "TEST", 0, 11], ["M.p", "TEST", 33, 36], ["A solution of compound", "TREATMENT", 48, 70], ["2 M LiBH 4 solution", "TREATMENT", 128, 147], ["general procedure I", "TREATMENT", 161, 180], ["the crude product", "TREATMENT", 185, 202], ["flash chromatography (silica gel", "TREATMENT", 222, 254], ["DCM/methanol", "TREATMENT", 256, 268], ["the same procedure", "TREATMENT", 398, 416], ["Enzyme assays", "TEST", 436, 449], ["inhibition studies", "TEST", 454, 472], ["The IC", "TREATMENT", 472, 478], ["enzyme assay", "TEST", 515, 527], ["protease inhibitors", "TREATMENT", 539, 558], ["3CLpro", "TREATMENT", 567, 573]]], ["Each compound was evaluated for anti-3CLpro effects up to 100 mM.", [["anti-3CLpro", "SIMPLE_CHEMICAL", 32, 43], ["anti-3CLpro effects", "PROBLEM", 32, 51]]], ["For the cell based assay, one day old HG23 cells (NV replicon harboring cells) were treated with various concentrations (1.0e100 mM) of each compound, and incubated for 48 h.", [["cell", "ANATOMY", 8, 12], ["HG23 cells", "ANATOMY", 38, 48], ["cells", "ANATOMY", 72, 77], ["cell", "CELL", 8, 12], ["HG23 cells", "CELL", 38, 48], ["NV replicon", "CELL", 50, 61], ["cells", "CELL", 72, 77], ["HG23 cells", "CELL_LINE", 38, 48], ["NV replicon harboring cells", "CELL_LINE", 50, 77], ["the cell based assay", "TEST", 4, 24], ["NV replicon harboring cells", "TREATMENT", 50, 77], ["various concentrations", "TREATMENT", 97, 119]]], ["Then total RNA was extracted from cells for qRT-PCR for norovirus and b-actin.", [["cells", "ANATOMY", 34, 39], ["cells", "CELL", 34, 39], ["norovirus", "ORGANISM", 56, 65], ["b-actin", "GENE_OR_GENE_PRODUCT", 70, 77], ["b-actin", "PROTEIN", 70, 77], ["total RNA", "TREATMENT", 5, 14], ["qRT", "TEST", 44, 47], ["PCR", "TEST", 48, 51], ["norovirus", "PROBLEM", 56, 65], ["b-actin", "TREATMENT", 70, 77]]], ["The EC 50 (50% inhibitory concentration in cell based assay) of each compound was calculated by the % reduction of RNA levels to Mock-treated cells after normalized with b-actin levels.", [["EC", "ANATOMY", 4, 6], ["cell", "ANATOMY", 43, 47], ["cells", "ANATOMY", 142, 147], ["EC", "CELL", 4, 6], ["cell", "CELL", 43, 47], ["cells", "CELL", 142, 147], ["b-actin", "GENE_OR_GENE_PRODUCT", 170, 177], ["Mock-treated cells", "CELL_LINE", 129, 147], ["b-actin", "PROTEIN", 170, 177], ["The EC", "TEST", 0, 6], ["cell based assay", "TEST", 43, 59], ["RNA levels", "TEST", 115, 125], ["Mock-treated cells", "TREATMENT", 129, 147], ["b-actin levels", "TEST", 170, 184]]], ["Cell cytotoxicity using HG23 was measured by a CytoTox96\u00ae nonradioactive cytotoxicity assay kit (Promega, Madison, WI) with serial dilution of each compound up to 100 mM following the manufacturer's instructions.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["HG23", "SIMPLE_CHEMICAL", 24, 28], ["CytoTox96", "SIMPLE_CHEMICAL", 47, 56], ["HG23", "CELL_LINE", 24, 28], ["Cell cytotoxicity", "TEST", 0, 17], ["a CytoTox96", "TEST", 45, 56], ["serial dilution of each compound", "TREATMENT", 124, 156]]], ["The CC 50 (50% cytotoxic concentration) was determined for each compound.", [["CC", "CHEMICAL", 4, 6], ["The CC", "TREATMENT", 0, 6], ["50% cytotoxic concentration", "TREATMENT", 11, 38]]], ["The IC 50 , EC 50 and CC 50 values were determined by at least two independent experiments.X-ray crystallographic studies.", [["CC", "CHEMICAL", 22, 24], ["EC", "CELL", 12, 14], ["The IC", "TEST", 0, 6], ["EC", "TEST", 12, 14], ["X-ray crystallographic studies", "TEST", 91, 121]]], ["Crystallization and data collectionPurified Norwalk virus 3CLpro (NV 3CLpro) in 100 mM NaCl, 50 mM PBS pH 7.2, 1 mM DTT at a concentration of 10 mg/mL was used for preparation of the NV 3CLpro-ligand complex.", [["NV 3CLpro", "CHEMICAL", 66, 75], ["NaCl", "CHEMICAL", 87, 91], ["DTT", "CHEMICAL", 116, 119], ["NaCl", "CHEMICAL", 87, 91], ["DTT", "CHEMICAL", 116, 119], ["DTT", "SIMPLE_CHEMICAL", 116, 119], ["NV 3CLpro-ligand complex", "PROTEIN", 183, 207], ["Crystallization", "TEST", 0, 15], ["data", "TEST", 20, 24], ["Norwalk virus 3CLpro", "TREATMENT", 44, 64], ["NV 3CLpro)", "TREATMENT", 66, 76], ["NaCl", "TREATMENT", 87, 91], ["PBS pH", "TEST", 99, 105], ["1 mM DTT", "TREATMENT", 111, 119], ["the NV 3CLpro-ligand complex", "TREATMENT", 179, 207]]], ["A stock solution of 100 mM compound 1, 3, or 10 was prepared in DMSO and each NV 3CLpro:inhibitor complex was prepared by mixing 12 mL of 1, 3 or 10 (3 mM) with 388 mL (0.49 mM) of NV 3CLpro and incubating on ice for 1 h.", [["DMSO", "CHEMICAL", 64, 68], ["NV 3CLpro", "CHEMICAL", 181, 190], ["DMSO", "CHEMICAL", 64, 68], ["DMSO", "SIMPLE_CHEMICAL", 64, 68], ["3CLpro", "SIMPLE_CHEMICAL", 81, 87], ["3CLpro", "SIMPLE_CHEMICAL", 184, 190], ["A stock solution", "TREATMENT", 0, 16], ["DMSO", "TREATMENT", 64, 68], ["each NV 3CLpro:inhibitor complex", "TREATMENT", 73, 105], ["NV 3CLpro", "TREATMENT", 181, 190]]], ["The buffer was exchanged to 100 mM NaCl, 20 mM Tris pH 8.0 using a Vivaspin-20 concentrator (MWCO \u00bc 5 kDa, Vivaproducts, Inc.) and the samples were concentrated to 10, 8.4 and 12.0 mg/mL respectively for crystallization screening.", [["samples", "ANATOMY", 135, 142], ["NaCl", "CHEMICAL", 35, 39], ["Vivaspin-20", "CHEMICAL", 67, 78], ["NaCl", "CHEMICAL", 35, 39], ["Vivaspin-20", "CHEMICAL", 67, 78], ["The buffer", "TREATMENT", 0, 10], ["Tris pH", "TEST", 47, 54], ["a Vivaspin", "TREATMENT", 65, 75], ["Vivaproducts", "TREATMENT", 107, 119], ["the samples", "TEST", 131, 142], ["crystallization screening", "TEST", 204, 229]]], ["All crystallization experiments were conducted Compact Jr. (Rigaku Reagents) sitting drop vapor diffusion plates at 20 C using equal volumes of protein and crystallization solution equilibrated against 75 mL of the latter.", [["Rigaku Reagents", "TREATMENT", 60, 75], ["sitting drop vapor diffusion plates", "TREATMENT", 77, 112], ["protein and crystallization solution", "TREATMENT", 144, 180]]], ["Crystals of NV 3CLpro-ligand 1 and NV 3CLpro-ligand 10 that displayed prismatic morphology were obtained in 1e2 days from the Index HT screen (Hampton Research) condition H12 (30% (w/v) PEG 2000 MME, 150 mM potassium bromide) ( Table 2 ).", [["HT", "DISEASE", 132, 134], ["potassium bromide", "CHEMICAL", 207, 224], ["PEG", "CHEMICAL", 186, 189], ["potassium bromide", "CHEMICAL", 207, 224], ["NV 3CLpro-ligand 1", "GENE_OR_GENE_PRODUCT", 12, 30], ["NV 3CLpro-ligand 10", "SIMPLE_CHEMICAL", 35, 54], ["potassium bromide", "SIMPLE_CHEMICAL", 207, 224], ["Crystals", "TEST", 0, 8], ["NV 3CLpro-ligand", "TREATMENT", 12, 28], ["NV 3CLpro-ligand", "TREATMENT", 35, 51], ["the Index HT screen", "TEST", 122, 141], ["condition H12", "TREATMENT", 161, 174], ["PEG", "TREATMENT", 186, 189], ["150 mM potassium bromide", "TREATMENT", 200, 224]]], ["Samples were transferred to a fresh drop composed of 80% crystallization solution and 20% glycerol and stored in liquid nitrogen.", [["Samples", "ANATOMY", 0, 7], ["glycerol", "CHEMICAL", 90, 98], ["glycerol", "CHEMICAL", 90, 98], ["nitrogen", "CHEMICAL", 120, 128], ["glycerol", "SIMPLE_CHEMICAL", 90, 98], ["80% crystallization solution", "TREATMENT", 53, 81], ["20% glycerol", "TREATMENT", 86, 98], ["liquid nitrogen", "TREATMENT", 113, 128]]], ["Crystals that displayed a plate morphology formed for NV 3CLpro-ligand 3 in 3 days from the Wizard 3 and 4 screen (Rigaku Reagents) A10 (20% (w/v) PEG3350, 200 mM sodium thiocyanate).", [["PEG3350", "CHEMICAL", 147, 154], ["sodium thiocyanate", "CHEMICAL", 163, 181], ["PEG3350", "CHEMICAL", 147, 154], ["sodium thiocyanate", "CHEMICAL", 163, 181], ["sodium thiocyanate", "SIMPLE_CHEMICAL", 163, 181], ["3CLpro", "PROTEIN", 57, 63], ["Crystals", "TEST", 0, 8], ["a plate morphology", "TEST", 24, 42], ["NV 3CLpro-ligand", "TEST", 54, 70], ["the Wizard", "TEST", 88, 98], ["Rigaku Reagents", "TREATMENT", 115, 130], ["A10", "TEST", 132, 135], ["PEG3350", "TREATMENT", 147, 154], ["200 mM sodium thiocyanate", "TREATMENT", 156, 181], ["plate morphology", "OBSERVATION_MODIFIER", 26, 42]]], ["The crystals tended to form clusters that needed to be separated in order to obtain a suitable sample for X-ray data collection.", [["The crystals", "PROBLEM", 0, 12], ["X-ray data collection", "TEST", 106, 127]]], ["Samples were transferred to a fresh drop composed of 80% crystallization solution and 20% PEG 200 and stored in liquid nitrogen.", [["Samples", "ANATOMY", 0, 7], ["PEG 200", "CHEMICAL", 90, 97], ["PEG", "CHEMICAL", 90, 93], ["nitrogen", "CHEMICAL", 119, 127], ["80% crystallization solution", "TREATMENT", 53, 81], ["20% PEG", "TREATMENT", 86, 93], ["liquid nitrogen", "TREATMENT", 112, 127]]], ["X-ray diffraction data were collected at the Advanced Photon Source beamline 17-ID using a Dectris Pilatus 6 M pixel array detector.Structure solution and refinementIntensities were integrated using XDS [36, 37] and the Laue class analysis and data scaling were performed with Aimless [38] which suggested that the highest probability Laue class was 2/m and space group C2 for NV CLpro:1 and NV 3CLpro:10.", [["X-ray diffraction data", "TEST", 0, 22], ["a Dectris Pilatus", "TREATMENT", 89, 106], ["XDS", "TEST", 199, 202], ["the Laue class analysis", "TEST", 216, 239], ["data scaling", "TEST", 244, 256]]], ["The Matthew's coefficient [39] suggested that there was a single molecule in the asymmetric unit (Vm \u00bc 1.8 \u00c5 3 /Da, % solvent \u00bc 32%) for NV 3CLpro:1, NV 3CLpro:10 and two molecules for NV 3CLPro:3 (Vm \u00bc 2.2 \u00c5 3 /Da, % solvent \u00bc 45%).", [["Vm", "TEST", 98, 100], ["Da", "TEST", 112, 114], ["solvent", "TEST", 118, 125], ["NV 3CLpro", "TEST", 137, 146], ["NV 3CLPro", "TEST", 185, 194], ["Vm", "TEST", 198, 200], ["Da", "TEST", 212, 214]]], ["Structure solution was conducted by molecular replacement with Phaser [40] using a previously determined structure of inhibitor bound NV 3CLpro (PDB: 3UR9 [13] ) as the search model and for NV 3CLpro:3, a single solution was obtained for two independent molecules in the asymmetric unit.", [["NV 3CLpro", "SIMPLE_CHEMICAL", 134, 143], ["Structure solution", "TREATMENT", 0, 18], ["molecular replacement with Phaser", "TREATMENT", 36, 69], ["a single solution", "TREATMENT", 203, 220], ["asymmetric", "OBSERVATION_MODIFIER", 271, 281]]], ["Structure refinement using and manual model building were conducted with Phenix [41] and Coot [42] respectively.", [["manual model building", "TREATMENT", 31, 52], ["Phenix", "TEST", 73, 79]]], ["Anisotropic atomic displacement parameters were refined for all atoms except solvent molecules for NV 3CLPro:1 and NV 3CLpro:10.", [["Anisotropic atomic displacement parameters", "TREATMENT", 0, 42], ["atomic displacement", "OBSERVATION", 12, 31]]], ["Disordered side chains were truncated to the point for which electron density could be observed.", [["electron", "SIMPLE_CHEMICAL", 61, 69], ["Disordered side chains", "PROBLEM", 0, 22], ["density", "OBSERVATION", 70, 77]]], ["Structure validation was conducted with Molprobity", [["Structure validation", "TEST", 0, 20]]]], "ebd6c0ca192ba99c97cd73610601818e124831ed": [["COVID-19, as a pandemic, has took already many precious lives and affects our social habits having tremendous impact on business worldwide with consequences we can not yet foresee.", [["COVID-19", "CHEMICAL", 0, 8]]], ["It is also a serious warning that similar viruses may occur in the future and we have to be better prepared for fight at all fronts including at the health care, economy, and social habits level.", [["viruses", "OBSERVATION", 42, 49]]], ["Unfortunately, no standard treatment for this disease has been discovered to date and several experimental strategies including certain drugs and even cellular therapies has been proposed.", [["cellular", "ANATOMY", 151, 159], ["cellular", "CELL", 151, 159], ["standard treatment", "TREATMENT", 18, 36], ["this disease", "PROBLEM", 41, 53], ["certain drugs", "TREATMENT", 128, 141], ["cellular therapies", "TREATMENT", 151, 169]]], ["It is nothing wrong to try this before vaccine will be developed, so far they do not bring danger of considerable side effects to the patients.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["vaccine", "TREATMENT", 39, 46]]]], "8d8d97c333a24cc19c5b0055001db53779087917": [["IntroductionThe generation of functional immunologic memory via long-lived T-and B-cell responses is paramount to protective immunity against recurrent pathogen infections and is the goal of current vaccine strategies.", [["B-cell", "ANATOMY", 81, 87], ["pathogen infections", "DISEASE", 152, 171], ["T", "CELL", 75, 76], ["B-cell", "CELL", 81, 87], ["recurrent pathogen infections", "PROBLEM", 142, 171], ["current vaccine strategies", "TREATMENT", 191, 217], ["infections", "OBSERVATION", 161, 171]]], ["1 The coordination of long-lived CD4, CD8 and B-cell responses is a hallmark of the adaptive arm of immunity and is an irreplaceable part of protective immunity.", [["B-cell", "ANATOMY", 46, 52], ["CD4", "GENE_OR_GENE_PRODUCT", 33, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 38, 41], ["B-cell", "CELL", 46, 52], ["CD4", "PROTEIN", 33, 36], ["CD8", "PROTEIN", 38, 41], ["CD8", "TEST", 38, 41]]], ["The quality of the long-term adaptive immunity is directly related to the amount of Ag-specific memory T and B cells that are generated following an initial Ag challenge.", [["memory T", "ANATOMY", 96, 104], ["B cells", "ANATOMY", 109, 116], ["Ag", "CHEMICAL", 84, 86], ["Ag", "CHEMICAL", 157, 159], ["Ag", "CHEMICAL", 84, 86], ["Ag", "CHEMICAL", 157, 159], ["Ag", "GENE_OR_GENE_PRODUCT", 84, 86], ["T", "CELL", 103, 104], ["B cells", "CELL", 109, 116], ["Ag", "PROTEIN", 84, 86], ["memory T and B cells", "CELL_TYPE", 96, 116], ["the long-term adaptive immunity", "TREATMENT", 15, 46], ["an initial Ag challenge", "TREATMENT", 146, 169]]], ["1 Hence, understanding the mechanisms that regulate the generation and maintenance of immune cells could lead to improved vaccine strategies and also help hosts harboring chronic pathogens or cancer tip the balance towards immune clearance and host survival.", [["immune cells", "ANATOMY", 86, 98], ["cancer", "ANATOMY", 192, 198], ["cancer", "DISEASE", 192, 198], ["immune cells", "CELL", 86, 98], ["cancer", "CANCER", 192, 198], ["immune cells", "CELL_TYPE", 86, 98], ["immune cells", "PROBLEM", 86, 98], ["improved vaccine strategies", "TREATMENT", 113, 140], ["harboring chronic pathogens", "PROBLEM", 161, 188], ["cancer tip the balance", "PROBLEM", 192, 214], ["immune clearance", "TREATMENT", 223, 239], ["host survival", "TREATMENT", 244, 257]]], ["In particular, this chapter will explore the contributions of the TNF-receptor family member, OX40, to T-cell memory generation and how to exploit OX40-specific pathways for clinical benefit in patients with autoimmunity, cancer and chronic pathogens.IntroductionThere has been a number of T-cell surface molecules linked to the biologic function of memory T-cell generation and function.", [["T-cell", "ANATOMY", 103, 109], ["cancer", "ANATOMY", 222, 228], ["T-cell surface", "ANATOMY", 290, 304], ["memory T-cell", "ANATOMY", 350, 363], ["autoimmunity", "DISEASE", 208, 220], ["cancer", "DISEASE", 222, 228], ["TNF-receptor", "GENE_OR_GENE_PRODUCT", 66, 78], ["OX40", "GENE_OR_GENE_PRODUCT", 94, 98], ["T-cell", "CELL", 103, 109], ["OX40", "GENE_OR_GENE_PRODUCT", 147, 151], ["patients", "ORGANISM", 194, 202], ["cancer", "CANCER", 222, 228], ["T-cell", "CELL", 290, 296], ["memory T-cell", "CELL", 350, 363], ["TNF-receptor family member", "PROTEIN", 66, 92], ["OX40", "PROTEIN", 94, 98], ["OX40", "PROTEIN", 147, 151], ["T-cell surface molecules", "PROTEIN", 290, 314], ["patients", "SPECIES", 194, 202], ["autoimmunity", "PROBLEM", 208, 220], ["cancer", "PROBLEM", 222, 228], ["chronic pathogens", "PROBLEM", 233, 250], ["cancer", "OBSERVATION", 222, 228], ["chronic", "OBSERVATION_MODIFIER", 233, 240], ["pathogens", "OBSERVATION", 241, 250]]], ["The list includes several TNF-receptors, 4-1BB, FAS, LT-2 protein (signaling subunit).", [["TNF-receptors", "GENE_OR_GENE_PRODUCT", 26, 39], ["4-1BB", "GENE_OR_GENE_PRODUCT", 41, 46], ["FAS", "GENE_OR_GENE_PRODUCT", 48, 51], ["LT-2", "GENE_OR_GENE_PRODUCT", 53, 57], ["TNF", "PROTEIN", 26, 29], ["1BB", "PROTEIN", 43, 46], ["FAS", "PROTEIN", 48, 51], ["LT-2 protein", "PROTEIN", 53, 65], ["signaling subunit", "PROTEIN", 67, 84], ["several TNF", "TEST", 18, 29], ["receptors", "TEST", 30, 39], ["FAS", "TEST", 48, 51], ["LT", "TEST", 53, 55]]], ["54 This report went on to show that anti-OX40-mediated survival of Ag stimulated CD4 T cells was dependent on IL-12 signaling.", [["CD4 T cells", "ANATOMY", 81, 92], ["Ag", "CHEMICAL", 67, 69], ["Ag", "CHEMICAL", 67, 69], ["anti-OX40", "GENE_OR_GENE_PRODUCT", 36, 45], ["Ag", "GENE_OR_GENE_PRODUCT", 67, 69], ["CD4", "GENE_OR_GENE_PRODUCT", 81, 84], ["IL-12", "GENE_OR_GENE_PRODUCT", 110, 115], ["anti-OX40", "PROTEIN", 36, 45], ["Ag", "PROTEIN", 67, 69], ["CD4 T cells", "CELL_TYPE", 81, 92], ["Ag stimulated CD4 T cells", "TEST", 67, 92], ["IL", "TEST", 110, 112]]], ["The data also showed that there was a critical window of IL-12R upregulation, 4-7 days after antigen priming/OX40 stimulation and if the cells did not encounter IL-12 during that time frame they would undergo activation-induced cell death.", [["cells", "ANATOMY", 137, 142], ["cell", "ANATOMY", 228, 232], ["death", "DISEASE", 233, 238], ["IL-12R", "GENE_OR_GENE_PRODUCT", 57, 63], ["antigen", "GENE_OR_GENE_PRODUCT", 93, 100], ["OX40", "GENE_OR_GENE_PRODUCT", 109, 113], ["cells", "CELL", 137, 142], ["IL-12", "GENE_OR_GENE_PRODUCT", 161, 166], ["cell", "CELL", 228, 232], ["IL", "PROTEIN", 57, 59], ["12R", "PROTEIN", 60, 63], ["OX40", "PROTEIN", 109, 113], ["IL", "PROTEIN", 161, 163], ["The data", "TEST", 0, 8], ["antigen priming/OX40 stimulation", "TREATMENT", 93, 125], ["induced cell death", "PROBLEM", 220, 238], ["cell death", "OBSERVATION", 228, 238]]], ["54 Exogenous OX40 agonist administration delivered in vivo also affects CD8 T-cell survival and memory development.", [["CD8 T-cell", "ANATOMY", 72, 82], ["OX40", "GENE_OR_GENE_PRODUCT", 13, 17], ["CD8 T-cell", "CELL", 72, 82], ["OX40", "PROTEIN", 13, 17], ["Exogenous OX40 agonist administration", "TREATMENT", 3, 40], ["OX40 agonist", "OBSERVATION", 13, 25]]], ["The investigators of this study used the OT1 TCR transgenic model (specific for ova) and immunized these mice with soluble ova in combination with anti-OX40 or rat Ig.", [["ova", "ANATOMY", 80, 83], ["ova", "ANATOMY", 123, 126], ["TCR", "CHEMICAL", 45, 48], ["OT1 TCR", "GENE_OR_GENE_PRODUCT", 41, 48], ["mice", "ORGANISM", 105, 109], ["ova", "ORGANISM_SUBSTANCE", 123, 126], ["anti-OX40", "SIMPLE_CHEMICAL", 147, 156], ["rat", "ORGANISM", 160, 163], ["Ig", "GENE_OR_GENE_PRODUCT", 164, 166], ["TCR", "PROTEIN", 45, 48], ["anti-OX40", "PROTEIN", 147, 156], ["rat Ig", "PROTEIN", 160, 166], ["mice", "SPECIES", 105, 109], ["rat", "SPECIES", 160, 163], ["mice", "SPECIES", 105, 109], ["rat", "SPECIES", 160, 163], ["this study", "TEST", 21, 31], ["the OT1 TCR transgenic model", "TREATMENT", 37, 65], ["ova)", "TREATMENT", 80, 84], ["soluble ova", "TREATMENT", 115, 126], ["anti-OX40 or rat Ig", "TREATMENT", 147, 166]]], ["5 The anti-OX40 Ab increased the initial expansion phase of Ag stimulated CD8 T cells two-fold compared to the controls.", [["CD8 T cells", "ANATOMY", 74, 85], ["Ag", "CHEMICAL", 60, 62], ["Ag", "CHEMICAL", 60, 62], ["anti-OX40 Ab", "GENE_OR_GENE_PRODUCT", 6, 18], ["Ag", "GENE_OR_GENE_PRODUCT", 60, 62], ["CD8 T", "GENE_OR_GENE_PRODUCT", 74, 79], ["anti-OX40 Ab", "PROTEIN", 6, 18], ["Ag", "PROTEIN", 60, 62], ["CD8 T cells", "CELL_TYPE", 74, 85], ["The anti-OX40 Ab", "TEST", 2, 18], ["expansion", "OBSERVATION_MODIFIER", 41, 50], ["phase", "OBSERVATION_MODIFIER", 51, 56]]], ["OX40 agonist administration also increased the long-term survival of the CD8 T cells, 5-10-fold.", [["CD8 T cells", "ANATOMY", 73, 84], ["OX40", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD8 T cells", "CELL", 73, 84], ["OX40", "PROTEIN", 0, 4], ["CD8 T cells", "CELL_TYPE", 73, 84], ["OX40 agonist administration", "TREATMENT", 0, 27], ["the CD8 T cells", "TEST", 69, 84], ["long-term", "OBSERVATION_MODIFIER", 47, 56]]], ["The surviving CD8 T cells were mostly of central memory phenotype and were functional upon re-encountering Ag.", [["CD8 T cells", "ANATOMY", 14, 25], ["CD8 T cells", "CELL", 14, 25], ["CD8 T cells", "CELL_TYPE", 14, 25], ["The surviving CD8 T cells", "TEST", 0, 25], ["central memory phenotype", "PROBLEM", 41, 65], ["central memory phenotype", "OBSERVATION", 41, 65]]], ["The OX40-stimulated CD8 T cells showed a large increase in IL-2 receptor expression early during the response, which might have conferred the increase in their survival.", [["CD8 T cells", "ANATOMY", 20, 31], ["OX40", "GENE_OR_GENE_PRODUCT", 4, 8], ["CD8", "GENE_OR_GENE_PRODUCT", 20, 23], ["IL-2 receptor", "GENE_OR_GENE_PRODUCT", 59, 72], ["OX40", "PROTEIN", 4, 8], ["CD8 T cells", "CELL_TYPE", 20, 31], ["IL-2 receptor", "PROTEIN", 59, 72], ["The OX40", "TEST", 0, 8], ["a large increase in IL", "PROBLEM", 39, 61], ["large", "OBSERVATION_MODIFIER", 41, 46], ["increase", "OBSERVATION_MODIFIER", 47, 55], ["increase", "OBSERVATION_MODIFIER", 142, 150]]], ["Anti-OX40 administration also greatly enhanced CD8 T-cell recall responses.", [["CD8 T-cell", "ANATOMY", 47, 57], ["Anti-OX40", "CHEMICAL", 0, 9], ["Anti-OX40", "SIMPLE_CHEMICAL", 0, 9], ["CD8", "GENE_OR_GENE_PRODUCT", 47, 50], ["CD8", "PROTEIN", 47, 50], ["Anti-OX40 administration", "TREATMENT", 0, 24]]], ["Both proliferation and survival of the recall specific T cells was increased and was in part CD4-dependent.", [["T cells", "ANATOMY", 55, 62], ["T cells", "CELL", 55, 62], ["CD4", "GENE_OR_GENE_PRODUCT", 93, 96], ["T cells", "CELL_TYPE", 55, 62], ["CD4", "PROTEIN", 93, 96], ["Both proliferation", "PROBLEM", 0, 18], ["proliferation", "OBSERVATION", 5, 18], ["survival", "OBSERVATION_MODIFIER", 23, 31]]], ["5 Although, it is clear that direct expression of OX40 on CD8 T cells also plays a key role for the OX40 agonist effect observed in both primary and secondary responses.", [["CD8 T cells", "ANATOMY", 58, 69], ["OX40", "GENE_OR_GENE_PRODUCT", 50, 54], ["CD8 T", "GENE_OR_GENE_PRODUCT", 58, 63], ["OX40", "GENE_OR_GENE_PRODUCT", 100, 104], ["OX40", "PROTEIN", 50, 54], ["CD8 T cells", "CELL_TYPE", 58, 69], ["OX40", "PROTEIN", 100, 104], ["the OX40 agonist effect", "TREATMENT", 96, 119]]], ["5 OX40 agonists were also shown to increase the effector/cytotoxicity function of antigen stimulated CD8 T cells by upregulating granzyme B levels, through an IL-2-dependent mechanism.", [["CD8 T cells", "ANATOMY", 101, 112], ["OX40", "GENE_OR_GENE_PRODUCT", 2, 6], ["CD8 T", "GENE_OR_GENE_PRODUCT", 101, 106], ["granzyme B", "GENE_OR_GENE_PRODUCT", 129, 139], ["IL-2", "GENE_OR_GENE_PRODUCT", 159, 163], ["OX40", "PROTEIN", 2, 6], ["CD8 T cells", "CELL_TYPE", 101, 112], ["granzyme B", "PROTEIN", 129, 139], ["the effector/cytotoxicity function", "TEST", 44, 78], ["granzyme B levels", "TEST", 129, 146], ["an IL", "TEST", 156, 161]]], ["55Altering Memory T-Cell Generation/Function through the OX40 Axis for Therapeutic Benefit in Autoimmunity, Cancer and Hosts Harboring Chronic PathogensIt is clear from the studies summarized above that signaling through OX40 on either CD4 or CD8 T cells has a dramatic effect on their effector function and survival.", [["Cell", "ANATOMY", 20, 24], ["Cancer", "ANATOMY", 108, 114], ["CD4", "ANATOMY", 236, 239], ["CD8 T cells", "ANATOMY", 243, 254], ["Autoimmunity", "DISEASE", 94, 106], ["Cancer", "DISEASE", 108, 114], ["OX40", "GENE_OR_GENE_PRODUCT", 57, 61], ["Cancer", "CANCER", 108, 114], ["OX40", "GENE_OR_GENE_PRODUCT", 221, 225], ["CD4", "GENE_OR_GENE_PRODUCT", 236, 239], ["CD8", "GENE_OR_GENE_PRODUCT", 243, 246], ["OX40", "PROTEIN", 57, 61], ["OX40", "PROTEIN", 221, 225], ["CD4 or CD8 T cells", "CELL_TYPE", 236, 254], ["Cancer", "PROBLEM", 108, 114], ["Chronic Pathogens", "PROBLEM", 135, 152], ["the studies", "TEST", 169, 180], ["CD8 T cells", "PROBLEM", 243, 254], ["Cancer", "OBSERVATION", 108, 114], ["dramatic", "OBSERVATION_MODIFIER", 261, 269]]], ["Hence, research groups have attempted to alter the course of diseases known to have T-cell involvement through either blocking or enhancing OX40 signaling in vivo.", [["T-cell", "ANATOMY", 84, 90], ["T-cell", "CELL", 84, 90], ["OX40", "GENE_OR_GENE_PRODUCT", 140, 144], ["OX40", "PROTEIN", 140, 144], ["diseases", "PROBLEM", 61, 69], ["T-cell involvement", "PROBLEM", 84, 102]]], ["What appears to make OX40 such a good target to alter T-cell function in vivo is its unique expression pattern, which is only upregulated after T-cell receptor engagement in vivo and quickly downregulated 24-48 hr after induction.", [["T-cell", "ANATOMY", 54, 60], ["T-cell", "ANATOMY", 144, 150], ["OX40", "GENE_OR_GENE_PRODUCT", 21, 25], ["T-cell", "CELL", 54, 60], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 144, 159], ["OX40", "PROTEIN", 21, 25], ["T-cell receptor engagement", "TREATMENT", 144, 170]]], ["Hence, in vivo expression at any time is extremely low, although OX40 is constitutively expressed on mouse T regulatory cells.", [["T regulatory cells", "ANATOMY", 107, 125], ["OX40", "GENE_OR_GENE_PRODUCT", 65, 69], ["mouse", "ORGANISM", 101, 106], ["T regulatory cells", "CELL", 107, 125], ["OX40", "PROTEIN", 65, 69], ["mouse T regulatory cells", "CELL_TYPE", 101, 125], ["mouse", "SPECIES", 101, 106], ["mouse", "SPECIES", 101, 106], ["low", "OBSERVATION", 51, 54]]], ["The highest expression of OX40 is found at sites of inflammation, such as the colon in inflammatory bowel disease, the CNS in mice with EAE and in tumors/tumor-draining LNs in mice and humans with cancer.", [["sites", "ANATOMY", 43, 48], ["colon", "ANATOMY", 78, 83], ["bowel", "ANATOMY", 100, 105], ["CNS", "ANATOMY", 119, 122], ["tumors", "ANATOMY", 147, 153], ["tumor", "ANATOMY", 154, 159], ["LNs", "ANATOMY", 169, 172], ["cancer", "ANATOMY", 197, 203], ["inflammation", "DISEASE", 52, 64], ["inflammatory bowel disease", "DISEASE", 87, 113], ["EAE", "DISEASE", 136, 139], ["tumors", "DISEASE", 147, 153], ["tumor", "DISEASE", 154, 159], ["cancer", "DISEASE", 197, 203], ["OX40", "GENE_OR_GENE_PRODUCT", 26, 30], ["colon", "ORGAN", 78, 83], ["bowel", "ORGAN", 100, 105], ["CNS", "ANATOMICAL_SYSTEM", 119, 122], ["mice", "ORGANISM", 126, 130], ["tumors", "CANCER", 147, 153], ["tumor", "CANCER", 154, 159], ["LNs", "MULTI-TISSUE_STRUCTURE", 169, 172], ["mice", "ORGANISM", 176, 180], ["humans", "ORGANISM", 185, 191], ["cancer", "CANCER", 197, 203], ["OX40", "PROTEIN", 26, 30], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 176, 180], ["humans", "SPECIES", 185, 191], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 176, 180], ["humans", "SPECIES", 185, 191], ["inflammation", "PROBLEM", 52, 64], ["inflammatory bowel disease", "PROBLEM", 87, 113], ["EAE", "PROBLEM", 136, 139], ["tumors/tumor", "PROBLEM", 147, 159], ["cancer", "PROBLEM", 197, 203], ["inflammation", "OBSERVATION", 52, 64], ["colon", "ANATOMY", 78, 83], ["inflammatory", "OBSERVATION_MODIFIER", 87, 99], ["bowel", "ANATOMY", 100, 105], ["disease", "OBSERVATION", 106, 113], ["CNS", "ANATOMY", 119, 122], ["tumors", "OBSERVATION", 147, 153], ["tumor", "OBSERVATION", 154, 159], ["draining LNs", "OBSERVATION", 160, 172], ["cancer", "OBSERVATION", 197, 203]]], ["OX40 T cells sorted from these sites of inflammation are enriched for either autoimmune-specific or cancer-specific T cells.", [["OX40 T cells", "ANATOMY", 0, 12], ["sites", "ANATOMY", 31, 36], ["cancer", "ANATOMY", 100, 106], ["T cells", "ANATOMY", 116, 123], ["inflammation", "DISEASE", 40, 52], ["cancer", "DISEASE", 100, 106], ["OX40", "GENE_OR_GENE_PRODUCT", 0, 4], ["cancer", "CANCER", 100, 106], ["T cells", "CELL", 116, 123], ["OX40 T cells", "CELL_TYPE", 0, 12], ["cancer-specific T cells", "CELL_TYPE", 100, 123], ["inflammation", "PROBLEM", 40, 52], ["autoimmune-specific or cancer", "PROBLEM", 77, 106], ["inflammation", "OBSERVATION", 40, 52], ["cancer", "OBSERVATION", 100, 106]]], ["16 Hence, targeting OX40 is a convenient way to home in on the relevant Ag-specific T cells without significantly affecting the peripheral T-cell repertoire.Altering Memory T-Cell Generation/Function through the OX40 Axis for Therapeutic Benefit in Autoimmunity, Cancer and Hosts Harboring Chronic PathogensTwo approaches have been used for OX40-specific therapy in autoimmune disease.", [["T cells", "ANATOMY", 84, 91], ["peripheral T-cell", "ANATOMY", 128, 145], ["Cancer", "ANATOMY", 263, 269], ["Ag", "CHEMICAL", 72, 74], ["Autoimmunity", "DISEASE", 249, 261], ["Cancer", "DISEASE", 263, 269], ["autoimmune disease", "DISEASE", 366, 384], ["Ag", "CHEMICAL", 72, 74], ["OX40", "GENE_OR_GENE_PRODUCT", 20, 24], ["Ag", "GENE_OR_GENE_PRODUCT", 72, 74], ["T cells", "CELL", 84, 91], ["peripheral T-cell", "CELL", 128, 145], ["OX40", "GENE_OR_GENE_PRODUCT", 212, 216], ["Cancer", "CANCER", 263, 269], ["OX40", "GENE_OR_GENE_PRODUCT", 341, 345], ["OX40", "PROTEIN", 20, 24], ["Ag", "PROTEIN", 72, 74], ["T cells", "CELL_TYPE", 84, 91], ["OX40", "PROTEIN", 212, 216], ["OX40", "PROTEIN", 341, 345], ["Cancer", "PROBLEM", 263, 269], ["Chronic Pathogens", "PROBLEM", 290, 307], ["OX40", "TREATMENT", 341, 345], ["autoimmune disease", "PROBLEM", 366, 384], ["Cancer", "OBSERVATION", 263, 269], ["autoimmune disease", "OBSERVATION", 366, 384]]], ["One involves direct deletion of OX40 positive cells through a cytotoxic Ab, while the other targets the OX40 ligand in attempt to decrease OX40-specific signaling.", [["cells", "ANATOMY", 46, 51], ["OX40", "GENE_OR_GENE_PRODUCT", 32, 36], ["Ab", "GENE_OR_GENE_PRODUCT", 72, 74], ["OX40", "GENE_OR_GENE_PRODUCT", 104, 108], ["OX40", "GENE_OR_GENE_PRODUCT", 139, 143], ["OX40", "PROTEIN", 32, 36], ["cytotoxic Ab", "PROTEIN", 62, 74], ["OX40 ligand", "PROTEIN", 104, 115], ["OX40", "PROTEIN", 139, 143], ["a cytotoxic Ab", "TEST", 60, 74], ["the OX40 ligand", "TREATMENT", 100, 115]]], ["15, 37 Antibody directed deletion of OX40 T cells showed therapeutic promise in EAE, as it was able to ameliorate ongoing signs of disease.", [["OX40 T cells", "ANATOMY", 37, 49], ["EAE", "DISEASE", 80, 83], ["OX40", "GENE_OR_GENE_PRODUCT", 37, 41], ["OX40 T cells", "CELL_TYPE", 37, 49], ["Antibody", "TEST", 7, 15], ["OX40 T cells", "TREATMENT", 37, 49], ["disease", "PROBLEM", 131, 138], ["disease", "OBSERVATION", 131, 138]]], ["15 This was accomplished using a ricin conjugated OX40-specific Ab that was shown to directly target myelin-specific T cells within the CNS of mice with EAE.", [["myelin", "ANATOMY", 101, 107], ["T cells", "ANATOMY", 117, 124], ["CNS", "ANATOMY", 136, 139], ["EAE", "DISEASE", 153, 156], ["OX40", "GENE_OR_GENE_PRODUCT", 50, 54], ["Ab", "GENE_OR_GENE_PRODUCT", 64, 66], ["myelin", "GENE_OR_GENE_PRODUCT", 101, 107], ["T cells", "CELL", 117, 124], ["CNS", "ANATOMICAL_SYSTEM", 136, 139], ["mice", "ORGANISM", 143, 147], ["OX40", "PROTEIN", 50, 54], ["myelin-specific T cells", "CELL_TYPE", 101, 124], ["mice", "SPECIES", 143, 147], ["mice", "SPECIES", 143, 147], ["a ricin conjugated OX40", "TREATMENT", 31, 54], ["CNS", "ANATOMY", 136, 139]]], ["This therapy led to a 2-log reduction in the myelin-specific T cells isolated from the CNS, which correlated well with a reduction in disease score.", [["myelin", "ANATOMY", 45, 51], ["T cells", "ANATOMY", 61, 68], ["CNS", "ANATOMY", 87, 90], ["myelin", "GENE_OR_GENE_PRODUCT", 45, 51], ["T cells", "CELL", 61, 68], ["CNS", "ANATOMICAL_SYSTEM", 87, 90], ["myelin-specific T cells", "CELL_TYPE", 45, 68], ["This therapy", "TREATMENT", 0, 12], ["a 2-log reduction", "TREATMENT", 20, 37], ["the myelin-specific T cells", "PROBLEM", 41, 68], ["a reduction in disease score", "PROBLEM", 119, 147], ["CNS", "ANATOMY", 87, 90]]], ["While this therapy worked well there has been some concern regarding this approach, because other cell types have more recently been identified to express OX40 including T regulatory cells and PMNs.", [["cell", "ANATOMY", 98, 102], ["T regulatory cells", "ANATOMY", 170, 188], ["PMNs", "ANATOMY", 193, 197], ["cell", "CELL", 98, 102], ["OX40", "GENE_OR_GENE_PRODUCT", 155, 159], ["T regulatory cells", "CELL", 170, 188], ["PMNs", "CELL", 193, 197], ["OX40", "PROTEIN", 155, 159], ["T regulatory cells", "CELL_TYPE", 170, 188], ["PMNs", "CELL_TYPE", 193, 197], ["this therapy", "TREATMENT", 6, 18], ["this approach", "TREATMENT", 69, 82], ["other cell types", "PROBLEM", 92, 108], ["PMNs", "TEST", 193, 197]]], ["10, 56 The second approach involves agents that target/bind to the OX40 ligand, thus limiting OX40-specific signals in activated T cells.", [["T cells", "ANATOMY", 129, 136], ["OX40", "GENE_OR_GENE_PRODUCT", 67, 71], ["OX40", "GENE_OR_GENE_PRODUCT", 94, 98], ["T cells", "CELL", 129, 136], ["OX40 ligand", "PROTEIN", 67, 78], ["OX40", "PROTEIN", 94, 98], ["activated T cells", "CELL_TYPE", 119, 136]]], ["The OX40 ligand is upregulated at the site of inflammation in several autoimmune models 2 and hence OX40 ligand blockade was a logical extension for treatment of inflammatory disorders.", [["inflammation", "DISEASE", 46, 58], ["inflammatory disorders", "DISEASE", 162, 184], ["OX40", "GENE_OR_GENE_PRODUCT", 4, 8], ["OX40", "GENE_OR_GENE_PRODUCT", 100, 104], ["OX40 ligand", "PROTEIN", 4, 15], ["OX40", "PROTEIN", 100, 104], ["inflammation", "PROBLEM", 46, 58], ["several autoimmune models", "PROBLEM", 62, 87], ["OX40 ligand blockade", "TREATMENT", 100, 120], ["a logical extension", "TREATMENT", 125, 144], ["inflammatory disorders", "PROBLEM", 162, 184], ["inflammation", "OBSERVATION", 46, 58], ["inflammatory", "OBSERVATION", 162, 174]]], ["Initial reports showed that injection of an OX40:Ig fusion protein was effective at inhibiting clinical signs of disease in EAE when administered after disease onset.", [["EAE", "DISEASE", 124, 127], ["OX40", "GENE_OR_GENE_PRODUCT", 44, 48], ["Ig", "GENE_OR_GENE_PRODUCT", 49, 51], ["OX40", "PROTEIN", 44, 48], ["Ig fusion protein", "PROTEIN", 49, 66], ["an OX40", "TREATMENT", 41, 48], ["Ig fusion protein", "TREATMENT", 49, 66], ["disease in EAE", "PROBLEM", 113, 127], ["disease onset", "PROBLEM", 152, 165], ["disease", "OBSERVATION", 113, 120]]], ["37 It was also shown that OX40 ligand blockade administered during a relapse episode was effective at tempering disease; however, as soon as treatment was stopped the mice relapsed.", [["OX40 ligand", "GENE_OR_GENE_PRODUCT", 26, 37], ["mice", "ORGANISM", 167, 171], ["OX40", "PROTEIN", 26, 30], ["mice", "SPECIES", 167, 171], ["mice", "SPECIES", 167, 171], ["OX40 ligand blockade", "TREATMENT", 26, 46], ["a relapse episode", "PROBLEM", 67, 84], ["tempering disease", "PROBLEM", 102, 119], ["treatment", "TREATMENT", 141, 150]]], ["37 Therefore, it appeared that blocking OX40 signaling was able to reduce T-cell effector function, but not eliminate the cells responsible for causing the disease.", [["T-cell", "ANATOMY", 74, 80], ["cells", "ANATOMY", 122, 127], ["OX40", "GENE_OR_GENE_PRODUCT", 40, 44], ["T-cell", "CELL", 74, 80], ["cells", "CELL", 122, 127], ["OX40", "PROTEIN", 40, 44], ["blocking OX40 signaling", "PROBLEM", 31, 54], ["the cells", "PROBLEM", 118, 127], ["the disease", "PROBLEM", 152, 163], ["disease", "OBSERVATION", 156, 163]]], ["OX40 ligand blockade has been used to temper a variety of autoimmune/inflammatory models including asthma, inflammatory bowel disease, viral-induced lung inflammation, graft-vs-host disease, diabetes and rheumatoid arthritis.", [["bowel", "ANATOMY", 120, 125], ["lung", "ANATOMY", 149, 153], ["graft", "ANATOMY", 168, 173], ["asthma", "DISEASE", 99, 105], ["inflammatory bowel disease", "DISEASE", 107, 133], ["lung inflammation", "DISEASE", 149, 166], ["graft-vs-host disease", "DISEASE", 168, 189], ["diabetes", "DISEASE", 191, 199], ["rheumatoid arthritis", "DISEASE", 204, 224], ["OX40", "GENE_OR_GENE_PRODUCT", 0, 4], ["bowel", "ORGAN", 120, 125], ["lung", "ORGAN", 149, 153], ["graft", "TISSUE", 168, 173], ["OX40", "PROTEIN", 0, 4], ["OX40 ligand blockade", "TREATMENT", 0, 20], ["autoimmune/inflammatory models", "PROBLEM", 58, 88], ["asthma", "PROBLEM", 99, 105], ["inflammatory bowel disease", "PROBLEM", 107, 133], ["viral-induced lung inflammation", "PROBLEM", 135, 166], ["host disease", "PROBLEM", 177, 189], ["diabetes", "PROBLEM", 191, 199], ["rheumatoid arthritis", "PROBLEM", 204, 224], ["inflammatory models", "OBSERVATION", 69, 88], ["asthma", "OBSERVATION", 99, 105], ["inflammatory bowel disease", "OBSERVATION", 107, 133], ["viral", "OBSERVATION_MODIFIER", 135, 140], ["lung", "ANATOMY", 149, 153], ["inflammation", "OBSERVATION", 154, 166], ["graft", "OBSERVATION", 168, 173], ["host disease", "OBSERVATION", 177, 189], ["diabetes", "OBSERVATION", 191, 199], ["rheumatoid arthritis", "OBSERVATION", 204, 224]]], ["2, 57 Genentech is now developing a humanized OX40 ligand Ab, which is currently being tested in a phase I clinical trial for asthma.", [["asthma", "DISEASE", 126, 132], ["OX40", "GENE_OR_GENE_PRODUCT", 46, 50], ["humanized OX40 ligand Ab", "PROTEIN", 36, 60], ["asthma", "PROBLEM", 126, 132]]], ["This Ab may have far reaching potential as a potent anti-inflammatory for several human diseases in future clinical trials.Altering Memory T-Cell Generation/Function through the OX40 Axis for Therapeutic Benefit in Autoimmunity, Cancer and Hosts Harboring Chronic PathogensEnhancing immune responses through in vivo administration of OX40 agonists has shown therapeutic promise in mouse models for cancer and chronic pathogen infections.", [["Cancer", "ANATOMY", 229, 235], ["cancer", "ANATOMY", 398, 404], ["Autoimmunity", "DISEASE", 215, 227], ["Cancer", "DISEASE", 229, 235], ["cancer", "DISEASE", 398, 404], ["pathogen infections", "DISEASE", 417, 436], ["Ab", "GENE_OR_GENE_PRODUCT", 5, 7], ["human", "ORGANISM", 82, 87], ["OX40", "GENE_OR_GENE_PRODUCT", 178, 182], ["Cancer", "CANCER", 229, 235], ["OX40", "GENE_OR_GENE_PRODUCT", 334, 338], ["mouse", "ORGANISM", 381, 386], ["cancer", "CANCER", 398, 404], ["OX40", "PROTEIN", 178, 182], ["OX40", "PROTEIN", 334, 338], ["human", "SPECIES", 82, 87], ["mouse", "SPECIES", 381, 386], ["human", "SPECIES", 82, 87], ["mouse", "SPECIES", 381, 386], ["a potent anti-inflammatory", "TREATMENT", 43, 69], ["several human diseases", "PROBLEM", 74, 96], ["clinical trials", "TREATMENT", 107, 122], ["Therapeutic Benefit", "TREATMENT", 192, 211], ["Autoimmunity", "PROBLEM", 215, 227], ["Cancer", "PROBLEM", 229, 235], ["Chronic Pathogens", "PROBLEM", 256, 273], ["OX40 agonists", "TREATMENT", 334, 347], ["cancer", "PROBLEM", 398, 404], ["chronic pathogen infections", "PROBLEM", 409, 436], ["Cancer", "OBSERVATION", 229, 235], ["cancer", "OBSERVATION", 398, 404], ["chronic", "OBSERVATION_MODIFIER", 409, 416], ["pathogen", "OBSERVATION_MODIFIER", 417, 425], ["infections", "OBSERVATION", 426, 436]]], ["57 Primarily, two agents have been used to achieve successful agonist stimulation: (1) an OX40 ligand:Ig fusion protein and (2) an OX40 agonist Ab.", [["Ab.", "CHEMICAL", 144, 147], ["Ab.", "CHEMICAL", 144, 147], ["OX40", "GENE_OR_GENE_PRODUCT", 90, 94], ["Ig", "GENE_OR_GENE_PRODUCT", 102, 104], ["OX40", "GENE_OR_GENE_PRODUCT", 131, 135], ["OX40 ligand", "PROTEIN", 90, 101], ["Ig fusion protein", "PROTEIN", 102, 119], ["OX40", "PROTEIN", 131, 135], ["successful agonist stimulation", "TREATMENT", 51, 81], ["Ig fusion protein", "TREATMENT", 102, 119]]], ["The initial report showed that both OX40L:Ig and anti-OX40 had similar activity to regress tumors in cancer-bearing mice.", [["tumors", "ANATOMY", 91, 97], ["cancer", "ANATOMY", 101, 107], ["tumors", "DISEASE", 91, 97], ["cancer", "DISEASE", 101, 107], ["OX40L", "GENE_OR_GENE_PRODUCT", 36, 41], ["Ig", "GENE_OR_GENE_PRODUCT", 42, 44], ["anti-OX40", "GENE_OR_GENE_PRODUCT", 49, 58], ["tumors", "CANCER", 91, 97], ["cancer", "CANCER", 101, 107], ["mice", "ORGANISM", 116, 120], ["OX40L", "PROTEIN", 36, 41], ["Ig", "PROTEIN", 42, 44], ["anti-OX40", "PROTEIN", 49, 58], ["mice", "SPECIES", 116, 120], ["tumors in cancer", "PROBLEM", 91, 107], ["tumors", "OBSERVATION", 91, 97], ["cancer", "OBSERVATION", 101, 107]]], ["14 Although, there has been a more recent report that suggests the OX40L:Ig fusion protein has better anti-tumor efficacy than the anti-mouse OX40 agonist Ab (termed OX86).", [["OX40L", "GENE_OR_GENE_PRODUCT", 67, 72], ["Ig", "GENE_OR_GENE_PRODUCT", 73, 75], ["anti-tumor", "CANCER", 102, 112], ["OX40", "GENE_OR_GENE_PRODUCT", 142, 146], ["Ab", "GENE_OR_GENE_PRODUCT", 155, 157], ["OX86", "GENE_OR_GENE_PRODUCT", 166, 170], ["OX40L", "PROTEIN", 67, 72], ["Ig fusion protein", "PROTEIN", 73, 90], ["anti-mouse OX40 agonist Ab", "PROTEIN", 131, 157], ["OX86", "PROTEIN", 166, 170], ["Ig fusion protein", "TREATMENT", 73, 90], ["the anti-mouse OX40 agonist Ab", "TREATMENT", 127, 157]]], ["58 The OX40-specific anti-tumor efficacy has been observed in several tumor models, including sarcoma, melanoma, colon cancer, breast carcinoma, lung cancer, glioma, prostate cancer.", [["anti-tumor", "ANATOMY", 21, 31], ["tumor", "ANATOMY", 70, 75], ["sarcoma", "ANATOMY", 94, 101], ["melanoma", "ANATOMY", 103, 111], ["colon cancer", "ANATOMY", 113, 125], ["breast carcinoma", "ANATOMY", 127, 143], ["lung cancer", "ANATOMY", 145, 156], ["glioma", "ANATOMY", 158, 164], ["prostate cancer", "ANATOMY", 166, 181], ["tumor", "DISEASE", 70, 75], ["sarcoma", "DISEASE", 94, 101], ["melanoma", "DISEASE", 103, 111], ["colon cancer", "DISEASE", 113, 125], ["breast carcinoma", "DISEASE", 127, 143], ["lung cancer", "DISEASE", 145, 156], ["glioma", "DISEASE", 158, 164], ["prostate cancer", "DISEASE", 166, 181], ["OX40", "GENE_OR_GENE_PRODUCT", 7, 11], ["anti-tumor", "CANCER", 21, 31], ["tumor", "CANCER", 70, 75], ["sarcoma", "CANCER", 94, 101], ["melanoma", "CANCER", 103, 111], ["colon cancer", "CANCER", 113, 125], ["breast carcinoma", "CANCER", 127, 143], ["lung cancer", "CANCER", 145, 156], ["glioma", "CANCER", 158, 164], ["prostate cancer", "CANCER", 166, 181], ["OX40", "PROTEIN", 7, 11], ["sarcoma", "PROBLEM", 94, 101], ["melanoma", "PROBLEM", 103, 111], ["colon cancer", "PROBLEM", 113, 125], ["breast carcinoma", "PROBLEM", 127, 143], ["lung cancer", "PROBLEM", 145, 156], ["glioma", "PROBLEM", 158, 164], ["prostate cancer", "PROBLEM", 166, 181], ["several", "OBSERVATION_MODIFIER", 62, 69], ["tumor", "OBSERVATION", 70, 75], ["sarcoma", "OBSERVATION", 94, 101], ["melanoma", "OBSERVATION", 103, 111], ["colon", "ANATOMY", 113, 118], ["cancer", "OBSERVATION", 119, 125], ["breast", "ANATOMY", 127, 133], ["carcinoma", "OBSERVATION", 134, 143], ["lung", "ANATOMY", 145, 149], ["cancer", "OBSERVATION", 150, 156], ["glioma", "OBSERVATION", 158, 164], ["prostate", "ANATOMY", 166, 174], ["cancer", "OBSERVATION", 175, 181]]], ["2 The anti-tumor efficacy generated by OX40 agonists is dependent on both CD4 and CD8 T cells and it has been shown that OX40 agonists do enhance tumor-Ag specific memory T-cell development.", [["CD4", "ANATOMY", 74, 77], ["CD8 T cells", "ANATOMY", 82, 93], ["tumor", "ANATOMY", 146, 151], ["memory T-cell", "ANATOMY", 164, 177], ["tumor", "DISEASE", 146, 151], ["Ag", "CHEMICAL", 152, 154], ["anti-tumor", "CANCER", 6, 16], ["OX40", "GENE_OR_GENE_PRODUCT", 39, 43], ["CD4", "GENE_OR_GENE_PRODUCT", 74, 77], ["CD8", "GENE_OR_GENE_PRODUCT", 82, 85], ["OX40", "GENE_OR_GENE_PRODUCT", 121, 125], ["tumor", "CANCER", 146, 151], ["Ag", "GENE_OR_GENE_PRODUCT", 152, 154], ["memory T-cell", "CELL", 164, 177], ["OX40", "PROTEIN", 39, 43], ["CD4 and CD8 T cells", "CELL_TYPE", 74, 93], ["OX40", "PROTEIN", 121, 125], ["OX40 agonists", "TREATMENT", 39, 52], ["OX40 agonists", "TREATMENT", 121, 134], ["enhance tumor", "PROBLEM", 138, 151], ["tumor", "OBSERVATION", 146, 151]]], ["14,59 Subsequently, another report has shown that anti-OX40 administration greatly augments the adoptive transfer of tumor-reactive T cells.", [["tumor-reactive T cells", "ANATOMY", 117, 139], ["anti-OX40", "CHEMICAL", 50, 59], ["tumor", "DISEASE", 117, 122], ["anti-OX40", "SIMPLE_CHEMICAL", 50, 59], ["tumor-reactive T cells", "CELL", 117, 139], ["anti-OX40", "PROTEIN", 50, 59], ["tumor-reactive T cells", "CELL_TYPE", 117, 139], ["anti-OX40 administration", "TREATMENT", 50, 74], ["tumor", "PROBLEM", 117, 122], ["reactive T cells", "PROBLEM", 123, 139], ["tumor", "OBSERVATION", 117, 122], ["reactive T cells", "OBSERVATION", 123, 139]]], ["60 Anti-OX40 showed similar therapeutic efficacy to IL-2 in supporting tumor-reactive T-cell mediated destruction of lung-metastases.", [["tumor", "ANATOMY", 71, 76], ["T-cell", "ANATOMY", 86, 92], ["lung-metastases", "ANATOMY", 117, 132], ["Anti-OX40", "CHEMICAL", 3, 12], ["tumor", "DISEASE", 71, 76], ["lung-metastases", "DISEASE", 117, 132], ["Anti-OX40", "GENE_OR_GENE_PRODUCT", 3, 12], ["IL-2", "GENE_OR_GENE_PRODUCT", 52, 56], ["tumor", "CANCER", 71, 76], ["T-cell", "CELL", 86, 92], ["lung", "ORGAN", 117, 121], ["IL-2", "PROTEIN", 52, 56], ["IL", "TEST", 52, 54], ["supporting tumor", "PROBLEM", 60, 76], ["reactive T-cell mediated destruction of lung", "PROBLEM", 77, 121], ["metastases", "PROBLEM", 122, 132], ["therapeutic", "OBSERVATION_MODIFIER", 28, 39], ["tumor", "OBSERVATION", 71, 76], ["reactive", "OBSERVATION_MODIFIER", 77, 85], ["T-cell mediated", "OBSERVATION_MODIFIER", 86, 101], ["destruction", "OBSERVATION", 102, 113], ["lung", "ANATOMY", 117, 121], ["metastases", "OBSERVATION", 122, 132]]], ["However, IL-2 in combination with adoptive immunotherapy did not support the eradication of brain metastases, while anti-OX40 showed powerful synergy to eradicate brain metastases.", [["brain metastases", "ANATOMY", 92, 108], ["brain metastases", "ANATOMY", 163, 179], ["brain metastases", "DISEASE", 92, 108], ["brain metastases", "DISEASE", 163, 179], ["IL-2", "GENE_OR_GENE_PRODUCT", 9, 13], ["brain", "ORGAN", 92, 97], ["anti-OX40", "SIMPLE_CHEMICAL", 116, 125], ["brain", "ORGAN", 163, 168], ["IL-2", "PROTEIN", 9, 13], ["anti-OX40", "PROTEIN", 116, 125], ["IL-2", "TREATMENT", 9, 13], ["adoptive immunotherapy", "TREATMENT", 34, 56], ["brain metastases", "PROBLEM", 92, 108], ["powerful synergy", "PROBLEM", 133, 149], ["brain metastases", "PROBLEM", 163, 179], ["brain", "ANATOMY", 92, 97], ["metastases", "OBSERVATION", 98, 108], ["brain", "ANATOMY", 163, 168], ["metastases", "OBSERVATION", 169, 179]]], ["60 It was not clear why anti-OX40 was able to augment the efficacy of T cells while IL-2 was not, but it may be linked to differential expression of T-cell surface proteins and their ability to help break the blood brain barrier.Altering Memory T-Cell Generation/Function through the OX40 Axis for Therapeutic Benefit in Autoimmunity, Cancer and Hosts Harboring Chronic PathogensWhile it is clear that OX40 agonists given as a single agent can enhance anti-tumor immunity in cancer-bearing hosts, there are models where its activity alone is not enough to cure mice of disease.", [["T cells", "ANATOMY", 70, 77], ["T-cell surface", "ANATOMY", 149, 163], ["blood brain", "ANATOMY", 209, 220], ["Cancer", "ANATOMY", 335, 341], ["anti-tumor", "ANATOMY", 452, 462], ["cancer", "ANATOMY", 475, 481], ["Autoimmunity", "DISEASE", 321, 333], ["Cancer", "DISEASE", 335, 341], ["cancer", "DISEASE", 475, 481], ["anti-OX40", "CHEMICAL", 24, 33], ["anti-OX40", "SIMPLE_CHEMICAL", 24, 33], ["T cells", "CELL", 70, 77], ["IL-2", "GENE_OR_GENE_PRODUCT", 84, 88], ["T-cell surface proteins", "GENE_OR_GENE_PRODUCT", 149, 172], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 209, 228], ["OX40", "GENE_OR_GENE_PRODUCT", 284, 288], ["Cancer", "CANCER", 335, 341], ["OX40", "GENE_OR_GENE_PRODUCT", 402, 406], ["anti-tumor", "CANCER", 452, 462], ["cancer", "CANCER", 475, 481], ["hosts", "ORGANISM", 490, 495], ["mice", "ORGANISM", 561, 565], ["anti-OX40", "PROTEIN", 24, 33], ["T cells", "CELL_TYPE", 70, 77], ["IL", "PROTEIN", 84, 86], ["T-cell surface proteins", "PROTEIN", 149, 172], ["OX40", "PROTEIN", 284, 288], ["OX40", "PROTEIN", 402, 406], ["mice", "SPECIES", 561, 565], ["mice", "SPECIES", 561, 565], ["T-cell surface proteins", "PROBLEM", 149, 172], ["the blood brain barrier", "TREATMENT", 205, 228], ["Cancer", "PROBLEM", 335, 341], ["Chronic Pathogens", "PROBLEM", 362, 379], ["OX40 agonists", "TREATMENT", 402, 415], ["a single agent", "TREATMENT", 425, 439], ["disease", "PROBLEM", 569, 576], ["Cancer", "OBSERVATION", 335, 341], ["disease", "OBSERVATION", 569, 576]]], ["Hence, there have been a number of studies that have attempted combination therapies with vaccines/cytokines and anti-OX40.", [["anti-OX40", "GENE_OR_GENE_PRODUCT", 113, 122], ["cytokines", "PROTEIN", 99, 108], ["anti-OX40", "PROTEIN", 113, 122], ["studies", "TEST", 35, 42], ["combination therapies", "TREATMENT", 63, 84], ["vaccines", "TREATMENT", 90, 98], ["cytokines", "TREATMENT", 99, 108], ["anti-OX40", "TREATMENT", 113, 122]]], ["54, 61, 62 These combination therapies have included GM-CSF secreting whole tumor vaccines as well as the addition of innate cytokines, both of which showed promising synergy.", [["tumor", "ANATOMY", 76, 81], ["GM", "CHEMICAL", 53, 55], ["tumor", "DISEASE", 76, 81], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 53, 59], ["tumor", "CANCER", 76, 81], ["innate cytokines", "PROTEIN", 118, 134], ["These combination therapies", "TREATMENT", 11, 38], ["GM", "TEST", 53, 55], ["CSF secreting whole tumor vaccines", "TREATMENT", 56, 90], ["innate cytokines", "TREATMENT", 118, 134], ["promising synergy", "PROBLEM", 157, 174], ["synergy", "OBSERVATION", 167, 174]]], ["54, 61, 62 It was shown that anti-OX40 in combination with a GM-CSF secreting whole cell vaccine expressing the Her-2/neu tumor Ag was able to enhance CD8 T-cell responses and regress tumors (breast cancer model).", [["whole cell", "ANATOMY", 78, 88], ["Her-2/neu tumor", "ANATOMY", 112, 127], ["CD8 T-cell", "ANATOMY", 151, 161], ["tumors", "ANATOMY", 184, 190], ["breast cancer", "ANATOMY", 192, 205], ["anti-OX40", "CHEMICAL", 29, 38], ["GM", "CHEMICAL", 61, 63], ["tumor", "DISEASE", 122, 127], ["tumors", "DISEASE", 184, 190], ["breast cancer", "DISEASE", 192, 205], ["anti-OX40", "SIMPLE_CHEMICAL", 29, 38], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 61, 67], ["cell", "CELL", 84, 88], ["Her-2", "GENE_OR_GENE_PRODUCT", 112, 117], ["neu", "GENE_OR_GENE_PRODUCT", 118, 121], ["CD8", "GENE_OR_GENE_PRODUCT", 151, 154], ["tumors", "CANCER", 184, 190], ["breast cancer", "CANCER", 192, 205], ["anti-OX40", "PROTEIN", 29, 38], ["CSF", "PROTEIN", 64, 67], ["Her-2/neu tumor Ag", "PROTEIN", 112, 130], ["CD8", "PROTEIN", 151, 154], ["anti-OX40", "TREATMENT", 29, 38], ["a GM-CSF secreting whole cell vaccine", "TREATMENT", 59, 96], ["neu tumor Ag", "PROBLEM", 118, 130], ["regress tumors (breast cancer model", "PROBLEM", 176, 211], ["tumor", "OBSERVATION", 122, 127], ["tumors", "OBSERVATION", 184, 190], ["breast", "ANATOMY", 192, 198], ["cancer", "OBSERVATION", 199, 205]]], ["62 However, the vaccine alone showed very little anti-tumor efficacy, which correlated with a weak Her-2-specific CD8 T-cell response.", [["CD8 T-cell", "ANATOMY", 114, 124], ["anti-tumor", "CANCER", 49, 59], ["Her-2", "GENE_OR_GENE_PRODUCT", 99, 104], ["CD8", "GENE_OR_GENE_PRODUCT", 114, 117], ["Her-2", "PROTEIN", 99, 104], ["CD8", "PROTEIN", 114, 117], ["the vaccine", "TREATMENT", 12, 23]]], ["It was subsequently shown that the increase in Her-2-specific CD8 T cells elicited via the combination treatment was dependent on anti-OX40 accentuating CD4 T-cell help.", [["CD8 T cells", "ANATOMY", 62, 73], ["CD4 T-cell", "ANATOMY", 153, 163], ["Her-2", "GENE_OR_GENE_PRODUCT", 47, 52], ["CD8", "GENE_OR_GENE_PRODUCT", 62, 65], ["anti-OX40", "SIMPLE_CHEMICAL", 130, 139], ["Her-2", "PROTEIN", 47, 52], ["CD8 T cells", "CELL_TYPE", 62, 73], ["anti-OX40", "PROTEIN", 130, 139], ["CD4", "PROTEIN", 153, 156], ["the increase in Her-2-specific CD8 T cells", "PROBLEM", 31, 73], ["the combination treatment", "TREATMENT", 87, 112], ["anti-OX40", "TREATMENT", 130, 139], ["increase", "OBSERVATION_MODIFIER", 35, 43]]], ["Another combinatorial approach that has shown great promise for tumor immunotherapy is combining anti-OX40 with innate cytokine(s), especially IL-12.", [["tumor", "ANATOMY", 64, 69], ["tumor", "DISEASE", 64, 69], ["tumor", "CANCER", 64, 69], ["anti-OX40", "GENE_OR_GENE_PRODUCT", 97, 106], ["IL-12", "GENE_OR_GENE_PRODUCT", 143, 148], ["anti-OX40", "PROTEIN", 97, 106], ["innate cytokine", "PROTEIN", 112, 127], ["IL-12", "PROTEIN", 143, 148], ["Another combinatorial approach", "TREATMENT", 0, 30], ["tumor immunotherapy", "TREATMENT", 64, 83], ["great", "OBSERVATION_MODIFIER", 46, 51], ["promise", "OBSERVATION_MODIFIER", 52, 59], ["tumor", "OBSERVATION", 64, 69]]], ["One of the theoretical limitations of priming the immune system to tumor-specific Ags is the lack of \"danger\" signals (e.g., CpG, dsRNA, LPS, etc\u2026) known to elicit innate cytokines when tumor Ags are presented to the immune system in vivo.", [["tumor", "ANATOMY", 67, 72], ["tumor", "ANATOMY", 186, 191], ["immune system", "ANATOMY", 217, 230], ["tumor", "DISEASE", 67, 72], ["tumor", "DISEASE", 186, 191], ["CpG", "CHEMICAL", 125, 128], ["tumor", "CANCER", 67, 72], ["LPS", "GENE_OR_GENE_PRODUCT", 137, 140], ["etc\u2026", "GENE_OR_GENE_PRODUCT", 142, 146], ["tumor", "CANCER", 186, 191], ["Ags", "GENE_OR_GENE_PRODUCT", 192, 195], ["immune system", "ANATOMICAL_SYSTEM", 217, 230], ["Ags", "PROTEIN", 82, 85], ["cytokines", "PROTEIN", 171, 180], ["Ags", "PROTEIN", 192, 195], ["tumor", "PROBLEM", 186, 191], ["tumor", "OBSERVATION", 67, 72], ["tumor", "OBSERVATION", 186, 191]]], ["As previously mentioned, IL-12 is necessary to mediate the survival of anti-OX40-stimulated CD4 T cells and the combination of anti-OX40 and IL-12 in tumor-bearing mice showed synergistic therapy.", [["CD4 T cells", "ANATOMY", 92, 103], ["tumor", "ANATOMY", 150, 155], ["tumor", "DISEASE", 150, 155], ["IL-12", "GENE_OR_GENE_PRODUCT", 25, 30], ["anti-OX40", "GENE_OR_GENE_PRODUCT", 71, 80], ["CD4 T cells", "CELL", 92, 103], ["anti-OX40", "GENE_OR_GENE_PRODUCT", 127, 136], ["IL-12", "GENE_OR_GENE_PRODUCT", 141, 146], ["tumor", "CANCER", 150, 155], ["mice", "ORGANISM", 164, 168], ["IL-12", "PROTEIN", 25, 30], ["anti-OX40", "PROTEIN", 71, 80], ["CD4 T cells", "CELL_TYPE", 92, 103], ["anti-OX40", "PROTEIN", 127, 136], ["IL-12", "PROTEIN", 141, 146], ["mice", "SPECIES", 164, 168], ["mice", "SPECIES", 164, 168], ["anti-OX40-stimulated CD4 T cells", "TREATMENT", 71, 103], ["anti-OX40 and IL", "TREATMENT", 127, 143], ["synergistic therapy", "TREATMENT", 176, 195], ["synergistic therapy", "OBSERVATION", 176, 195]]], ["54 This combination was therapeutically effective in the poorly immunogenic prostate cancer model, TRAMP-C1, where neither IL-12 nor anti-OX40 alone showed any therapeutic efficacy.", [["prostate cancer", "ANATOMY", 76, 91], ["TRAMP-C1", "ANATOMY", 99, 107], ["prostate cancer", "DISEASE", 76, 91], ["anti-OX40", "CHEMICAL", 133, 142], ["prostate cancer", "CANCER", 76, 91], ["TRAMP-C1", "GENE_OR_GENE_PRODUCT", 99, 107], ["IL-12", "GENE_OR_GENE_PRODUCT", 123, 128], ["anti-OX40", "SIMPLE_CHEMICAL", 133, 142], ["TRAMP", "PROTEIN", 99, 104], ["IL-12", "PROTEIN", 123, 128], ["anti-OX40", "PROTEIN", 133, 142], ["the poorly immunogenic prostate cancer", "PROBLEM", 53, 91], ["neither IL", "TEST", 115, 125], ["prostate", "ANATOMY", 76, 84], ["cancer", "OBSERVATION", 85, 91]]], ["54 IL-12 and anti-OX40 also showed dramatic therapeutic synergy in an active immunization model using a tumor-dendritic fusion vaccine injected directly into the spleen.", [["tumor", "ANATOMY", 104, 109], ["dendritic", "ANATOMY", 110, 119], ["spleen", "ANATOMY", 162, 168], ["tumor", "DISEASE", 104, 109], ["IL-12", "GENE_OR_GENE_PRODUCT", 3, 8], ["anti-OX40", "GENE_OR_GENE_PRODUCT", 13, 22], ["tumor", "CANCER", 104, 109], ["spleen", "ORGAN", 162, 168], ["IL", "PROTEIN", 3, 5], ["anti-OX40", "PROTEIN", 13, 22], ["dramatic therapeutic synergy", "PROBLEM", 35, 63], ["an active immunization model", "TREATMENT", 67, 95], ["a tumor-dendritic fusion vaccine", "TREATMENT", 102, 134], ["dramatic", "OBSERVATION_MODIFIER", 35, 43], ["therapeutic synergy", "OBSERVATION", 44, 63], ["spleen", "ANATOMY", 162, 168]]], ["54 Whether IL-12 actually enhances survival of OX40 stimulated tumor-reactive T cells or increases Th1/Tc1 immunity was not directly ascertained in these models, but most likely both mechanisms are involved to enhance OX40-mediated tumor destruction.", [["tumor-reactive T cells", "ANATOMY", 63, 85], ["tumor", "ANATOMY", 232, 237], ["tumor", "DISEASE", 63, 68], ["tumor", "DISEASE", 232, 237], ["IL-12", "GENE_OR_GENE_PRODUCT", 11, 16], ["OX40", "GENE_OR_GENE_PRODUCT", 47, 51], ["tumor-reactive T cells", "CELL", 63, 85], ["Tc1", "GENE_OR_GENE_PRODUCT", 103, 106], ["OX40", "GENE_OR_GENE_PRODUCT", 218, 222], ["tumor", "CANCER", 232, 237], ["IL-12", "PROTEIN", 11, 16], ["OX40 stimulated tumor-reactive T cells", "CELL_TYPE", 47, 85], ["OX40", "PROTEIN", 218, 222], ["OX40 stimulated tumor", "PROBLEM", 47, 68], ["reactive T cells", "PROBLEM", 69, 85], ["Th1/Tc1 immunity", "PROBLEM", 99, 115], ["tumor destruction", "PROBLEM", 232, 249], ["reactive", "OBSERVATION_MODIFIER", 69, 77], ["most likely", "UNCERTAINTY", 166, 177], ["tumor", "OBSERVATION", 232, 237]]], ["OX40 agonists have also been shown to enhance T-cell responses to chronic pathogens (e.g., viruses and bacteria).", [["T-cell", "ANATOMY", 46, 52], ["OX40", "GENE_OR_GENE_PRODUCT", 0, 4], ["T-cell", "CELL", 46, 52], ["OX40", "PROTEIN", 0, 4], ["chronic pathogens", "PROBLEM", 66, 83], ["viruses", "PROBLEM", 91, 98], ["bacteria", "PROBLEM", 103, 111], ["chronic", "OBSERVATION_MODIFIER", 66, 73], ["pathogens", "OBSERVATION", 74, 83]]], ["In particular, anti-OX40 was administered into mice harboring a chronic cytomegalovirus known to replicate in visceral organs (i.e., salivary gland).", [["visceral organs", "ANATOMY", 110, 125], ["salivary gland", "ANATOMY", 133, 147], ["anti-OX40", "CHEMICAL", 15, 24], ["anti-OX40", "CHEMICAL", 15, 24], ["anti-OX40", "GENE_OR_GENE_PRODUCT", 15, 24], ["mice", "ORGANISM", 47, 51], ["cytomegalovirus", "ORGANISM", 72, 87], ["visceral organs", "ORGAN", 110, 125], ["salivary gland", "ORGAN", 133, 147], ["anti-OX40", "PROTEIN", 15, 24], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51], ["anti-OX40", "TREATMENT", 15, 24], ["a chronic cytomegalovirus", "PROBLEM", 62, 87], ["chronic", "OBSERVATION_MODIFIER", 64, 71], ["cytomegalovirus", "OBSERVATION", 72, 87], ["visceral", "ANATOMY_MODIFIER", 110, 118], ["organs", "ANATOMY", 119, 125], ["salivary gland", "ANATOMY", 133, 147]]], ["63 The initial study showed that anti-OX40 enhanced viral specific effector T-cell differentiation leading decreased viral replication in the salivary gland.", [["T-cell", "ANATOMY", 76, 82], ["salivary gland", "ANATOMY", 142, 156], ["anti-OX40", "GENE_OR_GENE_PRODUCT", 33, 42], ["T-cell", "CELL", 76, 82], ["salivary gland", "ORGAN", 142, 156], ["anti-OX40", "PROTEIN", 33, 42], ["The initial study", "TEST", 3, 20], ["decreased viral replication in the salivary gland", "PROBLEM", 107, 156], ["decreased", "OBSERVATION_MODIFIER", 107, 116], ["viral replication", "OBSERVATION", 117, 134], ["salivary gland", "ANATOMY", 142, 156]]], ["Subsequently this group treated mice during the initial stage of infection and found that anti-OX40 greatly enhanced CD8 T-cell responses during the early stages of infection, which led to protective immunity.", [["CD8 T-cell", "ANATOMY", 117, 127], ["infection", "DISEASE", 65, 74], ["infection", "DISEASE", 165, 174], ["mice", "ORGANISM", 32, 36], ["anti-OX40", "GENE_OR_GENE_PRODUCT", 90, 99], ["CD8 T-cell", "CELL", 117, 127], ["CD8", "PROTEIN", 117, 120], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 32, 36], ["infection", "PROBLEM", 65, 74], ["infection", "PROBLEM", 165, 174], ["infection", "OBSERVATION", 65, 74], ["early stages", "OBSERVATION_MODIFIER", 149, 161], ["infection", "OBSERVATION", 165, 174]]], ["64 The OX40 agonist strategy was also beneficial against hosts infected with Cryptococcus neoformans, where the infection resides in the lungs and becomes persistent.", [["lungs", "ANATOMY", 137, 142], ["Cryptococcus neoformans", "DISEASE", 77, 100], ["infection", "DISEASE", 112, 121], ["OX40", "GENE_OR_GENE_PRODUCT", 7, 11], ["Cryptococcus neoformans", "ORGANISM", 77, 100], ["lungs", "ORGAN", 137, 142], ["OX40", "PROTEIN", 7, 11], ["Cryptococcus neoformans", "SPECIES", 77, 100], ["Cryptococcus neoformans", "SPECIES", 77, 100], ["The OX40 agonist strategy", "TREATMENT", 3, 28], ["Cryptococcus neoformans", "PROBLEM", 77, 100], ["the infection", "PROBLEM", 108, 121], ["Cryptococcus neoformans", "OBSERVATION", 77, 100], ["infection", "OBSERVATION", 112, 121], ["lungs", "ANATOMY", 137, 142], ["persistent", "OBSERVATION_MODIFIER", 155, 165]]], ["65 The persistence of this pathogen is characterized by immune deviation to a nonclearing Th2 response, leading to chronic eosinphilia in the lungs.", [["lungs", "ANATOMY", 142, 147], ["eosinphilia", "DISEASE", 123, 134], ["lungs", "ORGAN", 142, 147], ["this pathogen", "PROBLEM", 22, 35], ["immune deviation", "PROBLEM", 56, 72], ["a nonclearing Th2 response", "PROBLEM", 76, 102], ["chronic eosinphilia in the lungs", "PROBLEM", 115, 147], ["persistence", "OBSERVATION_MODIFIER", 7, 18], ["pathogen", "OBSERVATION", 27, 35], ["immune deviation", "OBSERVATION", 56, 72], ["Th2 response", "OBSERVATION", 90, 102], ["chronic", "OBSERVATION_MODIFIER", 115, 122], ["eosinphilia", "OBSERVATION", 123, 134], ["lungs", "ANATOMY", 142, 147]]], ["65 Administration of an OX40L:Ig fusion protein drove a cytokine switch from Th2 to Th1 and reduced the pathogen burden and reduced the eosinphilia.", [["OX40L", "GENE_OR_GENE_PRODUCT", 24, 29], ["Ig", "GENE_OR_GENE_PRODUCT", 30, 32], ["Th2", "GENE_OR_GENE_PRODUCT", 77, 80], ["Th1", "GENE_OR_GENE_PRODUCT", 84, 87], ["OX40L", "PROTEIN", 24, 29], ["Ig fusion protein", "PROTEIN", 30, 47], ["cytokine", "PROTEIN", 56, 64], ["Th1", "CELL_TYPE", 84, 87], ["an OX40L", "TREATMENT", 21, 29], ["Ig fusion protein", "TREATMENT", 30, 47], ["a cytokine switch", "TREATMENT", 54, 71], ["the pathogen burden", "PROBLEM", 100, 119], ["reduced the eosinphilia", "PROBLEM", 124, 147], ["pathogen burden", "OBSERVATION", 104, 119], ["reduced", "OBSERVATION_MODIFIER", 124, 131]]], ["OX40-specific elimination of C. neoformans was dependent on IFN-a/IL-12, as injection of an OX40 agonist to IFN-a or IL-12 ko mice harboring the pathogen was not able to resolve the infection.Altering Memory T-Cell Generation/Function through the OX40 Axis for Therapeutic Benefit in Autoimmunity, Cancer and Hosts Harboring Chronic PathogensIt is clear that OX40 agonists have potent immune stimulating properties in several disease models, which ultimately helps the host eradicate harmful/potentially lethal entities within the body.", [["Cancer", "ANATOMY", 298, 304], ["body", "ANATOMY", 531, 535], ["infection", "DISEASE", 182, 191], ["Autoimmunity", "DISEASE", 284, 296], ["Cancer", "DISEASE", 298, 304], ["OX40", "GENE_OR_GENE_PRODUCT", 0, 4], ["C. neoformans", "ORGANISM", 29, 42], ["IFN-a", "GENE_OR_GENE_PRODUCT", 60, 65], ["IL-12", "GENE_OR_GENE_PRODUCT", 66, 71], ["OX40", "GENE_OR_GENE_PRODUCT", 92, 96], ["IFN-a", "GENE_OR_GENE_PRODUCT", 108, 113], ["IL-12", "GENE_OR_GENE_PRODUCT", 117, 122], ["mice", "ORGANISM", 126, 130], ["OX40", "GENE_OR_GENE_PRODUCT", 247, 251], ["Cancer", "CANCER", 298, 304], ["OX40", "GENE_OR_GENE_PRODUCT", 359, 363], ["body", "ORGANISM_SUBDIVISION", 531, 535], ["OX40", "PROTEIN", 0, 4], ["IFN", "PROTEIN", 60, 63], ["IL-12", "PROTEIN", 66, 71], ["OX40", "PROTEIN", 92, 96], ["IFN", "PROTEIN", 108, 111], ["IL", "PROTEIN", 117, 119], ["OX40", "PROTEIN", 247, 251], ["OX40", "PROTEIN", 359, 363], ["C. neoformans", "SPECIES", 29, 42], ["mice", "SPECIES", 126, 130], ["C. neoformans", "SPECIES", 29, 42], ["mice", "SPECIES", 126, 130], ["C. neoformans", "PROBLEM", 29, 42], ["IFN", "TREATMENT", 60, 63], ["a/IL", "TREATMENT", 64, 68], ["an OX40 agonist", "TREATMENT", 89, 104], ["IFN", "TREATMENT", 108, 111], ["a or IL", "TREATMENT", 112, 119], ["the pathogen", "PROBLEM", 141, 153], ["the infection", "PROBLEM", 178, 191], ["Cancer", "PROBLEM", 298, 304], ["Chronic Pathogens", "PROBLEM", 325, 342], ["OX40 agonists", "TREATMENT", 359, 372], ["potent immune stimulating properties", "TREATMENT", 378, 414], ["several disease models", "PROBLEM", 418, 440], ["neoformans", "OBSERVATION", 32, 42], ["infection", "OBSERVATION", 182, 191], ["Cancer", "OBSERVATION", 298, 304], ["body", "ANATOMY", 531, 535]]], ["Recently, our group has translated these findings into a cancer patient-specific clinical trial.", [["cancer", "ANATOMY", 57, 63], ["cancer", "DISEASE", 57, 63], ["cancer", "CANCER", 57, 63], ["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71]]], ["Initially we tested the safety/dosing of a mouse anti-human OX40-specific monoclonal Ab in nonhuman primates.", [["mouse", "ORGANISM", 43, 48], ["anti-human", "ORGANISM", 49, 59], ["OX40", "GENE_OR_GENE_PRODUCT", 60, 64], ["nonhuman primates", "ORGANISM", 91, 108], ["mouse anti-human OX40", "PROTEIN", 43, 64], ["monoclonal Ab", "PROTEIN", 74, 87], ["mouse", "SPECIES", 43, 48], ["mouse", "SPECIES", 43, 48], ["a mouse anti-human OX40", "TREATMENT", 41, 64], ["specific monoclonal Ab in nonhuman primates", "TREATMENT", 65, 108]]], ["66 We found that OX40 agonist administration to nonhuman primates potentiated memory T-cell generation and increased Ag-specific Ab responses similar to what was observed in mice.", [["memory T-cell", "ANATOMY", 78, 91], ["Ag", "CHEMICAL", 117, 119], ["Ag", "CHEMICAL", 117, 119], ["OX40", "GENE_OR_GENE_PRODUCT", 17, 21], ["nonhuman", "ORGANISM", 48, 56], ["primates", "ORGANISM", 57, 65], ["memory T-cell", "CELL", 78, 91], ["Ag", "GENE_OR_GENE_PRODUCT", 117, 119], ["Ab", "GENE_OR_GENE_PRODUCT", 129, 131], ["mice", "ORGANISM", 174, 178], ["OX40", "PROTEIN", 17, 21], ["Ag", "PROTEIN", 117, 119], ["mice", "SPECIES", 174, 178], ["mice", "SPECIES", 174, 178], ["OX40 agonist administration", "TREATMENT", 17, 44], ["increased Ag", "PROBLEM", 107, 119]]], ["However, in contrast to the mouse studies we found that the adjuvant affect lasted longer, up to a month after the injection.", [["mouse", "ORGANISM", 28, 33], ["mouse", "SPECIES", 28, 33], ["mouse", "SPECIES", 28, 33], ["the mouse studies", "TEST", 24, 41], ["the adjuvant affect", "PROBLEM", 56, 75], ["the injection", "TREATMENT", 111, 124]]], ["We also observed a transient in drop in lymphocyte counts in the peripheral blood seven days after the initial Ab infusion and this was followed by a rebound where the lymphocyte numbers increased over base-line values.", [["lymphocyte", "ANATOMY", 40, 50], ["peripheral blood", "ANATOMY", 65, 81], ["lymphocyte", "ANATOMY", 168, 178], ["lymphocyte", "CELL", 40, 50], ["peripheral blood", "ORGANISM_SUBSTANCE", 65, 81], ["Ab", "GENE_OR_GENE_PRODUCT", 111, 113], ["lymphocyte", "CELL", 168, 178], ["a transient in drop in lymphocyte counts", "PROBLEM", 17, 57], ["the initial Ab infusion", "TREATMENT", 99, 122], ["a rebound", "TEST", 148, 157], ["the lymphocyte numbers", "TEST", 164, 186], ["transient", "OBSERVATION_MODIFIER", 19, 28], ["drop", "OBSERVATION_MODIFIER", 32, 36], ["lymphocyte counts", "OBSERVATION", 40, 57], ["peripheral", "ANATOMY_MODIFIER", 65, 75], ["blood", "ANATOMY", 76, 81], ["increased", "OBSERVATION_MODIFIER", 187, 196]]], ["Upon completion of the monkey studies, the FDA approved a Phase I clinical trial in patients with Stage IV cancer.", [["Stage IV cancer", "ANATOMY", 98, 113], ["cancer", "DISEASE", 107, 113], ["monkey", "ORGANISM", 23, 29], ["patients", "ORGANISM", 84, 92], ["Stage IV cancer", "CANCER", 98, 113], ["patients", "SPECIES", 84, 92], ["the monkey studies", "TEST", 19, 37], ["Stage IV cancer", "PROBLEM", 98, 113], ["cancer", "OBSERVATION", 107, 113]]], ["So far we have treated 17 patients with relatively low toxicity and we have observed immune stimulatory effects in most of the patients post-anti-OX40 treatment.", [["toxicity", "DISEASE", 55, 63], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 127, 135], ["OX40", "GENE_OR_GENE_PRODUCT", 146, 150], ["OX40", "PROTEIN", 146, 150], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 127, 135], ["relatively low toxicity", "PROBLEM", 40, 63], ["immune stimulatory effects", "TREATMENT", 85, 111], ["the patients post-anti-OX40 treatment", "TREATMENT", 123, 160]]], ["In particular we have observed an increase in cycling memory T cells starting with the CD4 T-cell population one week after Ab infusion, followed by CD8 T cells usually 2-4 weeks post-OX40 treatment.", [["memory T cells", "ANATOMY", 54, 68], ["CD4 T-cell", "ANATOMY", 87, 97], ["CD8 T cells", "ANATOMY", 149, 160], ["memory T cells", "CELL", 54, 68], ["Ab", "GENE_OR_GENE_PRODUCT", 124, 126], ["CD8 T cells", "CELL", 149, 160], ["OX40", "GENE_OR_GENE_PRODUCT", 184, 188], ["cycling memory T cells", "CELL_TYPE", 46, 68], ["CD4 T-cell population", "CELL_TYPE", 87, 108], ["CD8 T cells", "CELL_TYPE", 149, 160], ["OX40", "PROTEIN", 184, 188], ["an increase in cycling memory T cells", "PROBLEM", 31, 68], ["the CD4 T-cell population", "TREATMENT", 83, 108], ["Ab infusion", "TREATMENT", 124, 135], ["OX40 treatment", "TREATMENT", 184, 198], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["cycling memory T cells", "OBSERVATION", 46, 68]]], ["We have observed cycling T cells in both the central memory compartment (CD28 ) and effector memory (CD28 -) populations.", [["T cells", "ANATOMY", 25, 32], ["central memory compartment", "ANATOMY", 45, 71], ["effector memory (CD28 -) populations", "ANATOMY", 84, 120], ["T cells", "CELL", 25, 32], ["CD28", "GENE_OR_GENE_PRODUCT", 73, 77], ["CD28", "GENE_OR_GENE_PRODUCT", 101, 105], ["cycling T cells", "CELL_TYPE", 17, 32], ["CD28", "PROTEIN", 73, 77], ["effector memory (CD28 -) populations", "CELL_TYPE", 84, 120], ["cycling T cells", "PROBLEM", 17, 32], ["cycling T cells", "OBSERVATION", 17, 32], ["both", "ANATOMY_MODIFIER", 36, 40], ["central", "ANATOMY_MODIFIER", 45, 52], ["memory compartment", "ANATOMY", 53, 71]]], ["The increase in cycling memory T cells usually lasts 28-days following Ab infusion, however in some patients this effect lasted during the entire two-month evaluation period.", [["memory T cells", "ANATOMY", 24, 38], ["memory T cells", "CELL", 24, 38], ["Ab", "GENE_OR_GENE_PRODUCT", 71, 73], ["patients", "ORGANISM", 100, 108], ["cycling memory T cells", "CELL_TYPE", 16, 38], ["patients", "SPECIES", 100, 108], ["The increase in cycling memory T cells", "PROBLEM", 0, 38], ["Ab infusion", "TREATMENT", 71, 82], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["cycling memory", "OBSERVATION", 16, 30]]], ["There has been some hint of anti-tumor activity with four patients showing regression of some metastatic disease; however there have been no complete responders on this trial to date.ConclusionIn summary, OX40-specific signaling within T cells plays a key role in the generation of memory T cells as well as T-cell effector function.", [["T cells", "ANATOMY", 236, 243], ["memory T cells", "ANATOMY", 282, 296], ["T-cell", "ANATOMY", 308, 314], ["anti-tumor", "CANCER", 28, 38], ["patients", "ORGANISM", 58, 66], ["OX40", "GENE_OR_GENE_PRODUCT", 205, 209], ["T cells", "CELL", 236, 243], ["memory T cells", "CELL", 282, 296], ["T-cell", "CELL", 308, 314], ["OX40", "PROTEIN", 205, 209], ["T cells", "CELL_TYPE", 236, 243], ["memory T cells", "CELL_TYPE", 282, 296], ["patients", "SPECIES", 58, 66], ["some metastatic disease", "PROBLEM", 89, 112], ["anti-tumor activity", "OBSERVATION", 28, 47], ["some", "OBSERVATION_MODIFIER", 89, 93], ["metastatic", "OBSERVATION", 94, 104], ["no", "UNCERTAINTY", 138, 140]]], ["Its biologic function in vivo appears to be limited by expression of the OX40 ligand, which is expressed mainly on activated antigen presenting cells.", [["cells", "ANATOMY", 144, 149], ["OX40", "GENE_OR_GENE_PRODUCT", 73, 77], ["cells", "CELL", 144, 149], ["OX40 ligand", "PROTEIN", 73, 84], ["activated antigen presenting cells", "CELL_TYPE", 115, 149]]], ["OX40 ligand expressing cells are found within sites of inflammation in autoimmune disease and hence strategies have evolved to temper inflammation via blockade of OX40/OX40 ligand interaction.", [["cells", "ANATOMY", 23, 28], ["sites", "ANATOMY", 46, 51], ["inflammation", "DISEASE", 55, 67], ["autoimmune disease", "DISEASE", 71, 89], ["inflammation", "DISEASE", 134, 146], ["OX40", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 23, 28], ["OX40", "GENE_OR_GENE_PRODUCT", 163, 167], ["OX40", "GENE_OR_GENE_PRODUCT", 168, 172], ["OX40 ligand expressing cells", "CELL_TYPE", 0, 28], ["OX40", "PROTEIN", 163, 167], ["OX40", "PROTEIN", 168, 172], ["inflammation", "PROBLEM", 55, 67], ["autoimmune disease", "PROBLEM", 71, 89], ["temper inflammation", "PROBLEM", 127, 146], ["inflammation", "OBSERVATION", 55, 67], ["autoimmune disease", "OBSERVATION", 71, 89]]], ["In contrast, little to no OX40 ligand expression is observed in hosts harboring tumors and some chronic infections and therefore accentuating OX40 signaling can enhance immunity leading to the destruction of these harmful entities.", [["tumors", "ANATOMY", 80, 86], ["tumors", "DISEASE", 80, 86], ["chronic infections", "DISEASE", 96, 114], ["OX40", "GENE_OR_GENE_PRODUCT", 26, 30], ["tumors", "CANCER", 80, 86], ["OX40", "GENE_OR_GENE_PRODUCT", 142, 146], ["OX40", "PROTEIN", 26, 30], ["OX40", "PROTEIN", 142, 146], ["harboring tumors", "PROBLEM", 70, 86], ["some chronic infections", "PROBLEM", 91, 114], ["accentuating OX40 signaling", "PROBLEM", 129, 156], ["the destruction of these harmful entities", "PROBLEM", 189, 230], ["tumors", "OBSERVATION", 80, 86], ["some", "OBSERVATION_MODIFIER", 91, 95], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["infections", "OBSERVATION", 104, 114], ["destruction", "OBSERVATION", 193, 204], ["harmful", "OBSERVATION_MODIFIER", 214, 221]]], ["It is clear that tipping the balance of T-cell immunity through the OX40 axis could have important ramifications for several human diseases.", [["T-cell", "ANATOMY", 40, 46], ["T-cell", "CELL", 40, 46], ["OX40", "GENE_OR_GENE_PRODUCT", 68, 72], ["human", "ORGANISM", 125, 130], ["OX40", "PROTEIN", 68, 72], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["T-cell immunity", "TREATMENT", 40, 55], ["several human diseases", "PROBLEM", 117, 139], ["clear", "OBSERVATION_MODIFIER", 6, 11]]], ["The first stages of OX40-specific clinical trials are now being performed and efficacy of these trials will be determined in the future.", [["OX40", "GENE_OR_GENE_PRODUCT", 20, 24], ["OX40", "PROTEIN", 20, 24], ["these trials", "TREATMENT", 90, 102]]]], "PMC7457907": [], "PMC7515583": [], "PMC7169066": [["INTRODUCTIONSevere acute respiratory infections such as avian influenza A(H5N1)1 and A(H7N9) viruses2 with pandemic potential have continued to circulate widely in some poultry populations and infect humans sporadically.", [["respiratory", "ANATOMY", 25, 36], ["respiratory infections", "DISEASE", 25, 47], ["avian influenza A", "DISEASE", 56, 73], ["pandemic", "DISEASE", 107, 115], ["avian influenza A(H5N1)1", "ORGANISM", 56, 80], ["A(H7N9) viruses2", "ORGANISM", 85, 101], ["humans", "ORGANISM", 200, 206], ["avian influenza", "SPECIES", 56, 71], ["A(H5N1", "SPECIES", 72, 78], ["A(H7N9", "SPECIES", 85, 91], ["humans", "SPECIES", 200, 206], ["avian influenza A(H5N1)1", "SPECIES", 56, 80], ["humans", "SPECIES", 200, 206], ["acute respiratory infections", "PROBLEM", 19, 47], ["avian influenza A(H5N1)", "PROBLEM", 56, 79], ["A(H7N9) viruses2", "PROBLEM", 85, 101], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory", "ANATOMY", 25, 36], ["infections", "OBSERVATION", 37, 47], ["poultry populations", "OBSERVATION", 169, 188]]], ["Infection caused by these viruses may result in severe disease and high case fatality rates because most humans have no background immunity to these viruses.", [["Infection", "DISEASE", 0, 9], ["humans", "ORGANISM", 105, 111], ["humans", "SPECIES", 105, 111], ["humans", "SPECIES", 105, 111], ["Infection", "PROBLEM", 0, 9], ["these viruses", "PROBLEM", 20, 33], ["severe disease", "PROBLEM", 48, 62], ["high case fatality rates", "PROBLEM", 67, 91], ["viruses", "OBSERVATION", 26, 33], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["disease", "OBSERVATION", 55, 62]]], ["Sporadic human cases due to avian A(H5N6),3 A(H10N8)4 and A(H6N1)5 have also emerged in recent years.", [["human", "ORGANISM", 9, 14], ["avian A(H5N6)", "ORGANISM", 28, 41], ["3 A(H10N8)4", "ORGANISM", 42, 53], ["A(H6N1)5", "ORGANISM", 58, 66], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["Sporadic human cases", "PROBLEM", 0, 20]]], ["The global circulation of oseltamivir\u2010resistant seasonal influenza, the emergence of A(H1N1)pdm09 virus in 2009 followed by its continual circulation,6 the rising number of A(H7N9) infections in humans2 and the ongoing spread of A(H5N8) in recent months in the poultry populations in many countries in Asia, Africa, Europe and Middle East with pandemic potential7 all point to an urgent need for developing more effective antiviral therapies to reduce morbidity and mortality.", [["seasonal influenza", "DISEASE", 48, 66], ["infections", "DISEASE", 181, 191], ["A(H1N1)pdm09 virus", "ORGANISM", 85, 103], ["A(H7N9)", "ORGANISM", 173, 180], ["humans2", "CANCER", 195, 202], ["A(H5N8", "ORGANISM", 229, 235], ["H1N1)pdm09 virus", "SPECIES", 87, 103], ["A(H1N1)pdm09 virus", "SPECIES", 85, 103], ["H7N9", "SPECIES", 175, 179], ["A", "SPECIES", 229, 230], ["H5N8", "SPECIES", 231, 235], ["oseltamivir\u2010resistant seasonal influenza", "PROBLEM", 26, 66], ["A(H1N1)pdm09 virus", "PROBLEM", 85, 103], ["A(H7N9) infections in humans2", "PROBLEM", 173, 202], ["pandemic potential7", "TREATMENT", 344, 363], ["effective antiviral therapies", "TREATMENT", 412, 441], ["morbidity", "PROBLEM", 452, 461], ["global", "OBSERVATION_MODIFIER", 4, 10], ["circulation", "OBSERVATION_MODIFIER", 11, 22], ["seasonal influenza", "OBSERVATION", 48, 66], ["spread", "OBSERVATION_MODIFIER", 219, 225]]], ["This article reviews the epidemiology, clinical, diagnostic and treatment aspects of these important and emerging influenza viruses that are posing threats to human health in the Asia\u2010Pacific region.Seasonal influenza and pandemic influenza ::: EPIDEMIOLOGYSeasonal influenza is a major health problem.", [["influenza viruses", "DISEASE", 114, 131], ["influenza", "DISEASE", 208, 217], ["influenza", "DISEASE", 231, 240], ["influenza", "DISEASE", 266, 275], ["human", "ORGANISM", 159, 164], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 159, 164], ["emerging influenza viruses", "PROBLEM", 105, 131], ["Seasonal influenza", "PROBLEM", 199, 217], ["pandemic influenza", "PROBLEM", 222, 240], ["EPIDEMIOLOGYSeasonal influenza", "PROBLEM", 245, 275], ["influenza", "OBSERVATION", 208, 217]]], ["For instance, in Hong Kong, influenza A and B accounted for 39.4% and 10.2%, respectively, of hospital admissions confirmed to have viral infections.8 The average annual incidence of hospitalization with laboratory\u2010confirmed influenza A infection was 107.7/10 000 and 18.3/10 000 among children aged <5 years and elderly \u226565 years, respectively.", [["influenza A and B", "DISEASE", 28, 45], ["viral infections", "DISEASE", 132, 148], ["influenza A infection", "DISEASE", 225, 246], ["influenza A", "ORGANISM", 28, 39], ["B", "CANCER", 44, 45], ["children", "ORGANISM", 286, 294], ["children", "SPECIES", 286, 294], ["Hong Kong, influenza A", "SPECIES", 17, 39], ["influenza A", "TEST", 28, 39], ["viral infections", "PROBLEM", 132, 148], ["influenza A infection", "PROBLEM", 225, 246], ["viral", "OBSERVATION_MODIFIER", 132, 137], ["infections", "OBSERVATION", 138, 148], ["infection", "OBSERVATION", 237, 246]]], ["Furthermore, influenza A was the most common (45.5%) virus detected from patients who died of respiratory viral infections.", [["influenza A", "DISEASE", 13, 24], ["respiratory viral infections", "DISEASE", 94, 122], ["influenza A", "ORGANISM", 13, 24], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["influenza A", "SPECIES", 13, 24], ["influenza", "PROBLEM", 13, 22], ["virus", "PROBLEM", 53, 58], ["respiratory viral infections", "PROBLEM", 94, 122], ["respiratory", "ANATOMY", 94, 105], ["viral infections", "OBSERVATION", 106, 122]]], ["Although influenza B is usually associated with a less degree of disease burden, its impact on human health is substantial.", [["influenza B", "DISEASE", 9, 20], ["influenza B", "ORGANISM", 9, 20], ["human", "ORGANISM", 95, 100], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["influenza", "PROBLEM", 9, 18], ["disease burden", "PROBLEM", 65, 79], ["influenza", "OBSERVATION", 9, 18], ["less degree", "OBSERVATION_MODIFIER", 50, 61], ["disease", "OBSERVATION", 65, 72], ["substantial", "OBSERVATION_MODIFIER", 111, 122]]], ["Our previous study conducted in Hong Kong revealed that 24% of laboratory\u2010confirmed influenza\u2010associated hospital admissions were due to influenza B, and was much higher (41.9%) among older children and adolescents (aged 5\u201314 years).9 This observation is similar to data in Europe and North America.Seasonal influenza and pandemic influenza ::: EPIDEMIOLOGYIn the temperate region, influenza exhibits an annual seasonal peak in winter.", [["influenza B", "DISEASE", 137, 148], ["influenza", "DISEASE", 308, 317], ["influenza", "DISEASE", 331, 340], ["influenza", "DISEASE", 382, 391], ["children", "ORGANISM", 190, 198], ["children", "SPECIES", 190, 198], ["adolescents", "SPECIES", 203, 214], ["pandemic influenza", "SPECIES", 322, 340], ["Our previous study", "TEST", 0, 18], ["influenza B", "PROBLEM", 137, 148], ["This observation", "TEST", 235, 251], ["Seasonal influenza", "PROBLEM", 299, 317], ["pandemic influenza", "PROBLEM", 322, 340], ["influenza", "PROBLEM", 382, 391], ["influenza", "OBSERVATION", 308, 317]]], ["However, the seasonality in tropical and subtropical regions is more variable.", [["the seasonality in tropical and subtropical regions", "PROBLEM", 9, 60], ["seasonality", "OBSERVATION_MODIFIER", 13, 24], ["tropical", "ANATOMY_MODIFIER", 28, 36], ["subtropical", "ANATOMY_MODIFIER", 41, 52], ["regions", "ANATOMY_MODIFIER", 53, 60], ["more", "OBSERVATION_MODIFIER", 64, 68], ["variable", "OBSERVATION_MODIFIER", 69, 77]]], ["For instance, in Hong Kong, a subtropical city, most of the time, influenza exhibits two peaks during January\u2013March and June\u2013August, and occasionally, the two peaks merge without an obvious gap.8, 10 Such bimodal and variable seasonality of influenza is also observed in countries within the subtropical and tropical regions, and poses a challenge to implement annual influenza vaccination campaign as well as a question on whether the Northern or Southern Hemisphere version of influenza vaccine would be more appropriate.Seasonal influenza and pandemic influenza ::: EPIDEMIOLOGYA schematic diagram of the structure of influenza virion is shown in Figure 1.", [["influenza", "DISEASE", 66, 75], ["influenza", "DISEASE", 241, 250], ["influenza", "DISEASE", 532, 541], ["influenza", "DISEASE", 555, 564], ["influenza virion", "DISEASE", 621, 637], ["influenza", "PROBLEM", 66, 75], ["an obvious gap", "PROBLEM", 179, 193], ["influenza", "PROBLEM", 241, 250], ["annual influenza vaccination campaign", "TREATMENT", 361, 398], ["influenza vaccine", "TREATMENT", 479, 496], ["Seasonal influenza", "PROBLEM", 523, 541], ["influenza virion", "PROBLEM", 621, 637], ["obvious", "OBSERVATION_MODIFIER", 182, 189], ["gap", "OBSERVATION", 190, 193], ["influenza", "OBSERVATION", 241, 250], ["subtropical", "ANATOMY_MODIFIER", 292, 303], ["tropical regions", "ANATOMY", 308, 324], ["influenza", "OBSERVATION", 532, 541], ["influenza virion", "OBSERVATION", 621, 637]]], ["Influenza represents one of the few examples of viruses with segmented genome.", [["Influenza", "DISEASE", 0, 9], ["Influenza", "PROBLEM", 0, 9], ["viruses", "OBSERVATION", 48, 55], ["segmented genome", "OBSERVATION", 61, 77]]], ["This, together with the widespread infection with different subtypes in various animal species, allows robust evolution through the process of \u2018reassortment\u2019.", [["infection", "DISEASE", 35, 44], ["the widespread infection", "PROBLEM", 20, 44], ["different subtypes in various animal species", "PROBLEM", 50, 94], ["widespread", "OBSERVATION_MODIFIER", 24, 34], ["infection", "OBSERVATION", 35, 44], ["different subtypes", "OBSERVATION_MODIFIER", 50, 68], ["various animal species", "OBSERVATION", 72, 94]]], ["The prerequisite for reassortment is a simultaneous infection with more than one strain of viruses in a host referred to as the \u2018mixing vessel\u2019 that allows replication and swabbing of gene segments between different strains of viruses.", [["vessel", "ANATOMY", 136, 142], ["infection", "DISEASE", 52, 61], ["vessel", "MULTI-TISSUE_STRUCTURE", 136, 142], ["a simultaneous infection", "PROBLEM", 37, 61], ["viruses", "PROBLEM", 91, 98], ["swabbing of gene segments between different strains of viruses", "PROBLEM", 172, 234], ["simultaneous", "OBSERVATION_MODIFIER", 39, 51], ["infection", "OBSERVATION", 52, 61], ["viruses", "OBSERVATION", 91, 98], ["vessel", "ANATOMY", 136, 142], ["viruses", "OBSERVATION", 227, 234]]], ["Water birds are well\u2010known mixing vessels, but the reassortants are more likely to have a tropism restricted to avian species.", [["vessels", "ANATOMY", 34, 41], ["vessels", "MULTI-TISSUE_STRUCTURE", 34, 41], ["a tropism", "PROBLEM", 88, 97], ["mixing vessels", "OBSERVATION", 27, 41], ["tropism", "OBSERVATION", 90, 97]]], ["These new reassortants may pose problems in the land birds and poultry, and subsequently be of human concern.", [["human", "ORGANISM", 95, 100], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["new", "OBSERVATION_MODIFIER", 6, 9], ["reassortants", "OBSERVATION", 10, 22]]], ["Swine is another well\u2010known mixing vessel.", [["vessel", "ANATOMY", 35, 41], ["vessel", "MULTI-TISSUE_STRUCTURE", 35, 41], ["Swine", "SPECIES", 0, 5], ["mixing vessel", "OBSERVATION", 28, 41]]], ["The unique property of swine is their susceptibility to both avian and human influenza viruses.", [["influenza viruses", "DISEASE", 77, 94], ["swine", "ORGANISM", 23, 28], ["avian", "ORGANISM", 61, 66], ["human influenza viruses", "ORGANISM", 71, 94], ["swine", "SPECIES", 23, 28], ["avian", "SPECIES", 61, 66], ["human", "SPECIES", 71, 76], ["swine", "SPECIES", 23, 28], ["human influenza viruses", "SPECIES", 71, 94], ["human influenza viruses", "PROBLEM", 71, 94], ["influenza viruses", "OBSERVATION", 77, 94]]], ["Thus, reassortants from swine are more likely to gain tropism for infection in humans.", [["infection", "DISEASE", 66, 75], ["swine", "ORGANISM", 24, 29], ["humans", "ORGANISM", 79, 85], ["swine", "SPECIES", 24, 29], ["humans", "SPECIES", 79, 85], ["swine", "SPECIES", 24, 29], ["humans", "SPECIES", 79, 85], ["reassortants", "PROBLEM", 6, 18], ["infection in humans", "PROBLEM", 66, 85], ["infection", "OBSERVATION", 66, 75]]], ["Field observations made as early as 1990s have pointed out that influenza outbreaks that began with either pigs or people were then rapidly transferred to each other.11 Swine are likely to play the role of a mixing vessel in creating pandemic strains.", [["vessel", "ANATOMY", 215, 221], ["influenza outbreaks", "DISEASE", 64, 83], ["pigs", "ORGANISM", 107, 111], ["people", "ORGANISM", 115, 121], ["vessel", "MULTI-TISSUE_STRUCTURE", 215, 221], ["pigs", "SPECIES", 107, 111], ["people", "SPECIES", 115, 121], ["pigs", "SPECIES", 107, 111], ["influenza outbreaks", "PROBLEM", 64, 83], ["creating pandemic strains", "PROBLEM", 225, 250], ["vessel", "ANATOMY", 215, 221], ["pandemic strains", "OBSERVATION", 234, 250]]], ["Although the 1918 pandemic strain was most probably an entirely avian\u2010like virus,12 the 1957 and 1968 pandemic strains were reassortants of human\u2010 and avian\u2010origin viruses.13", [["avian\u2010origin viruses", "ORGANISM", 151, 171], ["the 1918 pandemic strain", "PROBLEM", 9, 33], ["an entirely avian\u2010like virus", "PROBLEM", 52, 80], ["pandemic strains", "PROBLEM", 102, 118], ["human\u2010", "TREATMENT", 140, 146], ["avian\u2010origin viruses", "PROBLEM", 151, 171]]]], "PMC4634723": [["FindingsAstroviruses are comprised of two genera with Avastrovirus infecting birds and Mamastrovirus infecting mammals.", [["birds", "ORGANISM", 77, 82], ["Mamastrovirus", "ORGANISM", 87, 100], ["FindingsAstroviruses", "PROBLEM", 0, 20], ["Avastrovirus infecting birds", "PROBLEM", 54, 82], ["Mamastrovirus infecting mammals", "PROBLEM", 87, 118], ["infecting birds", "OBSERVATION", 67, 82], ["infecting mammals", "OBSERVATION", 101, 118]]], ["These viruses are primarily transmitted fecal-orally, which is facilitated in agricultural systems due to host proximity, but they can persist in water [1].", [["fecal", "ORGANISM_SUBDIVISION", 40, 45], ["These viruses", "PROBLEM", 0, 13], ["viruses", "OBSERVATION", 6, 13]]], ["Avastroviruses have primarily been associated with infections of poultry, especially chicken, turkey, duck, and guineafowl production systems.", [["infections", "DISEASE", 51, 61], ["Avastroviruses", "GENE_OR_GENE_PRODUCT", 0, 14], ["chicken", "ORGANISM", 85, 92], ["turkey", "ORGANISM", 94, 100], ["duck", "ORGANISM", 102, 106], ["chicken", "SPECIES", 85, 92], ["turkey", "SPECIES", 94, 100], ["duck", "SPECIES", 102, 106], ["poultry", "SPECIES", 65, 72], ["chicken", "SPECIES", 85, 92], ["turkey", "SPECIES", 94, 100], ["Avastroviruses", "TREATMENT", 0, 14], ["infections of poultry", "PROBLEM", 51, 72], ["guineafowl production systems", "PROBLEM", 112, 141], ["infections", "OBSERVATION", 51, 61]]], ["Outcomes result in a spectrum of disease, ranging from asymptomic shedding to gasteroenteritis with diarrhea, stunting, failure to thrive and death [2].", [["gasteroenteritis", "DISEASE", 78, 94], ["diarrhea", "DISEASE", 100, 108], ["stunting", "DISEASE", 110, 118], ["failure to thrive", "DISEASE", 120, 137], ["death", "DISEASE", 142, 147], ["disease", "PROBLEM", 33, 40], ["gasteroenteritis", "PROBLEM", 78, 94], ["diarrhea", "PROBLEM", 100, 108], ["stunting", "PROBLEM", 110, 118], ["failure to thrive", "PROBLEM", 120, 137], ["death", "PROBLEM", 142, 147], ["disease", "OBSERVATION", 33, 40]]], ["Phylogenetic analysis shows that Avastrovirus forms three major groups, with support for Group 1 avastroviruses (including chickens, guineafowl, and several duck species) forming a further three monophyletic clades [3].FindingsRecently, avastroviruses have been discovered in a variety of wild birds, with the greatest numbers detected from aquatic species in the orders Anseriformes (i.e. teals, pintails, shovelers, and wigeons), Charadriiformes (i.e. greenshanks and sanderlings), and Pelecaniformes (i.e. herons and spoonbills) [3, 4].", [["Avastrovirus", "GENE_OR_GENE_PRODUCT", 33, 45], ["chickens", "ORGANISM", 123, 131], ["duck", "ORGANISM", 157, 161], ["avastroviruses", "CANCER", 237, 251], ["birds", "ORGANISM", 294, 299], ["avastroviruses", "PROTEIN", 237, 251], ["chickens", "SPECIES", 123, 131], ["duck", "SPECIES", 157, 161], ["chickens", "SPECIES", 123, 131], ["Phylogenetic analysis", "TEST", 0, 21], ["Group 1 avastroviruses", "TREATMENT", 89, 111], ["chickens, guineafowl", "TREATMENT", 123, 143], ["several duck species", "PROBLEM", 149, 169], ["aquatic species", "OBSERVATION", 341, 356]]], ["The only land dwelling wild bird species found to harbor astroviruses include members of the order Colombiformes (i.e. doves and pigeons) and Coraciiformes (i.e. European roller) [5\u20137].", [["pigeons", "SPECIES", 129, 136]]], ["Aside from avian influenza virus, there have been few studies examining endemic viruses in birds in Cambodia.", [["avian influenza virus", "DISEASE", 11, 32], ["avian influenza virus", "ORGANISM", 11, 32], ["birds", "ORGANISM", 91, 96], ["avian influenza virus", "SPECIES", 11, 32], ["avian influenza virus", "SPECIES", 11, 32], ["avian influenza virus", "PROBLEM", 11, 32], ["few studies", "TEST", 50, 61], ["endemic viruses", "PROBLEM", 72, 87], ["influenza virus", "OBSERVATION", 17, 32], ["few", "OBSERVATION_MODIFIER", 50, 53], ["endemic", "OBSERVATION_MODIFIER", 72, 79], ["viruses", "OBSERVATION", 80, 87]]], ["Here we report on the surveillance for a variety of viruses in species from four bird orders in Cambodia (Table 1) and the first detection of an astrovirus from the order Passeriformes.FindingsFrom February until December 2010 the Wildlife Conservation Society collected samples from wild birds in Cambodia to study circulating viruses in the country\u2019s avifauna.", [["astrovirus", "ORGANISM", 145, 155], ["viruses in species", "PROBLEM", 52, 70], ["an astrovirus", "PROBLEM", 142, 155], ["viruses", "OBSERVATION", 52, 59], ["astrovirus", "OBSERVATION", 145, 155]]], ["Paired oropharyngeal and cloacal swabs were collected from 119 birds at the two field sites (Table 1).", [["oropharyngeal", "ANATOMY", 7, 20], ["cloacal swabs", "ANATOMY", 25, 38], ["oropharyngeal", "ORGANISM_SUBDIVISION", 7, 20], ["cloacal swabs", "ORGANISM_SUBSTANCE", 25, 38], ["Paired oropharyngeal and cloacal swabs", "PROBLEM", 0, 38], ["oropharyngeal", "ANATOMY", 7, 20], ["cloacal swabs", "ANATOMY", 25, 38]]], ["Duplicate samples were taken and stored in either guanidine isothiocyanate or virus transport media for detection or culture, respectively.", [["samples", "ANATOMY", 10, 17], ["guanidine isothiocyanate", "CHEMICAL", 50, 74], ["guanidine isothiocyanate", "CHEMICAL", 50, 74], ["guanidine isothiocyanate", "SIMPLE_CHEMICAL", 50, 74], ["Duplicate samples", "TEST", 0, 17], ["guanidine isothiocyanate", "TREATMENT", 50, 74], ["virus transport media", "TREATMENT", 78, 99], ["culture", "TEST", 117, 124]]], ["Samples were kept at \u221280 \u00b0C until shipped to Duke-NUS Graduate Medical School Singapore for PCR screening.FindingsPaired samples in guanidine isothiocyanate were pooled, vortexed, centrifuged at 4,000 g for 5 min, and the clarified supernatant was removed for RNA extraction.", [["Samples", "ANATOMY", 0, 7], ["samples", "ANATOMY", 121, 128], ["supernatant", "ANATOMY", 232, 243], ["guanidine isothiocyanate", "CHEMICAL", 132, 156], ["guanidine isothiocyanate", "CHEMICAL", 132, 156], ["guanidine isothiocyanate", "SIMPLE_CHEMICAL", 132, 156], ["Samples", "TEST", 0, 7], ["PCR screening", "TEST", 92, 105], ["guanidine isothiocyanate", "TREATMENT", 132, 156], ["RNA extraction", "TREATMENT", 260, 274]]], ["Lysis buffer was added in a laminar flow hood before nucleic acid extraction using a QiaExtractor robot (Qiagen).", [["nucleic acid", "CHEMICAL", 53, 65], ["Lysis buffer", "TREATMENT", 0, 12], ["a laminar flow hood", "TREATMENT", 26, 45], ["nucleic acid extraction", "TREATMENT", 53, 76], ["a QiaExtractor robot (Qiagen)", "TREATMENT", 83, 112]]], ["Complementary DNA was synthesized using a Superscript II kit (Invitrogen) following the manufacturer\u2019s protocol using either a Uni-12 specific primer for detection of influenza or with random hexamers for detection of the other virus families.", [["influenza", "DISEASE", 167, 176], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["a Superscript II kit (Invitrogen", "TREATMENT", 40, 72], ["the manufacturer\u2019s protocol", "TREATMENT", 84, 111], ["influenza", "PROBLEM", 167, 176], ["random hexamers", "TREATMENT", 185, 200]]], ["A Taqman PCR assay was used to test for influenza A viruses, while family specific primer sets targeting conserved regions of the genome were used for detection of astroviruses, coronaviruses, flaviviruses, and paramyxoviruses (protocols and primer sets are available in Additional file 1: Supplementary Information).FindingsAn astrovirus positive PCR product from a black-naped monarch (Hypothymis azurea) was purified using a Qiagen PCR purification kit (Qiagen).", [["influenza A viruses", "ORGANISM", 40, 59], ["astrovirus", "ORGANISM", 328, 338], ["Hypothymis azurea", "ORGANISM", 388, 405], ["astrovirus positive PCR product", "PROTEIN", 328, 359], ["Hypothymis azurea", "SPECIES", 388, 405], ["influenza A viruses", "SPECIES", 40, 59], ["Hypothymis azurea", "SPECIES", 388, 405], ["A Taqman PCR assay", "TEST", 0, 18], ["influenza A viruses", "PROBLEM", 40, 59], ["astroviruses", "PROBLEM", 164, 176], ["coronaviruses", "PROBLEM", 178, 191], ["flaviviruses", "PROBLEM", 193, 205], ["paramyxoviruses", "PROBLEM", 211, 226], ["astrovirus positive PCR product", "PROBLEM", 328, 359], ["a Qiagen PCR purification kit", "TREATMENT", 426, 455], ["astroviruses", "OBSERVATION", 164, 176]]], ["This product was cloned using a Promega p-Gem T easy kit (ProMega).", [["a Promega p-Gem T easy kit (ProMega)", "TREATMENT", 30, 66]]], ["Plasmids were purified using an Omega MiniPrep (Omega) purification kit and sent for sequencing.", [["Omega", "PROTEIN", 48, 53], ["Plasmids", "TREATMENT", 0, 8], ["an Omega MiniPrep (Omega) purification kit", "TREATMENT", 29, 71], ["sequencing", "TEST", 85, 95]]], ["Two sequences generated from the same individual in this study were deposited in GenBank (accession numbers KT965674-KT965975).", [["Two sequences", "TEST", 0, 13], ["this study", "TEST", 52, 62]]], ["Attempts to generate additional genetic data using a 3\u2032 RACE PCR and culture in embryonated chicken eggs were unsuccessful.FindingsThe RNA dependent reverse polymerase (RdRp) sequences from representative mammal and bird species were aligned using MUSCLE in Geneious 7.1.6 [8] and then manually curated (see Additional file 2: Table S1).", [["eggs", "ANATOMY", 100, 104], ["chicken", "ORGANISM", 92, 99], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 100, 104], ["RNA dependent reverse polymerase (RdRp) sequences", "DNA", 135, 184], ["chicken", "SPECIES", 92, 99], ["chicken", "SPECIES", 92, 99], ["RACE PCR", "TEST", 56, 64], ["culture", "TEST", 69, 76], ["embryonated chicken eggs", "TREATMENT", 80, 104], ["The RNA dependent reverse polymerase (RdRp) sequences", "PROBLEM", 131, 184], ["bird species", "TEST", 216, 228], ["MUSCLE in Geneious", "TEST", 248, 266], ["RNA dependent", "OBSERVATION_MODIFIER", 135, 148], ["bird species", "OBSERVATION", 216, 228], ["MUSCLE", "ANATOMY", 248, 254]]], ["Nucleotide pairwise p-distances were calculated using Mega 6.06 [9].", [["Nucleotide pairwise p-distances", "TEST", 0, 31], ["Mega", "TEST", 54, 58]]], ["Maximum-likelihood (ML) trees were constructed in Geneious 7.1.6 using PHYML v2.2.0 [10] using a combined NNI and SPR topology search and support calculated with 500 ML bootstrap replicates.", [["NNI", "DNA", 106, 109], ["a combined NNI and SPR topology search", "TREATMENT", 95, 133], ["500 ML bootstrap", "TREATMENT", 162, 178]]], ["Bayesian analysis was conducted in Geneious 7.1.6 with MrBayes v3.2.2 [11] using two replicates of 5,000,000 generations sampled every 1,000 generations.", [["Bayesian analysis", "TEST", 0, 17], ["MrBayes v", "TEST", 55, 64]]], ["The convergence of chains and estimation of burn-in were assessed and Bayesian posterior probabilities were calculated from the consensus of 8,000 trees after excluding the first 2,000 trees as burn-in.", [["burn", "DISEASE", 44, 48], ["burn", "DISEASE", 194, 198], ["burn", "PROBLEM", 44, 48], ["Bayesian posterior probabilities", "PROBLEM", 70, 102], ["chains", "OBSERVATION_MODIFIER", 19, 25]]], ["Both analyses implemented a GTR + G nucleotide substitution model.", [["nucleotide", "CHEMICAL", 36, 46], ["GTR + G nucleotide", "CHEMICAL", 28, 46], ["a GTR + G nucleotide substitution model", "TREATMENT", 26, 65]]], ["Phylogenetic trees were visualized in FigTree v1.4.2 (http://tree.bio.ed.ac.uk/software/figtree/).FindingsAstrovirus was detected in one black-naped monarch from 119 birds tested with an overall prevalence of 0.8 % (Table 1).", [["birds", "ORGANISM", 166, 171], ["Phylogenetic trees", "PROBLEM", 0, 18], ["FigTree v", "TEST", 38, 47], ["an overall prevalence", "TEST", 184, 205]]], ["Influenza viruses, coronaviruses, paramyxoviruses and flaviviruses were not detected.", [["Influenza viruses, coronaviruses, paramyxoviruses and flaviviruses", "DISEASE", 0, 66], ["Influenza viruses", "ORGANISM", 0, 17], ["coronaviruses", "ORGANISM", 19, 32], ["Influenza", "SPECIES", 0, 9], ["Influenza viruses", "SPECIES", 0, 17], ["Influenza viruses", "PROBLEM", 0, 17], ["coronaviruses", "PROBLEM", 19, 32], ["paramyxoviruses", "PROBLEM", 34, 49], ["flaviviruses", "PROBLEM", 54, 66], ["viruses", "OBSERVATION", 10, 17]]], ["Comparison of the 391 bp nucleotide alignment of the two passerine avastrovirus RdRp clones detected in the black-naped monarch identified no polymorphic sites.", [["nucleotide", "CHEMICAL", 25, 35], ["nucleotide", "CHEMICAL", 25, 35], ["passerine avastrovirus RdRp clones", "DNA", 57, 91], ["black-naped monarch", "DNA", 108, 127], ["polymorphic sites", "DNA", 142, 159], ["the 391 bp nucleotide alignment", "TEST", 14, 45], ["the two passerine avastrovirus RdRp clones", "PROBLEM", 49, 91], ["polymorphic sites", "PROBLEM", 142, 159], ["RdRp clones", "OBSERVATION", 80, 91], ["black", "OBSERVATION_MODIFIER", 108, 113], ["no", "UNCERTAINTY", 139, 141], ["polymorphic sites", "OBSERVATION", 142, 159]]], ["For the remaining avastroviruses, pairwise nucleotide p-distance computations showed that within group similarity varied from 69.2 % (Group 1) to 77.6 % (Group 3).", [["nucleotide", "CHEMICAL", 43, 53], ["nucleotide", "CHEMICAL", 43, 53], ["pairwise nucleotide p-distance computations", "TEST", 34, 77]]], ["Between group nucleotide pairwise distances varied from 51.7 % (Group 2 vs Group 3) to 58.8 % similarity (Group 1 vs passerine avastrovirus) (Additional file 3: Table S2).", [["nucleotide", "CHEMICAL", 14, 24], ["nucleotide", "CHEMICAL", 14, 24], ["group nucleotide pairwise distances", "TEST", 8, 43], ["passerine avastrovirus", "TEST", 117, 139]]], ["These results suggest that the passerine avastrovirus is as divergent from the three described groups as those groups are from each other and may represent a unique avastrovirus lineage.FindingsBoth the ML and Bayesian analysis of the RdRp gene showed the same basic tree topology as Chu et al. [3] with the exception that the passerine astrovirus formed a divergent group that falls in a basal position to both avastrovirus groups 1 and 2 (Fig. 1).", [["astrovirus", "DISEASE", 337, 347], ["passerine avastrovirus", "ORGANISM", 31, 53], ["avastrovirus lineage", "CELL", 165, 185], ["passerine astrovirus", "ORGANISM", 327, 347], ["avastrovirus lineage", "CELL_TYPE", 165, 185], ["RdRp gene", "DNA", 235, 244], ["the passerine avastrovirus", "PROBLEM", 27, 53], ["a unique avastrovirus lineage", "PROBLEM", 156, 185], ["Bayesian analysis", "TEST", 210, 227], ["the RdRp gene", "TEST", 231, 244], ["the passerine astrovirus", "PROBLEM", 323, 347], ["may represent", "UNCERTAINTY", 142, 155], ["avastrovirus lineage", "OBSERVATION", 165, 185]]], ["Groups 1 and 2 are strongly supported as sister groups to each other and are in turn most closely related to the black-naped monarch virus sequences.", [["black-naped monarch virus sequences", "DNA", 113, 148], ["black-naped monarch virus", "SPECIES", 113, 138]]], ["Group 3 avastroviruses are comprised entirely of ducks and supported as a sister clade to all other avastroviruses.", [["ducks", "ORGANISM", 49, 54], ["avastroviruses", "CANCER", 100, 114], ["ducks", "SPECIES", 49, 54]]], ["Phylogenetic reconstruction and the pairwise distance analysis both indicate that the passerine avastrovirus forms a novel lineage that is well differentiated from all previously described avastroviruses.FindingsThis is the first astrovirus detection in a passerine bird.", [["astrovirus", "DISEASE", 230, 240], ["passerine avastrovirus", "ORGANISM", 86, 108], ["avastroviruses", "CANCER", 189, 203], ["astrovirus", "ORGANISM", 230, 240], ["passerine avastrovirus", "DNA", 86, 108], ["Phylogenetic reconstruction", "TREATMENT", 0, 27], ["the pairwise distance analysis", "TEST", 32, 62], ["the passerine avastrovirus", "PROBLEM", 82, 108]]], ["Phylogenetic analysis and nucleotide distances suggest that this avastrovirus forms a distinct lineage and may constitute a fourth avastrovirus group.", [["nucleotide", "CHEMICAL", 26, 36], ["nucleotide", "CHEMICAL", 26, 36], ["avastrovirus", "GENE_OR_GENE_PRODUCT", 65, 77], ["avastrovirus", "CANCER", 131, 143], ["avastrovirus", "DNA", 65, 77], ["Phylogenetic analysis", "TEST", 0, 21], ["nucleotide distances", "PROBLEM", 26, 46], ["this avastrovirus", "PROBLEM", 60, 77], ["a fourth avastrovirus group", "PROBLEM", 122, 149]]], ["Astroviruses are a genetically diverse group with a wide host range [12].", [["Astroviruses", "DISEASE", 0, 12], ["Astroviruses", "PROBLEM", 0, 12]]], ["Avastroviruses have previously been detected from domestic birds that tend to be communally housed (chickens, ducks, turkeys), birds specifically associated with water bodies (ducks, herons, spoonbills, and shorebirds), or gregarious birds exhibiting communal behaviors (wood pigeons and rock doves).", [["spoonbills", "ANATOMY", 191, 201], ["Avastroviruses", "GENE_OR_GENE_PRODUCT", 0, 14], ["chickens", "ORGANISM_SUBDIVISION", 100, 108], ["ducks", "ORGANISM_SUBDIVISION", 110, 115], ["turkeys", "ORGANISM_SUBDIVISION", 117, 124], ["ducks", "ORGANISM_SUBDIVISION", 176, 181], ["herons", "ORGANISM_SUBDIVISION", 183, 189], ["wood", "ORGANISM_SUBDIVISION", 271, 275], ["pigeons", "ORGANISM_SUBDIVISION", 276, 283], ["chickens", "SPECIES", 100, 108], ["ducks", "SPECIES", 110, 115], ["turkeys", "SPECIES", 117, 124], ["ducks", "SPECIES", 176, 181], ["chickens", "SPECIES", 100, 108], ["Avastroviruses", "TREATMENT", 0, 14]]], ["However, it is unknown where and how this individual acquired the infection because although black-naped monarchs will forage in mixed flocks, they tend to be solitary or roost in pairs [14].", [["infection", "DISEASE", 66, 75], ["the infection", "PROBLEM", 62, 75], ["black-naped monarchs", "PROBLEM", 93, 113], ["infection", "OBSERVATION", 66, 75]]], ["Interestingly, pond herons represented nearly 50 % of all birds sampled in our study, yet we detected no astrovirus positives even though avastroviruses have previously been detected in this species in Cambodia [3].FindingsOur understanding of the impact of astrovirus infection in wild birds is very limited, especially regarding fitness costs and transmission dynamics.", [["astrovirus infection", "DISEASE", 258, 278], ["astrovirus", "ORGANISM", 105, 115], ["avastroviruses", "CANCER", 138, 152], ["astrovirus", "ORGANISM", 258, 268], ["pond herons", "SPECIES", 15, 26], ["our study", "TEST", 75, 84], ["astrovirus positives", "PROBLEM", 105, 125], ["avastroviruses", "PROBLEM", 138, 152], ["astrovirus infection", "PROBLEM", 258, 278], ["astrovirus", "OBSERVATION_MODIFIER", 258, 268], ["infection", "OBSERVATION", 269, 278]]], ["There is evidence that cross-species transmission occurs and that individual species may host divergent astrovirus strains, indicating their receptiveness to infection [15, 16].", [["infection", "DISEASE", 158, 167], ["astrovirus", "ORGANISM", 104, 114], ["cross-species transmission", "PROBLEM", 23, 49], ["individual species", "PROBLEM", 66, 84], ["host divergent astrovirus strains", "PROBLEM", 89, 122], ["their receptiveness to infection", "PROBLEM", 135, 167]]], ["Astroviruses can also undergo recombination leading to the emergence of novel strains [17].", [["Astroviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["Astroviruses", "PROBLEM", 0, 12], ["novel strains", "PROBLEM", 72, 85]]], ["Birds in the order Passeriformes are highly diverse, comprising 60 % of all bird species, and occupy a tremendous variety of terrestrial ecological niches [18].", [["all bird species", "PROBLEM", 72, 88], ["highly", "OBSERVATION_MODIFIER", 37, 43], ["diverse", "OBSERVATION_MODIFIER", 44, 51], ["bird species", "OBSERVATION", 76, 88], ["tremendous", "OBSERVATION_MODIFIER", 103, 113]]], ["As such, the discovery of an astrovirus in one species raises the possibility that additional astrovirus lineages may exist in the Passeriformes.", [["astrovirus", "DISEASE", 29, 39], ["astrovirus", "ORGANISM", 29, 39], ["astrovirus", "ORGANISM", 94, 104], ["an astrovirus in one species", "PROBLEM", 26, 54], ["additional astrovirus lineages", "PROBLEM", 83, 113], ["astrovirus", "OBSERVATION", 29, 39], ["raises the possibility", "UNCERTAINTY", 55, 77], ["astrovirus lineages", "OBSERVATION", 94, 113]]]], "fb90bbec04c1f804eae18a815a3c0d3986a90b03": [["Countries around the world face a perfect storm of converging threats that might substantially increase the risk from infectious disease epidemics, despite improvements in technologies, communication, and some health systems.", [["infectious disease epidemics", "DISEASE", 118, 146], ["infectious disease epidemics", "PROBLEM", 118, 146], ["infectious", "OBSERVATION_MODIFIER", 118, 128]]], ["New pathogens emerge each year, some of which have high mortality and the potential for effi cient transmission-eg, severe acute respiratory syndrome (SARS), 1 Middle East respiratory syndrome coronavirus, 2 and avian infl uenza A H7N9.", [["acute respiratory syndrome", "DISEASE", 123, 149], ["SARS", "DISEASE", 151, 155], ["Middle East respiratory syndrome coronavirus", "DISEASE", 160, 204], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 160, 204], ["infl uenza A H7N9", "ORGANISM", 218, 235], ["Middle East respiratory syndrome coronavirus", "SPECIES", 160, 204], ["New pathogens", "PROBLEM", 0, 13], ["high mortality", "PROBLEM", 51, 65], ["effi cient transmission", "PROBLEM", 88, 111], ["severe acute respiratory syndrome", "PROBLEM", 116, 149], ["SARS)", "PROBLEM", 151, 156], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 160, 204], ["pathogens", "OBSERVATION", 4, 13], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory syndrome", "OBSERVATION", 129, 149], ["Middle", "ANATOMY_MODIFIER", 160, 166], ["respiratory syndrome", "OBSERVATION", 172, 192]]], ["3 Existing pathogens are becoming resistant to available antibiotics and several are now resistant to virtually all available treatment.", [["Existing pathogens", "PROBLEM", 2, 20], ["available antibiotics", "TREATMENT", 47, 68], ["treatment", "TREATMENT", 126, 135], ["pathogens", "OBSERVATION", 11, 20]]], ["4 There is also the potential threat of intentional release of biological agents, which can be developed or synthesised biologically and disseminated at low cost and with little scientifi c expertise.", [["biological agents", "TREATMENT", 63, 80]]], ["Moreover, the accelerated pace of globalisation amplifi es these risks: a disease is just a plane trip away, and an outbreak anywhere is a threat everywhere.", [["a disease", "PROBLEM", 72, 81], ["disease", "OBSERVATION", 74, 81]]]]}